WO2012033459A1 - Maturation of gastrointestinal tract - Google Patents
Maturation of gastrointestinal tract Download PDFInfo
- Publication number
- WO2012033459A1 WO2012033459A1 PCT/SE2011/051089 SE2011051089W WO2012033459A1 WO 2012033459 A1 WO2012033459 A1 WO 2012033459A1 SE 2011051089 W SE2011051089 W SE 2011051089W WO 2012033459 A1 WO2012033459 A1 WO 2012033459A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- activity
- pancreatic
- tract
- mixture
- enzymes
- Prior art date
Links
- 230000035800 maturation Effects 0.000 title claims abstract description 151
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 330
- 102000004190 Enzymes Human genes 0.000 claims abstract description 290
- 108090000790 Enzymes Proteins 0.000 claims abstract description 290
- 239000000203 mixture Substances 0.000 claims abstract description 185
- 238000000034 method Methods 0.000 claims abstract description 148
- 230000009471 action Effects 0.000 claims abstract description 112
- 210000000936 intestine Anatomy 0.000 claims abstract description 110
- 230000008569 process Effects 0.000 claims abstract description 49
- 229940088598 enzyme Drugs 0.000 claims description 288
- 239000004365 Protease Substances 0.000 claims description 148
- 108091005804 Peptidases Proteins 0.000 claims description 139
- 230000000968 intestinal effect Effects 0.000 claims description 104
- 108010065511 Amylases Proteins 0.000 claims description 88
- 102000013142 Amylases Human genes 0.000 claims description 88
- 239000004382 Amylase Substances 0.000 claims description 86
- 235000019418 amylase Nutrition 0.000 claims description 86
- 108090001060 Lipase Proteins 0.000 claims description 74
- 102000004882 Lipase Human genes 0.000 claims description 74
- 210000001842 enterocyte Anatomy 0.000 claims description 73
- 239000004367 Lipase Substances 0.000 claims description 72
- 235000019421 lipase Nutrition 0.000 claims description 72
- 230000037396 body weight Effects 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 37
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 37
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 claims description 35
- 102400000472 Sucrase Human genes 0.000 claims description 35
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 claims description 35
- 235000011073 invertase Nutrition 0.000 claims description 35
- 108010059881 Lactase Proteins 0.000 claims description 30
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 30
- 229940116108 lactase Drugs 0.000 claims description 28
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 27
- 206010051606 Necrotising colitis Diseases 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 25
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 25
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 25
- 241000271566 Aves Species 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000000090 biomarker Substances 0.000 claims description 17
- 235000019786 weight gain Nutrition 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 14
- 230000032683 aging Effects 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 210000000813 small intestine Anatomy 0.000 abstract description 136
- 102000035195 Peptidases Human genes 0.000 description 135
- 235000019419 proteases Nutrition 0.000 description 118
- 241000700159 Rattus Species 0.000 description 75
- 108010067035 Pancrelipase Proteins 0.000 description 60
- 229940092125 creon Drugs 0.000 description 59
- 230000000813 microbial effect Effects 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 108010001394 Disaccharidases Proteins 0.000 description 37
- 238000003556 assay Methods 0.000 description 35
- 210000000056 organ Anatomy 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 210000002784 stomach Anatomy 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 238000010521 absorption reaction Methods 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 230000012010 growth Effects 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 108090000526 Papain Proteins 0.000 description 20
- 229940098773 bovine serum albumin Drugs 0.000 description 20
- 238000011161 development Methods 0.000 description 20
- 230000018109 developmental process Effects 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 235000019834 papain Nutrition 0.000 description 20
- 229940055729 papain Drugs 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 208000028774 intestinal disease Diseases 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 17
- 229960000590 celecoxib Drugs 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 230000002496 gastric effect Effects 0.000 description 16
- 210000000496 pancreas Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 229920002521 macromolecule Polymers 0.000 description 15
- 241000894007 species Species 0.000 description 15
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 210000002919 epithelial cell Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 210000000110 microvilli Anatomy 0.000 description 14
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 13
- 238000001574 biopsy Methods 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 13
- 229960001680 ibuprofen Drugs 0.000 description 13
- 235000013336 milk Nutrition 0.000 description 13
- 239000008267 milk Substances 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- 210000001198 duodenum Anatomy 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 239000012472 biological sample Substances 0.000 description 10
- 238000002224 dissection Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 241000282887 Suidae Species 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000834 fixative Substances 0.000 description 9
- 210000003405 ileum Anatomy 0.000 description 9
- 210000002429 large intestine Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 8
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004534 cecum Anatomy 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000378 dietary effect Effects 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 230000003870 intestinal permeability Effects 0.000 description 8
- 230000021332 multicellular organism growth Effects 0.000 description 8
- -1 polyethylene Polymers 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 241000699694 Gerbillinae Species 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 7
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 7
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 150000002016 disaccharides Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 210000004347 intestinal mucosa Anatomy 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000003934 vacuole Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108010019160 Pancreatin Proteins 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000001079 digestive effect Effects 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000001630 jejunum Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 229940055695 pancreatin Drugs 0.000 description 6
- 230000002028 premature Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000011547 Bouin solution Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 230000005923 long-lasting effect Effects 0.000 description 5
- 210000005210 lymphoid organ Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 235000021055 solid food Nutrition 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000005367 Carboxypeptidases Human genes 0.000 description 4
- 108010006303 Carboxypeptidases Proteins 0.000 description 4
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108091016642 steapsin Proteins 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 238000008458 Glucose Oxidase Reagent Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- 102400000471 Isomaltase Human genes 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000001100 crypt cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000023011 digestive tract development Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000004204 exocrine pancreatic function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000004203 pancreatic function Effects 0.000 description 3
- 210000003134 paneth cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 230000007542 postnatal development Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 102100027674 CTD small phosphatase-like protein Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102100020855 Forkhead box protein E3 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 101000725950 Homo sapiens CTD small phosphatase-like protein Proteins 0.000 description 2
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
- 101000931489 Homo sapiens Forkhead box protein E3 Proteins 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 101000695522 Homo sapiens Synaptophysin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108700043492 SprD Proteins 0.000 description 2
- 102100028706 Synaptophysin Human genes 0.000 description 2
- 108010087472 Trehalase Proteins 0.000 description 2
- 102100029677 Trehalase Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000003892 absorptive cell Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000000742 appendix Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001815 ascending colon Anatomy 0.000 description 2
- 229950003616 azaperone Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 235000021045 dietary change Nutrition 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001861 endoscopic biopsy Methods 0.000 description 2
- 210000003158 enteroendocrine cell Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000006052 feed supplement Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940039412 ketalar Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001006 meconium Anatomy 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000013310 pig model Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000981399 Aspergillus melleus Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101710130006 Beta-glucanase Proteins 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710109676 Endo-1,3(4)-beta-glucanase 2 Proteins 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 102100027579 Forkhead box protein P4 Human genes 0.000 description 1
- 102100040136 Free fatty acid receptor 3 Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102100039544 Homeobox protein Hox-D10 Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 101000861403 Homo sapiens Forkhead box protein P4 Proteins 0.000 description 1
- 101000890662 Homo sapiens Free fatty acid receptor 3 Proteins 0.000 description 1
- 101000962573 Homo sapiens Homeobox protein Hox-D10 Proteins 0.000 description 1
- 101001082570 Homo sapiens Hypoxia-inducible factor 3-alpha Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 description 1
- 101001096074 Homo sapiens Regenerating islet-derived protein 4 Proteins 0.000 description 1
- 101000642676 Homo sapiens Syntaxin-2 Proteins 0.000 description 1
- 101000802356 Homo sapiens Tight junction protein ZO-1 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100030482 Hypoxia-inducible factor 3-alpha Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
- 229920002097 Lichenin Polymers 0.000 description 1
- 101710084369 Lipase 4 Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 1
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100034941 Protocadherin-7 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037889 Regenerating islet-derived protein 4 Human genes 0.000 description 1
- 108091006505 SLC26A2 Proteins 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 241000615724 Sucra Species 0.000 description 1
- 102100030113 Sulfate transporter Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100035936 Syntaxin-2 Human genes 0.000 description 1
- 241001136494 Talaromyces funiculosus Species 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- YERABYSOHUZTPQ-UHFFFAOYSA-P endo-1,4-beta-Xylanase Chemical compound C=1C=CC=CC=1C[N+](CC)(CC)CCCNC(C(C=1)=O)=CC(=O)C=1NCCC[N+](CC)(CC)CC1=CC=CC=C1 YERABYSOHUZTPQ-UHFFFAOYSA-P 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 108010002082 endometriosis protein-1 Proteins 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012478 homogenous sample Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940063149 nutropin Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003267 reducing disaccharides Chemical class 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention relates to the field of gastrointestinal function, particularly in a newborn. Particularly, the present invention relates to the maturation process of the gastrointestinal tract, such as the small intestine, induced by administration of a mixture of enzymes to a mammal such as a newborn.
- the gastrointestinal (Gl) tract in humans refers to the stomach and the intestine and sometimes to all the structures from the mouth to the anus.
- the upper gastrointestinal tract consists of the esophagus, stomach and duodenum. Some sources also include the mouth cavity and pharnyx. The exact demarcation between "upper” and “lower” can vary. Upon gross dissection, the duodenum may appear to be a unified organ, but it is often divided into two parts based upon function, arterial supply, or embryology.
- the integrated part of Gl tract is pancres and liver named the accessory organs of Gl tract.
- the lower gastrointestinal tract includes most of the small intestine and all of the large intestine. According to some sources, it also includes the anus.
- the intestine - or bowel - is divided into the small intestine and the large intestine.
- the small intestine has three parts: i) duodenum where the digestive juices from pancreas and liver mix together, ii) jejenum which is the midsection of the intestine, connecting duodenum to ileum and iii) ileum which has villi in where all soluble molecules are absorbed into the blood.
- the large intestine also has three parts: i) cacum where the vermiform appendix is attached to the cecum, ii) colon which consists of the ascending colon, transverse colon, descending colon and sigmoid flexure, and iii) rectum.
- the intestine has two main roles: digestion and absorption of nutrients, and maintenance of a barrier against the external environment. It also forms the largest endocrine organ in the body as well as the largest and most complex part of the immune system. In human adults the intestinal surface area is large, about 100 m 2 . This large area is continuously exposed to different antigens in the form of food constituents (the adult human encounter 12.5 kg of pure protein/year), normal intestinal microflora and pathogens.
- the intestinal mucosal surface is lined by a single layer of epithelial cells (IEC) which are continuously and rapidly replaced by replication of undifferentiated cells within the crypt
- the epithelial cell layer of the intestinal mucosa is very complex and unique. It secrets digestive enzymes from the apical part to lumen for food digestion. It also secretes different proteins from the second half to the lamina properia (LP).
- said epithelial cells are receiving signals from both the lumen (and then transmitting the information to the diverse populations of cells in the LP) and the basolateral side.
- the intestinal epithelial cells lECs
- lECs intestinal epithelial cells
- Signals on both sides are affected by their respective microenvironments, influencing the functional states, behaviours, and structures of enterocytes resulting in integrity and homeostasis of the gastrointestinal tract (5).
- Mammals are born with intestine that is not fully mature. Depending on the species, the complete maturation varies, but it is always achieved during the weaning period indicating that for the first couple of weeks all mammals haven an immature intestine. In rats, for example, the complete maturation coincides with the dietary shift from milk to solid food. Simultaneous with the onset of the maturation process, changes in the function and architecture of the epithelial cells in the intestine are seen as well as in the weight of the organs, the latter, of which is increasing in most mammals. Such functional and
- necrotizing enterocolitis is the most common gastrointestinal problem in the neonatal intensive care unit (NICU).
- NEC syndrome is characterized by rapid necrotic death of intestine, involving 75% or more of total length of jejunum, ileum and colon.
- Development of NEC relates to maturity of gastrointestinal tract and up to 90% of cases refer to preterm born babies. The more preterm the infant is, the higher risk for NEC, and unfortunately, no non-surgical treatment for this syndrome is officially reported . Therefore, N EC-related morbidity remains unchanged over the past 50 years.
- N EC enterocolitis
- P H A (phytohaemagglutinin), which has previously demonstrated effects on intestinal maturation, such as induction of mitosis, increase in cell membrane permeability and transport across a membrane, is a lectin found in plants, especially legumes.
- the substance has a number of physiological effects and is used in medical research. In high doses, however it is a toxin. As a toxin, it can cause poisoning.
- IL2 is an interleukin normally produced by the body during an immune response. IL-2 is also necessary during T cell development in the thymus for the maturation of subsets of T cells.
- One aspect of the present invention provides a method to induce maturation of an immature immature Gl-tract, such as intestine, e.g. small intestine, the method comprising the steps of
- the immature Gl-tract such as intestine, e.g. small intestine to monitor said maturation process.
- the immature Gl-tract such as intestine, e.g. small intestine is of mammalian origin, such as a cat, cow, horse, pig, rat, dog, mouse, or primate.
- immature Gl-tract such as intestine, e.g. small intestine is of human origin.
- the immature human Gl-tract such as intestine, e.g. small intestine, is of a newborn.
- the immature Gl-tract such as intestine, e.g. small intestine, is of an avian species.
- FIG. 1 Further embodiments are wherein at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the Gl-tract, such as intestine, e.g. small intestine, are analysed to monitor the maturation process, and wherein a change in at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the Gl-tract, such as intestine, e.g. small intestine, are indicative of intestinal maturation.
- Still further embodiments are wherein said intestinal enterocyte biomarkers in the maturation process analysed are enterocyte disaccharidase activity and where changes in disaccharidase activities from lactase activity to sucrase activity and maltase activity of enterocytes in the Gl-tract, such as intestine, e.g. small intestine, are indicative of Gl-tract, such as intestine, e.g. small intestine, maturation.
- changes in intestinal enterocyte morphology in the maturation process are changes from foetal-type intestinal enterocytes to adult type intestinal enterocytes, and wherein said changes in morphology are indicative of Gl-tract, such as intestine, e.g. small intestine, maturation process.
- Still further embodiments are wherein said weigh of parts of the Gl-tract, such as intestine, e.g. small intestine, analysed in the maturation process are changes of Gl-tract, such as intestine, e.g. small intestine, weigh and wherein an increase of Gl-tract, such as intestine, e.g. small intestine, weigh is indicative of the maturation process.
- mixture of enzymes is administered orally. Still even further embodiments are wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase.
- the enzyme mixture comprises the enzymes protease, lipase and amylase.
- the mixture of enzymes is a one enzyme mixture, i.e. comprising only one enzyme with pancreatic and/or pancreatic like action or activity.
- the mixture of enzyme comprises or consists of a protease.
- mixture of enzyme comprises or consists of a lipase.
- mixture of enzymes comprises or consists of an amylase.
- Still even further embodiments are wherein the amount of enzymes is about 25 000 - 500 000 Ph Eur /kg bodyweight and day of the enzyme lipase, about 600 - 20 000 Ph Eur /kg bodyweight and day of the enzyme protease, and about 14 000 to 600 000 Ph Eur /kg bodyweight and day of the enzyme amylase.
- Still further embodiments are wherein the maturation process takes about 3-10 days.
- FIG. 1 Further aspects of the invention are uses of a mixture of enzymes having pancreatic activity or action to induce maturation of an immature Gl-tract, such as intestine, e.g. small intestine
- FIG. 1 Further aspects of the invention are uses of a mixture of enzymes having pancreatic like action or activity to induce maturation of an immature Gl-tract, such as intestine, e.g. small intestine.
- the immature Gl-tract such as intestine, e.g. small intestine, is of a newborn.
- the immature Gl-tract such as intestine, e.g. small intestine
- the immature Gl-tract is of an avian species.
- Further aspects of the invention are a mixture of enzymes having pancreatic and/or pancreatic like action or activity for inducing maturation of an immature Gl-tract, such as intestine, e.g. small intestine.
- Further aspects of the invention provide a mixture of enzymes having pancreatic and/or pancreatic like action or activity for treatment of a disorder relating to an immature Gl- tract, such as intestine, e.g. small intestine.
- a disorder relating to an immature Gl- tract such as intestine, e.g. small intestine.
- said immature Gl-tract such as intestine, e.g. small intestine
- disorder is necrotizing enterocolitis.
- said disorder is a gut involution, disorder or a disfunction of a Gl-tract of an elderly subject.
- an immature gastrointestinal tract disorder such as an intestinal disorder e.g. small intestinal disorder.
- said immature gastrointestinal tract disorder such as an intestinal disorder e.g. small intestinal disorder is necrotizing enterocolitis.
- said disorder is a gut involution, disorder or a disfunction of a Gl-tract of an elderly subject.
- an immature gastrointestinal tract disorder such as an intestinal disorder e.g. small intestinal disorder
- inventions are wherein said disorder of an immature Gl-tract, such as intestine, e.g. small intestine, is necrotizing enterocolitis or a disfunction of a Gl-tract of an elderly subject. Further embodiments are wherein said patient in the need thereof is an infant or an elderly.
- Further embodiments is improved body growth by amylase of newborn and new hatched avians as well as older and aging mamals including humans and older avians.
- kits for inducing maturation of an Gl- tract such as intestine, e.g. small intestine
- said kit comprising a) a mixture of enzymes with pancreatic and/or pancreatic like action or activity to induce gastrointestinal tract, such as an intestinal e.g. small intestinal maturation,
- gastrointestinal tract such as an intestinal e.g. small intestinal maturation according to any of the methods disclosed herein.
- Figure 1 a-1 b shows in a) a schematic illustration of villi-crypt unit. Broken arrows show the direction of enterocyte replacement and in b) photomicrographs of H&E stained distal small intestinal sections, showing the enterocytes phenotype: fetal-type (left panel), 14 d- old suckling rat, and adult-type (right panel) 6 months-old rat.
- Figure 2a-c shows the results of photomicrographs of the distal part of rats intestine following the high dose of B. Creon, and C. Robavio treatment, respectively as compared to A. water control.
- Figure 3 shows the maturation degree of the epithelium in the distal part of rats' small intestine induced by different enzyme treatments. Results expressed as a mean ⁇ SD. Each treated group was compared to control using Student t-test. Significant results; P ⁇ 0.05O, P ⁇ 0.01 ( ** ), P ⁇ 0.001 ( *** ).
- Figure 4 shows photomicrograph of the H&E stained sections from the distal part of the rats' small intestine demonstrating the presence of the fetal-type enterocytes containing supranuclear vacuoles in control (A), lipase (B), and amylase (C) treated groups, while protease (D) and enzymes mixture (E) treated groups demonstrate mucosa with total replacement of enterocytes containing supra-nuclear vacuoles with adult-type epithelium.
- Figure 5 shows changes in brush-border enzyme activities for lactase (A), sucrase (B) and maltase (C) in the proximal part of the small intestine after administration of individual enzymes (amylase, lipase and protease) or their mixture to 14d old rat during 3 days. Results are expressed as mean ⁇ SD. Treated groups were compared to control using Student t-test. Significant differences; P ⁇ 0.05 ( * ), P ⁇ 0.01 ( ** )
- Figure 6 shows the effect individual enzyme administration: amylase, protease, lipase and their mixture (administered to the 14d old rats for 3 days), on the level of marker molecules absorption BIgG (A) and BSA (B) to the plasma in comparison to control.
- the results are given as mean ⁇ SD. Treated groups were compared to control using Student t-test. Significant results; P ⁇ 0.001 ( *** ).
- FIG. 7 shows the effects of different doses of protease on rat body weight gain during treatment (14, 15 and 16 days of age: Bwt1 , Bwt2, Bwt3, respectively) and 24 hours after last feeding (Bwt4). Results are expressed as mean ⁇ SD. Treated groups were compared to control using Student t-test. * P ⁇ 0.05
- Figure 9 shows the effect of high dose of protease (P 15 000USP) on body weight gain of rats during treatment, early and normal weaning up to 38 days of life in comparison to control groups. Results are expressed as mean ⁇ SD. Dotted bars are control, early weaning/EW, horizontally striped bars are control, normal weaning/NW, diagonally striped bars are Enzyme mixture, early weaning/EW, Black barrs are enzyme mixture, normal weaning/NW.
- Figure 10 shows the effect of microbial-derived enzymes with pancreatic activity: protease, lipase, amylase and their mixture on rat trypsin activity in the pancreatic homogenates after 3d of oral gavage to suckling 14d old rats. Treated groups were compared to control, * p ⁇ 0.05.
- Figure 13 shows results of activities of the brush-border enzymes lactase (13A), maltase (13B) and sucrase (13C) analyzed in the proximal part of the rats SI in groups treated with papain and protease. Results are expressed as mean ⁇ SD. * p ⁇ 0.05.
- Figure 14 shows the effect of microbial protease and fruit protease on the level of marker molecules absorption to the plasma in rats, after feeding them with cocktail of BSA (14B) and Big G (14A) on day 17, (at 3 hours before dissection). These data are given as mean ⁇ SD. Significant results; * p ⁇ 0.05; *** p ⁇ 0.001.
- Figure 16 shows the Crypt cell proliferation in the small intestine of suckling 14-15d old piglets after 1 week gavage treatment (twice a day) with preparation of enzymes having pancreatic-like activities of porcine and microbial origin. Groups were compared to control, * p ⁇ 0.05. Cont, control; LM, low dose mixture; HM, high dose mixture; LC, low dose Creon, HC, high dose Creon.
- Figure 17 shows weight of the the small intestine of suckling 1 4-1 5d old piglets after 1 week gavage treatment (twice a day) with preparation of enzymes having pancreatic-like activities of porcine and microbial origin.
- Cont control
- LM low dose mixture
- HM high dose mixture
- LC low dose Creon
- HC high dose Creon.
- Result demonstrate tendency of small intestine to increase its weight in dose- respond manner.
- Figure 19 shows effect of microbial-derived protease on bogy weight gain in % where striped bars show treated pigs and open bars show control.
- Figure 20 shows the effects of microbial enzyme on marker molecules absorption in pigs.
- Figure 21 shows the effect of protease on pancreatic function after 3 times administration, starting at 8d of life and every other day, the results represent material taken at 48h after last enzyme treatment (14d) and at weaning time (27d).
- Figure 21A shows pancreas weight, 21 B trypsin like activity. Black bars are enzyme treated and open bars are control.
- the "gastrointestinal (Gl) tract” is, when referring to humans, non-human mammals and avian species, intended to mean the stomach and the intestine and gut accessory organs, pancreas and liver, and sometimes to all the structures from the mouth to the anus.
- the upper gastrointestinal tract consists of the esophagus, stomach and duodenum. Some sources also include the mouth cavity and pharnyx. The exact demarcation between “upper” and “lower” can vary. Upon gross dissection, the duodenum may appear to be a unified organ, but it is often divided into two parts based upon function, arterial supply, or embryology.
- the lower gastrointestinal tract includes most of the small intestine and all of the large intestine.
- the intestine - or bowel - is divided into the small intestine and the large intestine.
- the small intestine has three parts: i) duodenum where the digestive juices from pancreas and liver mix together, ii) jejenum which is the midsection of the intestine, connecting duodenum to ileum and iii) ileum which has villi in where all soluble molecules are absorbed into the blood.
- the large intestine also has three parts: i) cacum where the vermiform appendix is attached to the cecum, ii) colon which consists of the ascending colon, transverse colon, descending colon and sigmoid flexure, and iii) rectum.
- the Gl tract in humans thus also include liver, pancreas, small and large intestine, if applicable to that particular species.
- Other mammals or avian species may have the same or different organs of the Gl-tract. Thus, the particular organs included in Gl-tract are species dependent.
- a "small intestine” is intended to mean the part of the " gastrointestinal part following the stomach and followed by the large intestine, and is where the vast majority of digestion and absorption of food takes place.
- the small intestine in an adult human measures on average about 5 meters (16 feet), with a normal range of 3 - 7 meters; it can measure around 50% longer at autopsy because of loss of smooth muscle tone after death. It is approximately 2.5-3 cm in diameter. Although the small intestine is much longer than the large intestine (typically around 3 times longer), it gets its name from its comparatively smaller diameter.
- the small intestine both for mammals and avian species, is divided into three structural parts, i) duodenum, ii) jejenum and iii) ileum.
- pancreatic like activity and/or “pancreatic like action” is intended to mean any enzyme activity having the same, equal or similar activity or action as pancreatic enzymes.
- Pant enzymes or “enzymes with pancreatic activity or action” are enzymes secreted by the pancreas. Examples of pancreatic enzymes or enzymes with pancreatic activity are given herein.
- subject is intended to mean any mammal including human having or suspected of having a disease, as well as a normal healthy subject. A “subject” includes a patient, such as a human patient having or suspected of having a disease.
- Subject as used herein also denotes a mammal, such as a rodent, e.g.
- a subject according to the invention is a human.
- a subject may also be of avian origin, such as a turkey, duck, hen, chicken or broiler.
- d refers to "day” or “days”.
- at least one is intended to mean one or more, i.e. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.
- infant is intended to mean a child or baby as the very young offspring of humans.
- a “newborn” or “neonate” is an infant who is within hours, days, or up to a few weeks from birth.
- a “newborn” or “neonate” also includes mammals of non-human species as well as avian species who is within hours, days, or up to a few weeks from birth.
- a “newborn” or “neonate” thus refers to an infant in the first 28 days of life (less than a month old) as well as mammals of non-human species in the first 28 days of life as well as avian species in the first 7 days of life.
- the term “newborn” includes premature infants, postmature infants and full term newborns.
- Detection includes qualitative and/or quantitative detection (measuring levels) with or without reference to a control, and further refers to the identification of the presence, absence, or quantity of a given substance, e.g. mRNA or protein or any other substance, or activity, such as e.g. any enzymatic activity.
- a given substance e.g. mRNA or protein or any other substance, or activity, such as e.g. any enzymatic activity.
- Healthy refers to a subject possessing good health. Such a subject demonstrates a normal Gl tract including the intestine, e.g. the small intestine, mature or immature, and is wherein the maturation process of the intestine proceeds normal.
- a "healthy individual” or “healty subject” is only healthy in that they have a normal intestinal maturation process, a “healthy individual” or “healthy subject” may have other diseases or conditions that would normally not be considered “healthy”.
- Treatment or “therapy” as used herein is defined as the attempted remediation of a health problem and includes e.g. management of a patient through medical or surgical means.
- treatment or therapy improves or alleviates at least one symptom of a medical condition or disease and is required to provide a cure.
- treatment outcome or “outcome of treatment” as used herein is the physical effect upon the patient of the treatment.
- treatment includes both therapeutic and prophylactic treatment of a subject or patient.
- prophylactic is used to encompass the use of an enzyme mix or formulation described herein which improves intestinal maturation or alleviates at least one symptom of a medical condition or disease due to absence of intestinal maturation in a mammal such as a subject or a patient.
- the enzyme mixtures or the enzyme alone described herein have utility in both the medical and veterinary fields.
- the enzyme mixture in all its embodiments herein may be used in the treatment of both human and non-human animals, such as horses, dogs, mice, rats, apes, monkeys, pigs, and cats.
- the patient is human, such as a newborn infant or neonatal.
- the enzyme mixtures described herein in all its embodiments are used in treatment of avian species, i.e. birds, e.g. in chickens or broilers of hens, ducks, turkeys etc.
- avian species i.e. birds, e.g. in chickens or broilers of hens, ducks, turkeys etc.
- researchers have induced and accelerated gut maturation by using exogenous factor like PHA.
- the present invention uses an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, to induce maturation of the Gl tract including the intestine, e.g. the small intestine.
- the present invention thus in one aspect relates to a method to induce and monitor maturation of an immature Gl tract including the intestine, e.g. the small intestine.
- Said method comprises the steps of a) administering a mixture of enzymes to the immature Gl-tract, said enzymes having a pancreatic activity or action, or pancreatic like activity or action,
- Said method may also in further embodiments include the step to prevent and monitor gut involution, disorders and dysfunctions at elderly by the steps a and b in the method to induce and monitor maturation of an immature Gl-tract.
- the enzyme mixture is described and exemplified further herein and all embodiments may be used in all the methods and uses herein.
- the above method may relate to any subject of mammalian species, such as human or non-human origin or avian Gl tract, e.g. the intestine, more particularly the small intestine, such as an intestine of a rat, mouse, rabbit, guinea pig or any other rodent, cat, cow, sheep, horse, or a pig. It may also be an intestine of an avian species such as a bird, a hen, turkey, or duck, or chicken or broilers thereof, or it may also be a human intestine, from an adult or a child or infant, or even a newborn infant, including a premature infant, postmature infants and full term newborns.
- mammalian species such as human or non-human origin or avian Gl tract
- the intestine more particularly the small intestine, such as an intestine of a rat, mouse, rabbit, guinea pig or any other rodent, cat, cow, sheep, horse, or a pig. It
- meconium Newborns' digestive tracts, which of course have never been used prior to birth, are filled with a greenish-black, sticky material called meconium. This has the function of standing in for fecal material and allows the intestines to develop to the point where they can process milk immediately on birth. This meconium material is passed by the child in the first few days. The digestive tract is, during suckling and breast feeding still considered as relatively immature compared to adults and the process of maturation is further induced normally during the weaning process.
- the immature Gl tract including the intestine e.g. the small intestine, is of mammalian origin.
- the immature Gl tract including the intestine e.g. the small intestine
- the immature human Gl tract including the intestine e.g. the small intestine is of an infant, such as e.g. a newborn infant, including a premature infants, postmature infants and full term newborns.
- the immature Gl-tract including the intestine e.g. the small intestine, is of avian origin.
- Characteristical changes in between the immature and mature intestine include i) structural changes of enterocytes from foetal type enterocytes to adult type enterocytes, ii) functional changes of enterocytes that includes a change in disaccharide activities from a predominant lactase activity in the immature mode to a sucrase and maltase activity in the adult mode, and iii) a change in weight, e.g. an increase, in organ weight, for example weight of the intestine, such as the small intestine, or the liver or pancreas.
- the functional change of the enterocytes may thus be used as biomarkers if the maturation process.
- Analysing the maturation process of the intestine to monitor said maturation process may thus be analysing at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the parts of the Gl-tract such as the intestine, e.g. small intestine, are analysed to monitor the maturation process in the methods given herein, and wherein a change in at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the organs of the Gl tract including the intestine, e.g. the small intestine, are indicative of gastrointestinal tract maturation, such as an intestinal e.g. small intestinal maturation.
- Analysing the maturation process may further include, apart from the above
- lactase activity to sucrase activity and maltase activity of enterocytes in the small intestine (IEC) are indicative of gastrointestinal tract maturation, such as an intestinal e.g. small intestinal, maturation.
- Various disaccharidases maltase, isomaltase, sucrase, and trehalase falls into this category and thus their developmental patterns are indirect contrast to that of lactase.
- Maltase has low activity during the first two postnatal weeks and then undergoes a 5- to 10-fold increase during the next two weeks. For sucrase, isomaltase, and threalase, the transition is even more sudden.
- Disaccharidase is a group of enzymes which are components of the brush border of the intestinal epithelium and which hydrolyze disaccharides to monosaccharides.
- the disaccaridase enzymes include but are not limited to lactase, maltase, sucrase, trehalase, isomaltase and galactosidase. Enteric infections may cause a temporary deficiency of lactase leading to the development of an osmotic-type diarrhoea. All disaccharidases are not present immediately following birth and feeding sucrose to young calves will result in diarrhoea. Assays to measure intestinal brush-border disaccharidase activity are known in the art.
- the method is especially advantageous for the determination of the hydrolysis of reducing disaccharides (see e.g. Dahlqvist, A. Method for Assay of intestinal disaccharidases. ASALYTICAL BIOCHEMISTRY 7, 18-25 (1964) and Dahlqvist, A, Assay of intestinal disaccharidases, Scand J Clin Lab Invest, 44, 169- 172, 1984 incorporated herein by reference) and may thus be used to measure
- Assays to analyse lactase activity are known in the art and include e.g. the assay of Dahlqvist and Asp (see e.g. Dahlqvist and Asp, Accurate assay of low intestinal lactase activity with a fluorometric method, Analytical Biochemistry, Vol 44, pg 654-657, Dahlqvist, A. Method for Assay of intestinal disaccharidases.
- Assays to analyse sucrase activity are known in the art and include the method described by Lee et al. (see e.g. Lee et al, A method for assaying intestinal brush-border sucrase in an intact intestinal preparation, PNAS March 3, 1998 vol. 95 no. 5 21 1 1 -21 16, Dahlqvist, A. Method for Assay of intestinal disaccharidases. ASALYTICAL BIOCHEMISTRY 7, 18- 25 (1964) and Dahlqvist, A, Assay of intestinal disaccharidases, Scand J Clin Lab Invest, 44, 169-172, 1984 all incorporated herein by reference) and may thus be used to measure sucrase activity in the methods given herein.
- Assays to analyse maltase activity are known in the art and include e.g. the assay by Dahlqvist, A. (see Assay of intestinal disaccharidases. Scand. J. clin. Lab. Invest. 44, 169-172.1984, incorporated herein by reference) which is a modified and updated description of the author's method for the assay of intestinal disaccharidases from 1963 (supra, both incorporated herein by reference) and may thus be used to measure maltase activity in the methods given herein.
- an intestinal homogenate is incubated with the appropriate disaccharide, such as a maltase.
- the disaccharidase e.g. maltase activity is then interrupted by the addition of TRIS, and the glucose liberated is measured with a glucose oxidase reagent, and compared to standard.
- Changes in intestinal enterocyte morphology in the maturation process may be changes from foetal-type intestinal enterocytes to adult type intestinal enterocytes. Said changes in morphology are thus indicative of intestinal maturation process in the methods given herein.
- the function of the small intestine is the digestion of food and absorption of nutrients.
- the small intestine consist of three parts: the upper duodenum attached to the pyloric end of the stomach, the jejunum, and the ileum.
- the duodenum contains the entrances of both the pancreatic and the bile ducts, but in the rat there is only one common pancreatic- biliary duct.
- the small intestine has a huge surface area formed by millions of finger-like extrusions - the villi and crypts, which are both covered by epithelial cells.
- the complex of specialized membrane extrusions found on the apical side of the enterocytes, the microvilli is usually referred to as the brush border.
- the crypt-villus complex is considered to be the functional unit of the small intestine - see fig 1 a and 1 b. In each intestinal crypt there is continuous cell proliferation, resulting in the production of new epithelial cells which migrate up along the villus and differentiate, simultaneously cells are shed from the top of the villi.
- cell turnover On the villous takes place every 2-5 days, depending on the species. In addition, in young mammals or infants, cell turnover occurs at lower rate in comparison to that in adult.
- enterocytes Absorptive cells
- goblet cells micus-secreting
- Paneth cells secreting antibacterial peptides and enzymes
- enteroendocrine cells secreting hormones
- the immature intestine shows a high permeability for milk- borne macromolecules, hormones and other factors.
- the transport of macromolecules follows two pathways: specific receptor-mediated and non-specific absorption.
- Specific trancytosis has been reported for immunoglobulins which bind to the neonatal Fc-receptor expressed by the enterocytes in the proximal small intestine, while non-specific absorption is the pathway for the uptake of other milk proteins.
- the fetal-type enterocytes found universally in the distal part of small intestine contain large supranuclear vacuoles and have a high absorptive capacity for macromolecules compared to adult mature intestine.
- the intestinal mucosa expresses high activities of the brush-border enzyme lactase principally in relation to the digestion of milk components, while maltase activity is low and that of sucrase cannot be detected.
- the suckling period passes gradually into the weaning period, when the intake of solid food increases and milk decreases.
- this process is characterized by rapid growth and vast structural and functional changes in the Gl tract.
- the crypt depth in the small intestine increases due to an increase in the cell proliferation, and the absorptive capacity of the small intestine enlarges due to epithelial hyperplasia.
- weight of the parts of the Gl tract including the intestine may be analysed in combination with the other markers of the maturation process given herein such as changes of weight of the parts of the Gl tract including the intestine, e.g. the small intestine and wherein an increase of intestinal weigh is indicative of the maturation process.
- a larger tissue specimen may also be obtained by using an endoscope (a flexible viewing tube), or by using a thin tube with a small cutting instrument at the end. The latter procedure, using the cutting instrument, is ordered when larger specimens than those provided by endoscopic biopsy are needed, because it allows removal of tissue from areas beyond the reach of an endoscope.
- biological sample encompasses a variety of sample types obtained from any parts of the small intestine of a mammal.
- a typical subject is a human infant or neonate; however, any mammal or avian species that has an intestine can serve as a source of a biological sample or biopsy.
- Exemplary biological samples and biopsies useful in the disclosed methods include but are not limited to biological samples disclosed herein such as e.g. solid tissue samples such as a biopsy specimen or tissue cultures or cells derived there from, and the progeny thereof.
- biological samples include cells obtained from a tissue sample collected from an individual suspected of having an immature Gl tract including the intestine, e.g.
- tissue samples encompass clinical samples, cells in culture, cell supernatants, cell lysates, and tissue samples, e.g. a transrectal biopsy or endoscopic biopsy.
- tissue samples e.g. a transrectal biopsy or endoscopic biopsy.
- a mercury-weighted bag is attached to one end of the capsule, while a thin polyethylene tube about 60 inches long is attached to the other end. Once the bag, capsule, and tube are in place in the small intestine, suction on the tube draws the tissue into the capsule and closes it, cutting off the piece of tissue within. This is an invasive procedure, but it causes little pain and complications are rare.
- the capsule and the tube are introduced, and the patient is asked to swallow as the tube is advanced.
- the patient is then placed on the right side and the instrument tip is advanced another 20 inches or so.
- the tube's position is checked by fluoroscopy or by instilling air through the tube and listening with a stethoscope for air to enter the stomach.
- the tube is advanced two to four inches at a time to pass the capsule through the stomach outlet (pylorus).
- fluoroscopy confirms that the capsule has passed the pylorus
- small samples of small intestine tissue are obtained by the instrument's cutting edge, after which the instrument and tube are withdrawn. The entire procedure may be completed in minutes.
- This procedure will provide tissue specimens from the small intestine through means of a tube inserted into the stomach through the mouth.
- the patient is to withhold food and fluids for at least eight hours before the test.
- the patient should not have anything to eat or drink until the topical anesthetic wears off (usually about one to two hours). If intravenous sedatives were administered during the procedure, the patient should not drive for the remainder of the day. Complications from this procedure are uncommon, but may occur.
- the patient is to note any abdominal pain or bleeding and report either immediately to the doctor. Complications from this procedure are rare, but can include bleeding (hemorrhage), bacterial infection with fever and pain, and bowel puncture (perforation). The patient should immediately report any abdominal pain or bleeding to the physician in charge.
- Biopsy is contraindicated in uncooperative patients, those taking aspirin or anticoagulants, and in those with uncontrolled bleeding disorders. Tissue biopsies are then analyzed for biomarkers and morphology on gross examination of the specimen(s) or under the microscope after tissue preparation. Further examples are small intestinal biopsies and/or autopsy tissues, or intestinal cell samples. Samples may be fresh or processed post-collection (e.g., for archiving purposes). In some examples, processed samples may be fixed (e.g., formalin-fixed) and/or wax- (e.g., paraffin-) embedded.
- Fixatives for mounted cell and tissue preparations are well known in the art and include, without limitation, 95% alcoholic Bouin's fixative; 95% alcohol fixative; B5 fixative, Bouin's fixative, formalin fixative, Karnovsky's fixative (glutaraldehyde), Hartman's fixative, Hollande's fixative, Orth's solution (dichromate fixative), and Zenker's fixative (see, e.g., Carson, Histotechology: A Self-Instructional Text, Chicago:ASCP Press, 1997).
- the sample or a fraction thereof
- the sample is present on a solid support.
- Solid supports useful in a disclosed method need only bear the biological sample/biopsy and, optionally, but advantageously, permit convenient detection of biomarkers or morphology of interest in the sample.
- Exemplary supports include microscope slides (e.g., glass microscope slides or plastic microscope slides), coverslips (e.g., glass coverslips or plastic coverslips), tissue culture dishes, multi-well plates, membranes (e.g., nitrocellulose or polyvinylidene fluoride (PVDF)) or BIACORE ® ; chips.
- analysis of biomarkers, such as proteins, mRNA or enzyme activity may be determined by immunohistochemistry which includes a scoring system, such as of mRNA, protein expression or enzyme activity which may optionally be used.
- the scoring may be semi-quantitative; for example, with mRNA or protein expression levels recorded as 0, 1 , 2, or 3 (including, in some instances plus (or minus) values at each level, e.g., 1 +, 2+, 3+) with 0 being substantially no detectable mRNA or protein expression and 3 (or 3+) being the highest detected protein expression.
- an increase or decrease in the corresponding protein expression is measured as a difference in the score as compared the applicable control (e.g.
- a score of 3+ in a test sample as compared to a score of 0 for the control represents increased mRNA or protein expression in the test sample
- a score of 0 in a test sample as compared to a score of 3+ for the control represents decreased mRNA or protein expression in the test sample
- Immunohistochemistry is one exemplary technique useful for detecting protein expression in the disclosed methods and uses.
- Antibodies e.g., monoclonal and/or polyclonal antibodies
- specific for each protein expression marker are used to detect the expression.
- the antibodies can be detected, as further described herein, by direct labelling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horseradish peroxidase or alkaline phosphatase.
- an indirect labelling is used where unlabeled primary antibody is used in conjunction with a labelled secondary antibody, comprising e.g.
- IHC protocols are well known in the art and are commercially available, see e.g. Antibodies: A Laboratory Manual, Harlow and Lane (Cold Spring Harbor Laboratoty press, Cold Spring Harbor, NY 1988) and Current Protocols in Immonology, and Current
- non-invasive methods may, of course, be used in any mammal such as the mammals exemplified herein or any other mammal. Further embodiments are wherein the mammal is a human, such as e.g. an adult or an infant or neonatal.
- Non-invasive methods Methods for analysing intestinal maturation by non-invasive methods are known in the art and examples of such methods include the methods developed by Chapkin et al. (Noninvasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells, Am. J.
- the method by Chapman et al. encompasses a non-invasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells.
- the method by Chapman is a molecular methodology whereby stool samples containing intact sloughed epithelial cells are used to quantify intestinal gene expression profiles in the developing human neonate and where particular gene sets are used as identifiers for the maturation process including structural and functional adaptation of the intestine as a response to feeding.
- Exfoliated cells are isolated of its mRNA by standard procedures, e.g. directly from faeces, which contain sloughed small intestinal and colon cells, and thus, does not result in any discomfort to the subject.
- faeces which contain sloughed small intestinal and colon cells
- Exfoliated cells are isolated of its mRNA by standard procedures, e.g. directly from faeces, which contain sloughed small intestinal and colon cells, and thus, does not result in any discomfort to the subject.
- a sterile spoon about 10g of freshly voided faecal stool specimens may be collected into a sterile 50 ml conical tube containing 20 ml of guanidinium denaturation solution (e.g. provided by AMbion, Austin, TX). Samples may then be mixed by hand to create a homogenous sample, which may be immediately frozen at -20 ° C until transported on ice for further analysis. Samples are held at -80 ° C and
- Poly-A mRNA may then be isolated according to any known method in the art, e.g.
- Arrays may be inspected for spot morphology. Marginal spots may be flagged as background spots (contaminated, irregularly shaped, or saturated) in the scanning software. Spots that passes the quality-control standards may, in the scanning software be categorized as good. In addition, a set L-value and reading thereof for "low” values, may indicate "near background", such as that low L-values may reflect true low gene expression levels or may have been caused by degradation of the mRNA. Further, for the purpose of normalisation, housekeeping genes may be used.
- suitable genes analysed by non-invasive methods are one-, two-, and three gene sets, such as e.g. one genes: EPAS1 , NR5A2, NR3C1 , PCDH7, ITGB2, FGF5, TJP1 , MYB, EPIM, BAD; and for two-gene sets: EPAS1 and UCP1 , CTDSPL and NR3C1 , NR3C1 and TNFRSF10B, FOXP4 and NR3C1 , CDK4 and EPAS1 , EPAS1 and SYP, NR3C1 and SLC26A2, GPR41 and TJPI , F0XP1 and NR3C1 , HSPAIA and NR3C1.
- one genes EPAS1 , NR5A2, NR3C1 , PCDH7, ITGB2, FGF5, TJP1 , MYB, EPIM, BAD
- EPAS1 and UCP1 CTDSPL and NR
- examples of three gene sets are EPAS1 , FOXE3, and SYP; CTDSPL, FOXE3 and NR3C1 ; EPAS1 , TLR5, and UCP2; EPAS1 , REG4, and UCP2; EPAS1 , LIFR, and UCP2; EPAS1 , NODAL, and UCP2; EPAS1 , HIF3A, and UCP2; EPAS1 , HOXD10, and UCP2; EPAS1 , KIT, and UCP2 as well as ALOX, EPAS1 , and UCP2 (see Chapkin et al., Table 2 in Non-invasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells, Am. J. Physiol Gastrointest Liver Physiol, 298: G582-G589, 2010, incorporated herein by reference).
- the mixture of enzymes or, as in some embodiments, comprising or consisting only of one of the enzymes such as an amylase or a protease may be administered orally, or via stomach if a tube is placed into the stomach, enterally, intraperitoneal or intravenous or any other route known in the art.
- the mixture of enzymes according to the invention comprises enzymes having a pancreatic activity or action or pancreatic like action or activity.
- the enzyme mixture and also in its most simple form comprising or consisting of only one of the enzymes, e.g. amylase or protease, may be used in all its embodiments in all methods and uses herein, as is evident from the appending examples and claims.
- the mixture of enzyme comprises or consist of at least one of a protease, a lipase or an amylase. It may further comprise protease and lipase, protease and amylase or lipase and amylase, or all three enzymes together in a mixture i.e. protease, lipase and amylase.
- the enzyme mixture comprises or consist of the enzymes protease, lipase and amylase.
- Commercial sources of enzyme mixtures with pancreatic activity or action, or pancreatic like activity or action include but are not limited to, Creon ® (Abbot, Inc., US).
- Enzymes may also be bought separately from commercial sources, as given herein, and mixed where appropriate.
- the enzymes may be of eukaryotic or prokaryotic origin, or may be made by recombinant means of expressing proteins.
- the pancreatic activity and pancreatic like action or activity is measured by measuring enzyme activity.
- Pancreatic enzymes are enzymes secreted by the panceras, the main digestive gland in our body. Pancreatic enzymes include, but are not limited to, trypsin, chymotrypsin, steapsin, carboxypeptidase, elastases, nucleases, pancreatic and amylase.
- Trypsin is a protease that breaks down proteins at the basic amino acids. Chymotrypsin is a protease that breaks down proteins at the aromatic amino acids. Steapsin degrades triglycerides into fatty acids and glycerol. Carboxypeptidase is a protease that takes off the terminal acid group from a protein. Elastases are a group of enzymes that degrade the protein elastin and some other proteins. Nucleases are a group of enzymes that degrade nucleic acids, like DNAase and RNAase. Pancreatic amylase that, besides starch and glycogen, degrades most other carbohydrates. Humans lack the enzyme to digest the carbohydrate cellulose.
- said mixtures may further comprise pancreatic enzymes, or, as in embodiments mentioned herein, wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase, e.g. only a protease, only an amylase or only a lipase as well in some embodiments. Even further embodiments are wherein the enzyme mixture comprises the enzymes protease, lipase and amylase.
- Said enzymes may be of mammalian origin, as in Creon ® , or be of any eukaryotic or prokaryotic origin, such as e.g. bacterial origin, fungal origin.
- said enzymes are of prokaryotic origin, such as bacterial or fungal, they possess the same, or similar, activity as mammalian, e.g. human, pancreatic enzymes and are herein referred to as enzymes with pancreatic like activity or action.
- a trypsin is a protease that breaks down proteins at the basic amino acids
- chymotrypsin is a protease that breaks down proteins at the aromatic amino acids
- steapsin degrades triglycerides into fatty acids and glycerol
- carboxypeptidase is a protease that takes off the terminal acid group from a protein
- elastases are a group of enzymes that degrade the protein elastin and some other protein
- nucleases are a group of enzymes that degrade nucleic acids, like DNAase and RNAase, pancreatic amylase that, besides starch and glycogen, degrades most other carbohydrates. Humans lack the enzyme to digest the carbohydrate cellulose.
- said mixture comprises enzymes with pancreatic activity or action, or pancreatic like activity or action, or, as in embodiments mentioned herein, wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase of eukaryotic or prokaryotic origin, or any microbiological origin, bacterial, fungal, or even recombinant origin.
- the enzyme mixture comprises the enzymes protease, lipase and amylase of eukaryotic or prokaryotic origin, or any microbiological origin, bacterial, fungal, or even recombinant origin.
- Enzymes like lipase, amylase, and protease are available commercially, from e.g. Novo Nordisk A/S (DK), Sigma and Amano Enzyme, Inc., Nagoya, Japan. Still even further embodiments are wherein the amount of enzymes is about 12 000 - 120 000 Ph Eur (equals USP) /kg bodyweight and day of lipase; 608 - 6 080 Ph Eur (38 000 - 380 000 USP) of protease /kg bodyweight and day, or amylase 14 458 - 144 580 Ph Eur (60 000 - 600 000 USP) /kg bodyweight and day of at least one of the enzymes.
- One embodiment comprises all the three enzymes, i.e. lipase, protease, and amylase.
- twice as much, three times as much or even four times as much are given as a daily dose of at least one of the enzymes i.e. about 25 000, 50 000, 100 000, 150 000, 200 000, 300 000, 400 000 or even 500 000 Ph Eur (equals USP) /kg bodyweight and day of lipase, 600, 1 200, 2 000, 2 500, 6 000, 12 000, 20 000, or even, 10 000 Ph Eur, e.g. 40 000, 80 000, 120 000, 160 000 US U) of protease /kg bodyweight and day, or 14 000, 28 000, 42 000, 56 000 - 150 000, 300 000, 450 000, or even 600 000 Ph Eur, e.g. 60 000, 120 000, 180 000, 240 000, - 600 000, 1 200 000, 1 800 000, or even 2 400 000 USP) of amylase.
- the enzymes i.e. about 25 000, 50 000, 100 000, 150 000, 200 000, 300 000, 400 000 or even 500 000
- pancreatic activity or action may be measured by standard methods known in the art for enzyme activity of e.g. trypsin, chymotrypsin, steapsin, carboxypeptidase, elastases, nucleases, pancreatic and amylase. Examples of suitable assays are given herein. In brief, the following enzymatic assays for measuring enzyme activity may be used;
- a Lipase Olive Oil assay may be used: The lipase samples may be assessed for activity against olive oil at pH 7.7 using slight modifications to the procedure described by Ruyssen and Lauwers. The lipase activity is determined by titrating the released fatty acids from olive oil against sodium hydroxide. The assay may be automated using a Radiometer pH-Stat titrator (TitralabTM). Activity units are defined as microequivalents (mEq) of NaOH required per min to maintain a constant pH of 7.7. Fatty acids released during the assay by lipase hydrolysis of triglycerides are titrated by NaOH.
- mEq microequivalents
- the mEq of NaOH represent the mEq of fatty acid hydrogen liberated.
- the initial rate is equivalent to base consumption in mL/min.
- the specific activity ⁇ moles/min/mg protein) initial rate x 1000 x concentration of the titrant/amount of enzyme.
- the ratio of activity units of the Olive Oil Assay: USP assay is ca. 1.75.
- the lipase activity may be determined by USP Assay for Lipase determined by titrating the released fatty acids from olive oil against sodium hydroxide as described by U.S. Pharmacopeia (Assay for lipase activity in Pancreatin, USP 24).
- the lipase activity in USP units are calculated by comparison to the activity of the standard, using the lipase activity stated on the label of USP Pancreatin Lipase RS.
- the activity of proteases may be determined by an USP Assay for Protease determined by using casein as a substrate as described by U.S. Pharmacopeia (Assay for protease activity in Pancreatin, USP 24).
- the protease activity in USP units may be calculated by comparison to the activity of the standard, using the protease activity stated on the label of USP Pancreatin Amylase and Protease RS.
- the activity of amylases may be estimated using starch as substrate as described by U.S.
- Pharmacopeia Assay for amylase activity in Pancreatin, USP 24.
- the amylase activity in USP units was calculated by comparison to the activity of the standard, using the amylase activity stated on the label of USP Pancreatin Amylase and Protease RS.
- Gl tract and related organs Development and maturation of the Gl tract and related organs is different between species during the fetal period. It mostly depends on the gestational period. If a species has a longer gestational period, they have a more mature Gl tract at the birth.
- the infant starts to use maternal milk as the only source of nutrition.
- replacement of milk high fat and low carbohydrate diet
- solid food low fat and high carbohydrate diet
- Protein level before and after weaning is in principle the same.
- Genetic background, body size, age, hormones secreted from intestine and other parts of the body i.e. insulin, corticoesterone
- milk-born hormones and as endogenous factors and diet, microflora as exogenous sources are the main factors that affect Gl tract development during the postnatal period.
- Rats are well studied in their development and for many studies could be used as a model.
- the main changes in the Gl tract are visible after 3 weeks of life. These changes include morphological changes, epithelial cell kinetic changes, mucosal enzyme activity and transport function changes.
- Increase in the number of chief cells and decrease in the number of parietal cells are signs of maturation in the stomach.
- Increase in the number of chief cells makes the glandular part of stomach thicker (the mucosal epithelium is thinner during early age).
- the secretion of pepsin, after a few days of the birth is 1.5 times higher than in adults.
- the pH of the stomach is higher in the neonates compared to that in the adults and decreases with time. Gastrin levels are low till day 18.
- the stomach does not secrete pepsin so the milk proteins are not broken down but are absorbed directly from the intestine intact.
- VFE Vacuolated fetal type enterocytes
- Enterocyte cells divide a few more times along the villi and change to become absorptive cells.
- Vacuolated fetal type enterocytes are created in the distal part of the small intestine and then diffuse to the lower part into the jejunum and ileum.
- VFEs are located along the villi (mostly on the tip of the villi) and have two main functions. These cells transfer colostral and milk protein from the lumen of the intestine into the circulation and also have a digestive function.
- VFEs in the duodenum exist only during birth time. In the proximal part of the jejunum they remain for 3 or 4 days and then disappear.
- VFEs In the middle and distal section of the jejunum VFEs stay longer, until 14 days of age, and then fade away. During the weaning period, VFEs disappear from jejunum and ileum. The mature enterocytes have no large supranuclear vacuoles and have different pattern in function.
- the main carbohydrate during the suckling is lactose but in the weaning period the diet changes to a rich source of sucrose and maltose.
- brush-border disaccharidases lactase, maltase, and sucrase in respective periods
- the activity and secretion of brush border enzymes changes such that the secretion of lactase decreases and the activity of maltase and sucrase increased.
- rat pups has open intestine up to 20 days after birth. It means that macromolecules can be absorbed intact to the general circulation via specific FcRn receptor, e.g. maternal IgG, or unspecificaly, e.g. epidermal growth factor. Decreasing of intestinal permeability for macromolecules is one of several markers for intestinal maturation during development.
- NEC Necrotizing enterocolitis
- exogenous enzyme preparation with pancreatic like activities e.g. Creon and microbial enzymes preparation showed a positive and promoting effects on gut maturation and development. This phenomenon is probably possible since animals during suckling period produce a lot of endogenous enzyme inhibitors, thus effect of enzymes can be limited.
- the trypsin inhibitors are probably most important since active trypsin is activator of all other pro-enzymes.
- three experimental sets were designed and performed in suckling rat model.
- the maturation process depends on species and other factors. Normally, the process of maturation after induction takes 1 -10 days, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9, or even 10 days.
- the maturation process takes about 3-10 days, in another embodiment 3-9, 3-8, 3-7, 3-6, 3- 5 or 3-4 days, or 3, 4, 5, 6, 7, 8, 9, or 10 days. In one embodiment, the maturation process takes about 3 days.
- a further aspect of the invention is the use of a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, to induce maturation of an immature Gl tract including the intestine, e.g. the small intestine.
- the immature Gl tract including the intestine e.g. the small intestine is of a new-born infant of a mammal, such as exemplified herein, e.g. a human, rat or pig, or, a human infant such as a new-born human infant. It may also be an immature Gl-tract of a non-mammal, such as from an avian species e.g. a chicken, broiler, turkey or hen.
- an avian species e.g. a chicken, broiler, turkey or hen.
- the enzyme mix may, depending on circumstances, comprise at least one of the enzymes with pancreatic activity or action, or pancreatic like activity or action, e.g. at least one of a protease, a lipase of an amylase.
- Said mixtures may also be of a lipase or an amylase or a protease, or a protease and a lipase, or a protease and an amylase, or a lipase and an amylase, or a protease, an amylase and a lipase.
- said enzyme mixture comprises at least two enzymes, such as a protease and a lipase; a protease and an amylase; a lipase and amylase.
- the enzyme mixture according to the invention comprises three enzymes, such as a protease, an amylase and a lipase. In one embodiment, it is only a protease of the above enzymes in said mixture.
- further aspects of the invention encompass a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, for inducing maturation of an immature Gl tract including the intestine, e.g.
- a further aspect of the invention is a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, for treatment of an immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder.
- an immature Gl-tract disorder e.g. intestinal disorder, such as a small intestinal disorder.
- said immature Gl-tract disorder e.g. intestinal disorder, such as a small intestinal disorder is necrotizing enterocolitis.
- necrotizing enterocolitis is a medical condition primarily seen in premature infants where portions of the bowel undergo necrosis (tissue death). The condition is typically seen in premature infants, and the timing of its onset is generally inversely proportional to the gestational age of the baby at birth, i.e. the earlier a baby is born, the later signs of NEC are typically seen.
- Initial symptoms include feeding intolerance, increased gastric residuals, abdominal distension and bloody stools.
- Symptoms may progress rapidly to abdominal discoloration with intestinal perforation and peritonitis and systemic hypotension requiring intensive medical support.
- Even further aspects of the invention are use of a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, for the preparation of a medicament for treatment of an immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder, e.g. wherein said immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder is necrotizing enterocolitis.
- an immature Gl-tract disorder e.g. intestinal disorder, such as a small intestinal disorder
- an immature Gl-tract disorder e.g. intestinal disorder
- a small intestinal disorder such as a small intestinal disorder is necrotizing enterocolitis.
- one further aspect is a method of treating an individual or subject or patient, all of which may be a newborn, with an immature Gl-tract disorder,
- intestinal disorder such as a small intestinal disorder
- said method comprising the steps of administering to a patient in the need thereof an effective amount of a mixture of enzymes with pancreatic activity or action, or pancreatic like activity or action, to induce Gl-tract, e.g. intestinal, such as a small intestinal maturation, e.g., wherein said disorder of an immature Gl-tract, e.g. intestinal, such as a small intestinal, is necrotizing enterocolitis.
- a further aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, as disclosed herein and a pharmaceutically acceptable excipient, diluent or carrier.
- pharmaceutical composition means a therapeutically effective formulation.
- a “therapeutically effective amount”, or “effective amount”, or “therapeutically effective”, as used herein, refers to that amount which provides a therapeutic effect for a given condition and administration regimen; for example, an amount sufficient to induce maturation of the Gl tract including the intestine, e.g. the small intestine.
- This is a predetermined quantity of active material calculated to produce a desired therapeutic effect in association with the required additive and diluent, i.e. a carrier or administration vehicle.
- a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in a host.
- the amount of a compound may vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of active composition calculated to produce the desired therapeutic effect in association with the required diluent.
- a therapeutically effective amount of the active component is provided.
- a therapeutically effective amount can be determined by the ordinary skilled medical or veterinary worker based on patient characteristics, such as age, weight, sex, condition, complications, other diseases, etc., as is well known in the art. It will be appreciated by persons skilled in the art that such an effective amount of the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, or formulation thereof may be delivered as a single bolus dose (i.e. acute administration) or, 5 more preferably, as a series of doses over time (i.e. chronic administration).
- the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, for use in the methods, kits and uses of the invention may be administered in combination with one or more other 10 conventional agents for the treatment of immature gastrointestinal tract, e.g. intestine, such as small intestine.
- suitable conventional agents include, but are not limited to, PHA, and/or IL2.
- the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, according to the invention may be formulated at various concentrations, depending on the efficacy and toxicity.
- the amount of enzymes is about 12 000 - 120 000 Ph Eur (equals US U) /kg bodyweight and day of lipase, 608 - 6 080 Ph Eur (38 000 - 380 000 US U) of protease /kg bodyweight and day or amylase 14 458 -
- a protease or an amylase or a lipase. In one embodiment, it is only a protease.
- One embodiment comprises all the three enzymes, i.e. lipase, protease, and amylase. Further embodiments comprise at least two of the enzymes, such as a protease and a lipase, or a protease and an amylase, and an amylase and a lipase.
- twice as much, three times as much or even four times as much are given as a daily dose of at least one of the enzymes i.e. about 25 000, 50 000, 100 000, 150 000, 200 000, 300 000, 400 000 or even 500 000 Ph Eur (equals US U) /kg bodyweight and day of lipase, 600, 1 200, 2 000, 2 500, 6 000, 12 000, 20 000, or even, 30 10 000 Ph Eur, e.g. 40 000, 80 000, 120 000, 160 000 US U) of protease /kg bodyweight and day, or 14 000, 28 000, 42 000, 56 000 - 150 000, 300 000, 450 000, or even 600 000 Ph Eur, e.g. 60 000, 120 000, 180 000, 240 000, - 600 000, 1 200 000, 1 800 000, or even 2 400 000 US U) of amylase.
- formulations may comprise a lower concentration of a compound of the invention.
- a pharmaceutical formulation comprising an amount of enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, effective to treat a condition of an immature Gl tract including the intestine, e.g. the small intestine, e.g. NEC (as described above).
- the medicaments and agents will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice (for example, see Remington: The Science and Practice of Phamtacy, 1 9 edit ion, 1995, Ed. Alfonso Gennaro, Mack Publishng Company,
- the medicaments and agents can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or
- suspensions which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release applications.
- flavouring or colouring agents for immediate-, delayed- or controlled-release applications.
- the medicaments and agents may also be used as flavouring or colouring agents, for immediate-, delayed- or controlled-release applications.
- Tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (for example, corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as
- polyvinylpyrrolidone hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
- Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
- Exemplary excipients in this regard include lactose, starch, cellulose, milk sugar or high molecular weight polyethylene glycols.
- the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
- the medicaments and agents can also be administered parenterally, for example, intravenously, intra-articularly, intra-arterially, intraperitoneally, intrathecally,
- aqueous solutions should be suitably buffered (for example, to a pH of from 3 to 9), if necessary.
- suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
- Formulations suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- the daily dosage level of the medicaments and agents will usually be as exemplified herein administered in single or divided doses.
- an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action will depend on the type of disease to be treated, the severity and of course of the disease, whether the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, is administered for preventative or therapeutic purposes, the course of previous therapy and the patient's clinical history and response to the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action according to the present invention is suitably administered to the patient at one time or over a series of treatments depending on the type and severity of the disease. Administration may be, for example, by one or more separate administrations, or by continuous infusion. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression or alleviation of the disease symptoms occurs, and a desired Gl-tract, e.g. intestinal, such as a small intestinal, maturation.
- a desired Gl-tract e.g. intestinal, such as a small intestinal, maturation.
- the enzyme mixture, medicaments and agents can also be administered intranasal or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoro-methane,
- a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoro-methane
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the pressurized container, pump, spray or nebulizer may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g.
- Capsules and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
- Aerosol or dry powder formulations may be arranged so that each metered dose or puff contains at least 1 mg of a compound of the invention for delivery to the patient. It will be appreciated that the overall daily dose with an aerosol will vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
- sustained-release drug delivery system such as a microsphere. These are designed specifically to reduce the frequency of injections.
- An example of such a system is Nutropin Depot which encapsulates recombinant human growth hormone (rhGH) in biodegradable microspheres that, once injected, release rhGH slowly over a sustained period.
- rhGH human growth hormone
- This system may thus be useful as a slow release for delivering at least one enzyme composition according to the invention, alone or in a mixture.
- Sustained-release enzyme compositions also include liposomally entrapped enzymes. Liposomes containing the enzymes are prepared by methods known per se. See, for example Epstein et al., Proc. Natl.
- the liposomes are of the small (about 200 to about 800 Angstroms), unilamellar type in which the lipid content is greater than about 30 mole percent (mol. %) cholesterol; the selected proportion being adjusted for the optimal enzyme therapy.
- polypeptide medicaments and agents can be administered by a surgically implanted device that releases the drug directly to the required site.
- thermosensitive ReGel injectable An alternative method of enzyme delivery is the thermosensitive ReGel injectable. Below body temperature, ReGel is an injectable liquid while at body temperature it immediately forms a gel reservoir that slowly erodes and dissolves into known, safe, biodegradable polymers or enzyme. The active drug or enzyme is delivered over time as the biopolymers dissolve.
- Enzyme mixture with pancreatic activity or action, or pancreatic like activity or action as described herein in all its embodiments, can also be delivered orally.
- Such a system employs a natural process for oral uptake.
- kits for inducing maturation of a Gl tract including the intestine and accessory organs, e.g. the small intestine and pancreas, or being a kit to improve body weight gain, said kit comprising a) a mixture of enzymes with pancreatic activity or action, or
- pancreatic like activity or action to induce Gl tract maturation, e.g. intestinal maturation, or to improve body weight gain
- a kit includes positive or negative controls and control samples, such as a cell line or tissue known to be mature or immature samples or tissues of intestine of species to be analysed, such as a mammal, e.g. a human new-born, or an avian species such as a bird, e.g. a turkey, duck, hen, chicken or broiler thereof.
- positive or negative controls and control samples such as a cell line or tissue known to be mature or immature samples or tissues of intestine of species to be analysed, such as a mammal, e.g. a human new-born, or an avian species such as a bird, e.g. a turkey, duck, hen, chicken or broiler thereof.
- a kit includes instructional materials disclosing, for example, means of use of the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, for induction of Gl-tract, e.g. intestinal, such as a small intestinal maturation according to the detection means, or means of use for a particular reagent.
- the instructional materials may be written, in an electronic form (e.g., computer diskette or compact disk) or may be visual (e.g., video files).
- the kits may also include additional components to facilitate the particular application for which the kit is designed.
- the kit can include buffers and other reagents routinely used for the practice of a particular disclosed method. Such kits and appropriate contents are well known to those of skill in the art.
- the kit may further comprise, in an amount sufficient for at least one assay, the enzyme mixture described herein to as a separately packaged reagent, as well as separate instructions for its use to induce Gl-tract, e.g. intestinal, such as a small intestinal, maturation. Instructions for use of the packaged reagent are also typically included. Such instructions typically include a tangible expression describing reagent concentrations and/or at least one assay method parameter such as the relative amounts of reagent and sample to be mixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like.
- kit embodiments can include a carrier means, such as a box, a bag, a satchel, plastic carton (such as moulded plastic or other clear packaging), wrapper (such as, a sealed or sealable plastic, paper, or metallic wrapper), or other container.
- kit components will be enclosed in a single packaging unit, such as a box or other container, which packaging unit may have compartments into which one or more components of the kit can be placed.
- a kit includes a one or more containers, for instance vials, tubes, and the like that can retain, for example, one or more biological samples to be tested.
- kit embodiments include, for instance, syringes, cotton swabs, or latex gloves, which may be useful for handling, collecting and/or processing a biological sample. Kits may also optionally contain implements useful for moving a biological sample from one location to another, including, for example, droppers, syringes, and the like. Still other kit embodiments may include disposal means for discarding used or no longer needed items (such as subject samples, etc.). Such disposal means can include, without limitation, containers that are capable of containing leakage from discarded materials, such as plastic, metal or other impermeable bags, boxes or containers. Anti-aging effect
- Enzyme mixture with pancreatic activity or action, or pancreatic like activity or action in all its embodiments described herein may according to the invention also be used to feed an elderly population of most species, e.g. subjects defined herein, to prevent or limit aging of the gastro-intestinal tract.
- the present invention thus provides an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action for use in preventing, postponing, limiting, reducing aging of the Gl-tract in a subject. It may thus further be used for treating aging as an anti-aging composition or mixture.
- an anti-aging effect means to postpone, limit, reduce, reverse or even prevent aging of the Gl-tract.
- the enzyme mixtures described herein in all its embodiments may be used in an anti-aging composition or formulation as f.ex. a food, a feed supplement or a medicament for preventing aging of the Gl-tract, or preventing gut involution, disorders and dis- functions of elderly.
- the mixture of enzyme comprises at least one of protease, lipase and amylase. It may further comprise protease and lipase, protease and amylase or lipase and amylase, or all three enzymes together in a mixture i.e. protease, lipase and amylase.
- the enzyme mixture described herein in all its embodiments, may be used for the manufacture of a medicament, food- or feed-supplement for treating or preventing aging of the Gl-tract.
- the enzyme mixture provided herein may further be used in postpone, limit, reduce, reverse or even prevent aging of the Gl-tract, or to prevent gut involution, disorders and disfunctions.
- the enzyme mixture provided herein may further be used in a specific embodiment comprising amylase.
- Amylase stimulates growth, i.e. improvement of body weight gain, as seen in e.g. figure 1 1 , but less or no maturation.
- Proteases however are excellent stimulators of maturation of the Gl-tract, but stimulates growth or improvement of body weight gain less (see e.g. figure 7 and 4).
- one aspect of the invention provides a mixture of enzymes comprising amylase to stimulate growth, i.e. increase in body weight or improvement of body weight gain.
- a further aspect provides a mixture of enzymes comprising both an amylase and a protease, as described in further embodiments herein, stimulating both growth, i.e. gain in body weight or improvement of body weight gain as well as maturation of an immature Gl- tract, or even preventing gut involution, disorders and disfunction of a Gl-tract of an elderly subject.
- a use of a mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action to induce an increase in body- weight or improve body weight gain in a subject.
- Further aspects are use of a mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action for the preparation of a medicament for increasing body-weight or improving body weight gain in a subject.
- the uses to increase or improve body-weight gain are wherein the mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity are according to any of the embodiments of the enzyme mixtures as described herein.
- mixture of enzyme comprises or consists of amylase. Examples of doses of amylase and other enzymes are mentioned elswhere herein and may also be used for improving body weight gain.
- compositions, mixture or formulation mentioned herein in all its embodiments may be used together with an acceptable carrier and/or diluent, which may be pharmaceutically acceptable, salts and other nutrients if appropriate.
- RovabioTM e.g. RovabioTM Excel AP
- RovabioTM Excel AP is a concentrated powder whose main enzymatic activities are xylanase and ⁇ -glucanase obtained from a fermentation broth of Penicillium funiculosum.
- RovabioTM Excel AP product hydrolyses pentosans and ⁇ -glucans in vegetable raw materials. Thus, RovabioTM does not possess any pancreatic or pancreatic like activity.
- Assays for measuring endo-1 ,4-3-xylanase activity are based on the enzymatic hydrolysis of a standard wheat arabinoxylan solution, the activity being determined by the reduction in relative viscosity (viscometer developed by Orange Leaf Company), or by measuring absorbance at 590 nm that enables endo-1 ,4-3-xylanase activity to be determined by a colorimetric method with a chromophore substratum
- Assays for endo-1 ,3(4)-3-glucanase activity includes measuring absorbance at 590 nm that enables endo-1 ,3(4)-3-glucanase activity to be determined by a colorimetric method with a chromophore substratum.
- Assays for cellulase (endo 1 ,4-3-glucanase) activity include the reaction, catalysed by cellulase, involving the endohydrolysis of the 1 ,4-3-D-glucosidic bonds in cellulose (lichenin and cereal ⁇ -D-glucans) forming ⁇ -1 ,4 glucan oligosaccharides. Assays are available form e.g. Adisseo (France).
- Creon ® have shown some effects on disaccharidases activities, as there was significant increase in sucrase and maltase activity, while these changes were not observed in the case of Rovabio ® .
- the higher sucrase and maltase expression in the intestine of rats indicates the presence of a higher number of mature enterocytes in it.
- Creon ® animal origin
- nonpancreatic like enzyme preparation yielded no effects on intestine weight, disaccharidesases nor on the development of enterocytes to mature phenotypes, supporting the ability or possibility of pancreatic enzymes to induce maturation which is safer than other materials like PHA, opening a door for a new generation of therapies for treatment of immature intestine.
- Creon ® Although the effects of Creon ® on the digestive system are similar, responses of the immune system to each differs. There were slightly decreased and increased immune cell expansions with Creon ® . It was noted that both CD25 and CD45 marker shrunk and expanded together within both enzymes.
- pancreatic enzymes were shown to be quite effective in preventing food allergies, due to its roles in food digestion and the breaking up of food antigens into small fragments, preventing sensitivity of intestinal epithelial cells to many intact antigens, furthermore, individuals who do not produce enough pancreatic enzymes will typically suffer from multiple allergies and, and for this reason pancreatic enzymes have been used as anti-inflammatory materials.
- Creon ® can decrease the sensitivity of cell to luminal antigens which could be decreased some inflammatory mediators leading to decrease of immune cells in LP later on, as with Creon ® .
- Celocoxib ® the reason why there was little action with Celocoxib ® could be due to its dose, which was the minimum allowed dose administered once daily while the recommended dose (loaded dose) was four times more than what was used, and administered twice daily.
- Animal model This study was performed on rats ⁇ Rattus norvegicus) of Sprague-Dawley stock (Mol:SPRD Han; Taconic M&B A/S, Ry, Denmark) conventionally bred in the Departmental animal unit in a controlled environment with a temperature of about 20 ⁇ 1 °C, with a relative humidity of 50 ⁇ 10% and a dark-light cycle of 12:12h. Dams with their litters housed individually in a polycarbonate cage on chopped aspen wood bedding with free access to water and chow from a lid feed hoper. Experimental procedures: In both of the following experiments 14-d-old pups were weighed and divided into groups and further to subgroups depending on the aim of each experiment.
- Pups were fed intragastrically via a feeding tube (0.96mm outer diameter, PE50, Becton Dickinson, Sparks, MD, USA), in a volume 0.01 mL/g b.wt.
- the dose(s) for each pup was repeated once daily in corresponding manner for three days (14, 15, 16-d- old).
- Protein estimation The protein contents were determined by the method of Lowry et al (Lowry OH, Rosebrough NJ, Farr AL & Randall RJ Protein measurement with the Folin phenol reagent, J Biol Chem ; 1951 : 193, 265-275.), modified for 96- well microplates as described in Pierzynowsk et al (Pierzynowsk SG, Westrom BR, Svendsen J & Karlsson BW. Development of exocrine pancreas function in chronically cannulated pigs during 1- 13 weeks of postnatal life. J Pediatr Gastroenterol Nutr 1990;10:206-212), and using serial dilutions of BSA (Sigma chemicals) as a standard.
- Histology and morphomertry All the samples from the distal SI were embedded into paraffin, cut laterally into 5mm thick sections, deparaffinated, and stained with hematoxylin and eosin according to standard procedures. All the samples were then imaged by using an Olympus PROVIS microscope (objective x10) utilizing an Olympus DP50 camera (Olympus, Tokyo, Japan). Morphomertic analysis by measuring the ratio of the length of the adult-like epithelium to whole villi length was done by using ImageJ 1 .36 program (National Institute of Health, Bethesda, MD).
- Immunohistochemistry Staining of immune cells: All samples from distal part were embedded, cut, deparaffinated, followed by incubation in PBS pH 7.2 containing 0.5% peroxidise, washed in PBS (pH 7.2), and incubated overnight at 4°C with specific primary Abs. It was rabbit polyclonal Ab against rat CD45 (diluted 1 :50) and mouse Ab against rat CD25 (diluted in1 :50), markers expressed on all leukocytes and effector T cells respectively (3).
- CD45 Ab and CD25 Ab were used as the substrate.
- complex of 3,3-diaminobenzidine tetrahydrochloride Sigma Chemicals
- the pups in each litter were divided into three groups: One group received a dose of one enzyme mix (see below) and was referred to as high dose, while the second group received a dose five times lower than the first group and was referred to as low dose while the last group received DW (distilled water) and this group is referred to as control.
- the first group fed with Creon ® (Abbotte, Germany) in doses of 1.5 and 0.3 mg/g b.wt (body weight) for high and low dose respectively, diluted in a DW with final volume of 0.01 mL/g b.wt for both.
- the second group were treated with Rovabio (Adisseo, France) respectively.
- the dose was 0.5 and 0.1 mg/g b.wt for high and low doses respectively, diluted in DW giving final volume of 0.01 mL/g b.wt for both.
- the third group was treated with microbial-derived enzyme mixture in high dose 0.7 mg/ g b.wt. and low dose as 0.14 mg/g b.wt., in volume 0.01 mL/g b.wt.
- the control group of the above litters received the same volume of DW (0.01 mL/g b.wt).
- Each enzyme preparation contains such composition of enzymes with corresponding activities: 150mg of Creon capsule (lipase 10 000USP, potease 37 500USP, amylase 33 200USP); 100mg of microbial enzyme mixture powder (lipase 17 600USP, protease 12 500USP, amylase 1 875USP) and for 1 g of Rovabio Exel AP(endo-1 ,4-beta-xylanase 22 000 visco units and endo-1 ,3(4)-beta-glucanase 2 000 AGL units (explanation: 1 visco unit of endo-1 ,4-3-xylanase is defined as the amount of enzyme which will hydrolyze the substrate, reducing the viscosity of the solution, to give a change in relative fluidity of 1 (dimensionless) unit/mn/g of enzyme under the conditions of the assay (viscometer developed by Orange Leaf company); 1 AGL unit is defined as the release of oligomers from a chrom
- Table 2 shows the results of the effect of high doses of Creon ® as compared to control on disaccharidase activity (lactase, maltase sucrase) in distal part of rat intestinal
- Table 4 shows a comparison between the effects of the high dose of Creon (enzymes of animal origin) on immune cells in the LP of distal small intestine.
- Table 5 shows effect of Creon at dose 1.5 mg/g body weight on small intestine length and weight in presence of Ibuprofen and Celecoxib.
- Table 6 shows effect of Creon at dose 1.5 mg/g body weight on small intestine length and weight in presence of Ibuprofen and Celecoxib.
- Pa ncreetk enzymes. none (wat r J
- Table 6 illustrates the percentage of mature entrocytes along villi for each group of treatment. Values are expressed as means with standard deviations. Results considered to be significant if P ⁇ 0.05; the different capital letters showed significant differences between compared groups. Table 7
- the examples 3-5 were carried out on Rattus norvegicus (14 day old pups) from Sprague- Dawley strain (Mol: SPRD Han; Taconic M & B, Denmark).
- the dams were placed in the animal facility under standard environment (20 ⁇ 1 C, 50 ⁇ 10 RH%, 12:12 hr light-dark cycle) in individual polycarbonate cages with the bedding material inside it. They had free access to the rodent laboratory chow (RM1 , SDS, Essex, England) and the bottled tap water placed over their cages.
- the cage of pregnant females was checked regularly to define the birth date as day 0.
- the litter size for each dam was restricted to 12 or 13 pups, to reduce variability.
- Example 3 - Set I In this set suckling pups were divided into five groups; control (water) amylase 10 OOOUSP/rat/day, lipase 4 OOOUSP/rat/day, protease 15 OOOUSP/rat/day, and mixture of these enzyme with corresponding activities per rat and day.
- control (water) amylase 10 OOOUSP/rat/day
- lipase 4 OOOUSP/rat/day
- protease 15 OOOUSP/rat/day
- Each of the enzymes (Amylase, Protease and Lipase) (Sigma Aldrich) was available in the powder form and was resolved in distilled water prior to stomach feeding during days 14, 15 and 16.
- the volume of administered enzymes and distilled water (for control groups) was 0.01 ml/g BW.
- the pups were weighed.
- pups were starving for 2 hours prior to feeding with marker molecule solution containing BSA (1.25 mg/g BW) and BlgG (1 .25 mg/g BW),
- pancreas was immediately dissected and rinsed with cold 0.9% NaCI, weighted and stored at -70C.
- the SI was removed and its length was measured then divided into two halves, proximal and distal. Each segment was flushed out with cold 0.9% NaCI to clean the lumen and was then weighed separately. About 2 cm from middle part of these segments was taken for histology and the rest of the intestine was frozen in -70 for disaccharidase analysis, Dahlqvist method (1984). The stomach was removed and its content was collected into the tube (for measuring its pH) and frozen.
- cecum was dissected out, opened, rinse and weighed as well as liver and lymphoid organs spleen and thymus were dissected and weighted. All samples taken for histology were immediately fixed in the Bouin's solution for 24 hours then were transferred into the 70% ethanol. The plasma were collected after centrifuging at 3,000 for 15 minutes at 4°C and frozen at -20°C for further studies.
- Example 4 - Set II The second study was about comparing the effect of different doses of protease (15000USP, 7500USP, 3750USP and 1850USP) on the development of the Gl tract with control.
- protease 15000USP, 7500USP, 3750USP and 1850USP
- the feeding was during 3 continuous days, once a day. 24 hours after the last feeding, on day 17, similar dissection steps and analytical procedures as mentioned for the previous experiment were followed.
- the proximal samples of the SI were de-frozen and weighted and then homogenized with 9 parts of 0.9% NaCI (9w/v).
- the homogenates 50 ⁇ diluted samples
- the appropriate disaccharide 50 ⁇ of 0.056M sucrose, maltose and lactose
- the liberated glucose was determined by adding glucose oxidase reagent (Sigma Chemicals), and incubated for 30 minutes.
- samples were transferred into the 96-well plate in triplication and the absorbance was measured at 450 nm.
- Lowry method was used, where BSA (Bovine Serum Albumin) was used as a standard. The results are presented as specific activity units per mg of protein (u/mg).
- the plasma level of marker molecules was quantified by using immunoassay rocket electrophoresis and SRI (single radial immunodiffusion) for plasma BSA and BlgG respectively.
- the contents of the stomach were de-frozen and then resolved with 1 ml of cold 0.9% NaCI. After resolving, they were centrifuged and the pH was measured in the supernatant using pH-meter.
- Example 3 Effects of individual pancreatic-like enzymes, amylase, lipase, protease and their mixture on gut maturation
- Table 8 shows the body weight of rats treated for 3 days with individual enzymes or their mixture and weights of the digestive and lymphoid organs.
- the results show that groups treated with protease and mixture had lower body weight compared to that in the other groups and control, may be due to diarrhoea observed after receiving the first dose. After one day of losing weight, they start to gain weight in a regular basis again.
- the result showed significant increase in organs along digestive tube: small intestine and cecum as well as accessory organ pancreas.
- both proximal and distal parts of SI had significantly higher weight, while the length of the SI was longer in comparison to other groups and control.
- the weight of the thymus was significantly lower compared to that in control showing developmental changes in immune system, while spleen weight was unchanged.
- the slides prepared from the distal part of SI were analysed for the present of foetal and adult type enterocytes.
- Fig 4 In pups treated with protease and mixture, all of the vacuolated enterocytes were replaced with adult type enterocytes (Fig 4).
- Example 4 Set II. Effects of different doses enzymes with pancreatic-like activity on body and organ weights
- Table 9A demonstrates the weight of different organs
- Table 9B showed the mean body weights of rats during treatment period (from 14 to 16 d of age and the day of dissection, 17d of life) and Fig 7. shows the rats body weight during treatment.
- the group treated with the highest dose of protease had signs of diarrhoea after receiving the first dose on day 14.
- the results of digestive organs demonstrate that rats treated with protease 15 000USP and 7 500USP had increased weight for Gl organs and the length of the SI was longer in this group compared to that in control. Additionally, the thymus weight was significantly lower in the highest dose compare to control.
- SI small intestine
- P protease
- BW body weight
- Table 9B mean body weights during treatment period and (14-16d of life) and day of dissection (17d)
- the slides prepared from the distal part of SI were analysed for the maturation degree of mucosa by measuring the apperance of adult type enterocytes.
- fetal- type epithelium with vacuolated enterocytes still expanded along the whole villi, while in groups treated with proteases P 7500USP, 3750USP and 1875USP these cells limited to the middle and the tip of the villi, and in P 15000USP group all of the vacuolated enterocytes disappeared by giving place to adult type enterocytes demonstrating dose- dependent effect of protease treatment on intestinal morphology (Fig. 8).
- Example 5 Effects of individual enzymes with pancreatic-like activity on body and organ weights
- pancreatic-like enzymes of microbial origin might contribute in Gl development after 3 days exposure.
- protease has the most prominent effect on gut growth as well as structural and functional maturation of gut organs compared to other enzymes.
- amylase also had some effects on SI maturation seeing from change in the enterocyte replacement, while lipase had effect on small intestinal growth in the distal portion, respectively.
- Example 6 Effects of individual pancreatic-like enzymes, amylase, lipase, protease and their mixture on exocrine pancreatic secretion
- protease is the most efficient enzyme for stimulation of the pancreatic function in young rat.
- Example 7 Effect of microbial derived amylase and lipase on growth of rats.
- the laboratory animals used in this experiment were Rattus norvegicus (14 day old pups) from Sprague-Dawley strain.
- the dams were placed in the animal facility under standard environment (20 ⁇ 1 C, 50 ⁇ 10 RH%, 12: 12 hr light-dark cycle) in individual polycarbonate cages with the bedding material inside it, with access to the rodent laboratory chow and the bottled tap water placed over the cages.
- the pregnant rats were checked regularly to define the birth date as day 0.
- the litter size for each dam was limited to 12 or 13 pups, to reduce variability. Pups were restricted to reach to the solid food by using 7 cm wall extensor over each cage and were kept with their dam until dissection day (day 17).
- the enzymes are available in the market in form of powders and were resolved in distilled water prior to stomach feeding during 14-16d of age.
- the administered dose for each enzyme was 10000 USP/animal.
- the volume of administered enzymes and water (for control groups) was 0.01 ml/g b.wt. Prior to the feeding procedure, the pups were weighed.
- Results are shown in Table 10 below showing effects of fruit papain on body and organ weight in comparison to microbial protease.
- I n general, result demonstrated decreasing of small intestinal permeability after protease and papain treatment.
- I n Figure 14 the effect of microbial protease and fruit protease on the level of marker molecules absorption to the plasma, after feeding them with cocktail of BSA (14B) and Big G (14A) on day 17, (at 3 hours before dissection) is shown. These data are given as mean ⁇ SD. Significant results; * p ⁇ 0.05; *** p ⁇ 0.001
- FIG 16. The effect on intestinal crypt proliferation is shown in figure 16.
- Cont is control;
- LM low dose mixture;
- HM high dose mixture;
- LC low dose Creon,
- HC high dose Creon.
- Groups were compared to control, * p ⁇ 0.05
- the dose of enzymes was 60mg/ml with activity 1000USP per 1 mg, the adninistration volume was 4 ml/kg b. wt, the frequency of administration was every second day (ones a day). Treatment via gavage feeding was started at 8d of age and was done 3 times, (i.e. 8, 10, 12d of life).
- piglets (6 enzyme treated and 6 control pigs) were fed with marker molecule solution (Bovine serum albumin (BSA) in comcentration 125mg/ml and sodium fluorescein (NaF) in concentration 2.5mg/ml; the administration volume was 4ml/kg b.wt) at age 14d of life and 27d of life (the weaning day). Blood was collected at 0, 1 ⁇ 2, 1 , 2, 4, 8, and 24 hours after marker-cocktail feeding.
- marker molecule solution Bovine serum albumin (BSA) in comcentration 125mg/ml and sodium fluorescein (NaF) in concentration 2.5mg/ml; the administration volume was 4ml/kg b.wt
- BSA bovine serum albumin
- NaF sodium fluorescein
- Figure 19 shows the effect of microbial derived proteases on body weight gain in % where striped bars show treated piglets and open bars show control, Effects of microbial enzyme on marker molecules absorption
- Figure 20 shows the effects of microbial enzyme on marker molecules absorption in vivo.
- FIG. 21 The effect of protease on pancreatic function after 3 times administration, starting at 8d of life and every other day, the results represent material taken at 48h after last enzyme treatment (14d) and at weaning time (27d) is shown in figure 21 .
- Figure 21A shows pancreas weight and 21 B trypsin like activity. Black bars are enzyme treated, open bars are control.
- This example will show the long-lasting anti-aging dietary effect on old Monglian gerbils, specifically analyzing gastro intestinal tract (GIT)mucosa amorphology and function of pancreatic like enzymes (lipase, amylase and proteinase of microbal origin).
- GIT gastro intestinal tract
- pancreatic like enzymes lipase, amylase and proteinase of microbal origin.
- pancreatic like enzymes lipase, amylase and proteinase of microbal origin
- the experiment will a) investigate gastrointestinal tract after long-lasting dietary effect by pancreatic like enzymes to old gerbils, b) study the level of the dietary fat, protein, carbohydrate and mineral metabolities in the blood after long-lasting dietary effect by pancreatic like enzymes to old gerbils and c) study hormonal profile of aging animals.
- Control group - (n 24) recessive standard diet
- Treatment group - (n 24) recessive standard diet + selected pancreatic like enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a method to induce maturation of an immature GI-tract, such as intestine, e.g. small intestine, the method comprising the steps of administering a mixture of enzymes to the immature GI-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action, and analysing the maturation process of the GI-tract to monitor said maturation process. Provided herein are also uses and kits to provide for GI-tract maturation.
Description
MATURATION OF GASTROINTESTINAL TRACT
TECHNICAL FIELD
The present invention relates to the field of gastrointestinal function, particularly in a newborn. Particularly, the present invention relates to the maturation process of the gastrointestinal tract, such as the small intestine, induced by administration of a mixture of enzymes to a mammal such as a newborn.
BACKGROUND OF THE INVENTION
The gastrointestinal (Gl) tract in humans refers to the stomach and the intestine and sometimes to all the structures from the mouth to the anus. The upper gastrointestinal tract consists of the esophagus, stomach and duodenum. Some sources also include the mouth cavity and pharnyx. The exact demarcation between "upper" and "lower" can vary. Upon gross dissection, the duodenum may appear to be a unified organ, but it is often divided into two parts based upon function, arterial supply, or embryology. The integrated part of Gl tract is pancres and liver named the accessory organs of Gl tract. The lower gastrointestinal tract includes most of the small intestine and all of the large intestine. According to some sources, it also includes the anus. The intestine - or bowel - is divided into the small intestine and the large intestine. The small intestine has three parts: i) duodenum where the digestive juices from pancreas and liver mix together, ii) jejenum which is the midsection of the intestine, connecting duodenum to ileum and iii) ileum which has villi in where all soluble molecules are absorbed into the blood. The large intestine also has three parts: i) cacum where the vermiform appendix is attached to the cecum, ii) colon which consists of the ascending colon, transverse colon, descending colon and sigmoid flexure, and iii) rectum. The intestine has two main roles: digestion and absorption of nutrients, and maintenance of a barrier against the external environment. It also forms the largest endocrine organ in the body as well as the largest and most complex part of the immune system.
In human adults the intestinal surface area is large, about 100 m2. This large area is continuously exposed to different antigens in the form of food constituents (the adult human encounter 12.5 kg of pure protein/year), normal intestinal microflora and pathogens.
The intestinal mucosal surface is lined by a single layer of epithelial cells (IEC) which are continuously and rapidly replaced by replication of undifferentiated cells within the crypt
(7x106 cell / min). The epithelial cell layer of the intestinal mucosa is very complex and unique. It secrets digestive enzymes from the apical part to lumen for food digestion. It also secretes different proteins from the second half to the lamina properia (LP).
Further, said epithelial cells are receiving signals from both the lumen (and then transmitting the information to the diverse populations of cells in the LP) and the basolateral side. On the basolateral side the intestinal epithelial cells (lECs) receive many signals from various immune cells, nerve cells and stromal cells. Signals on both sides are affected by their respective microenvironments, influencing the functional states, behaviours, and structures of enterocytes resulting in integrity and homeostasis of the gastrointestinal tract (5). One divides the postnatal development of the intestines into different phases: early suckling (change from amniotic fluid to colostrum), suckling (change from colostrum to milk), weaning (change from liquid diet, milk, to solid feed) and adulthood (adaptive changes due to diet variation) (Walthal K, et al., Birth Defects Research, 2005, part B, 74:132-156, review). Thus, by manipulating the condition on one side of the epithelial cell layer of the intestinal mucosal surface, the process of postnatal development of gut - including the intestine - could be accelerated or delayed. Past research has confirmed the possibility of accelerating the rate of gut maturation by using exogenous material like PHA (Radberg K, Biernat M, Linderoth A, Zabielski R, Pierzynowski SG & Westrom BR (2001 ) Enteral exposure to crude red kidney bean lectin induces maturation of the gut in suckling pigs. J Anim Sci 2001 ;79:2669-2678) and IL-2 (Peulen O, Dandrifosse G. Spermine- induced maturation in Wistar rat intestine: a cytokine-dependent mechanism. J Pediatr Gastroenterol Nutr 2004, 38:524-532), but at present it is not known in detail as to which types of compounds that could induce fast acceleration.
Mammals are born with intestine that is not fully mature. Depending on the species, the complete maturation varies, but it is always achieved during the weaning period indicating that for the first couple of weeks all mammals haven an immature intestine. In rats, for example, the complete maturation coincides with the dietary shift from milk to solid food. Simultaneous with the onset of the maturation process, changes in the function and architecture of the epithelial cells in the intestine are seen as well as in the weight of the organs, the latter, of which is increasing in most mammals. Such functional and
architectural markers are used to identify and measure the onset of the gut and intestinal maturation.
Investigation of gut development is quite a challenge. However, it is an attractive objective for many researchers in gastrointestinal area due to the fact that immature intestine and intestinal diseases are interrelated. In humans, for example, necrotizing enterocolitis (NEC) is the most common gastrointestinal problem in the neonatal intensive care unit (NICU). NEC syndrome is characterized by rapid necrotic death of intestine, involving 75% or more of total length of jejunum, ileum and colon. Development of NEC relates to maturity of gastrointestinal tract and up to 90% of cases refer to preterm born babies. The more preterm the infant is, the higher risk for NEC, and unfortunately, no non-surgical treatment for this syndrome is officially reported . Therefore, N EC-related morbidity remains unchanged over the past 50 years. First described over a century ago necrotising enterocolitis (N EC) is now the most common gastrointestinal emergency occurring in neonates. It is an acquired disorder with a mortality as high as 50% (10-44% in infants less than 1500 g, 0-20% in infants over 2500 g). Prematurity and low birthweight are the most important risk factors. Average yearly infant death rate from NEC has been reported as 12.4 deaths per 100,000 live births with an incidence of 0.5 to 5 patients per 1000 live births. N EC is characterized by an immature gastrointestinal tract and high mucosal permeability to antigen leading to systemic shock and rapid death in some cases (Kosloske, A. M. Epidemiology of necrotizing enterocolitis. Acta Paediatr. Suppl. 1994;396:2-7 ).
At present, there are a very limited number of therapies known of a condition originating form an immature gastrointestinal tract such as e.g. necrotizing enterocolitis. Further, it is d e s i ra b l e to u s e l e s s tox i c s u b sta n ce s , p a rt i c u l a rl y i n n ewb o rn s . P H A (phytohaemagglutinin), which has previously demonstrated effects on intestinal maturation, such as induction of mitosis, increase in cell membrane permeability and
transport across a membrane, is a lectin found in plants, especially legumes. The substance has a number of physiological effects and is used in medical research. In high doses, however it is a toxin. As a toxin, it can cause poisoning. IL2 is an interleukin normally produced by the body during an immune response. IL-2 is also necessary during T cell development in the thymus for the maturation of subsets of T cells.
It may thus be less favorable to use PHA or IL2 in infants with gastrointestinal problem in a neonatal intensive care unit.
There is thus an urgent need to develop novel therapies and prevent disease such as necrotizing enterocolitis, particularly in newborn. Thus, understanding gastrointestinal development and particularly maturation of the small intestine is of great importance in newborns. Accordingly, the present invention seeks to provide means and methods to address such needs and interests.
SUMMARY OF THE INVENTION One aspect of the present invention provides a method to induce maturation of an immature immature Gl-tract, such as intestine, e.g. small intestine, the method comprising the steps of
a) administering a mixture of enzymes to the immature Gl-tract, such as intestine, e.g. small intestine, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action,
b) analysing the maturation process of the immature Gl-tract, such as intestine, e.g. small intestine to monitor said maturation process.
Further embodiments are wherein the immature Gl-tract, such as intestine, e.g. small intestine is of mammalian origin, such as a cat, cow, horse, pig, rat, dog, mouse, or primate.
Further embodiments are wherein the immature Gl-tract, such as intestine, e.g. small intestine is of human origin.
Further embodiments are wherein the immature human Gl-tract, such as intestine, e.g. small intestine, is of a newborn.
Further embodiments are wherein the immature Gl-tract, such as intestine, e.g. small intestine, is of an avian species.
Further embodiments are wherein at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the Gl-tract, such as intestine, e.g. small intestine, are analysed to monitor the maturation process, and wherein a change in at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the Gl-tract, such as intestine, e.g. small intestine, are indicative of intestinal maturation.
Still further embodiments are wherein said intestinal enterocyte biomarkers in the maturation process analysed are enterocyte disaccharidase activity and where changes in disaccharidase activities from lactase activity to sucrase activity and maltase activity of enterocytes in the Gl-tract, such as intestine, e.g. small intestine, are indicative of Gl-tract, such as intestine, e.g. small intestine, maturation.
Further embodiments are wherein said changes in intestinal enterocyte morphology in the maturation process are changes from foetal-type intestinal enterocytes to adult type intestinal enterocytes, and wherein said changes in morphology are indicative of Gl-tract, such as intestine, e.g. small intestine, maturation process.
Still further embodiments are wherein said weigh of parts of the Gl-tract, such as intestine, e.g. small intestine, analysed in the maturation process are changes of Gl-tract, such as intestine, e.g. small intestine, weigh and wherein an increase of Gl-tract, such as intestine, e.g. small intestine, weigh is indicative of the maturation process.
Even further embodiments are wherein the mixture of enzymes is administered orally.
Still even further embodiments are wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase.
Even further embodiments are wherein the enzyme mixture comprises the enzymes protease, lipase and amylase.
Even further embodiments are wherein the mixture of enzymes is a one enzyme mixture, i.e. comprising only one enzyme with pancreatic and/or pancreatic like action or activity. Thus, further embodiments are wherein the mixture of enzyme comprises or consists of a protease.
Even further embodiments are wherein the mixture of enzyme comprises or consists of a lipase.
Even further embodiments are wherein the mixture of enzymes comprises or consists of an amylase.
Still even further embodiments are wherein the amount of enzymes is about 25 000 - 500 000 Ph Eur /kg bodyweight and day of the enzyme lipase, about 600 - 20 000 Ph Eur /kg bodyweight and day of the enzyme protease, and about 14 000 to 600 000 Ph Eur /kg bodyweight and day of the enzyme amylase.
Still further embodiments are wherein the maturation process takes about 3-10 days.
Further aspects of the invention are uses of a mixture of enzymes having pancreatic activity or action to induce maturation of an immature Gl-tract, such as intestine, e.g. small intestine
Further aspects of the invention are uses of a mixture of enzymes having pancreatic like action or activity to induce maturation of an immature Gl-tract, such as intestine, e.g. small intestine.
Further embodiments are wherein the immature Gl-tract, such as intestine, e.g. small intestine, is of a newborn.
Further embodiments are wherein the immature Gl-tract, such as intestine, e.g. small intestine, is of an avian species.
Further aspects of the invention are a mixture of enzymes having pancreatic and/or pancreatic like action or activity for inducing maturation of an immature Gl-tract, such as intestine, e.g. small intestine.
Further aspects of the invention provide a mixture of enzymes having pancreatic and/or pancreatic like action or activity for treatment of a disorder relating to an immature Gl- tract, such as intestine, e.g. small intestine. Further embodiments are wherein said immature Gl-tract, such as intestine, e.g. small intestine, disorder is necrotizing enterocolitis. Further embodiments are wherein said disorder is a gut involution, disorder or a disfunction of a Gl-tract of an elderly subject.
Further aspects of the invention provide use of a mixture of enzymes having pancreatic and/or pancreatic like action or activity for the preparation of a medicament for treatment of an immature gastrointestinal tract disorder, such as an intestinal disorder e.g. small intestinal disorder.
Further embodiments are wherein said immature gastrointestinal tract disorder, such as an intestinal disorder e.g. small intestinal disorder is necrotizing enterocolitis. Further embodiments are wherein said disorder is a gut involution, disorder or a disfunction of a Gl-tract of an elderly subject.
Further aspects of the invention provides a method of treating an individual with an immature gastrointestinal tract disorder, such as an intestinal disorder e.g. small intestinal disorder, said method comprising the steps of administering to a patient in the need thereof an effective amount of a mixture of enzymes with pancreatic and/or pancreatic like action or activity to induce gastrointestinal tract maturation, such as an intestinal e.g. small intestinal maturation.
Further embodiments are wherein said disorder of an immature Gl-tract, such as intestine, e.g. small intestine, is necrotizing enterocolitis or a disfunction of a Gl-tract of an elderly subject.
Further embodiments are wherein said patient in the need thereof is an infant or an elderly.
Further embodiments is improved body growth by amylase of newborn and new hatched avians as well as older and aging mamals including humans and older avians.
Further aspects of the present invention provides a kit for inducing maturation of an Gl- tract, such as intestine, e.g. small intestine, said kit comprising a) a mixture of enzymes with pancreatic and/or pancreatic like action or activity to induce gastrointestinal tract, such as an intestinal e.g. small intestinal maturation,
b) instructions to induce gastrointestinal tract, such as an intestinal e.g. small intestinal maturation according to any of the methods disclosed herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 a-1 b shows in a) a schematic illustration of villi-crypt unit. Broken arrows show the direction of enterocyte replacement and in b) photomicrographs of H&E stained distal small intestinal sections, showing the enterocytes phenotype: fetal-type (left panel), 14 d- old suckling rat, and adult-type (right panel) 6 months-old rat.
Figure 2a-c shows the results of photomicrographs of the distal part of rats intestine following the high dose of B. Creon, and C. Robavio treatment, respectively as compared to A. water control. Figure 3 shows the maturation degree of the epithelium in the distal part of rats' small intestine induced by different enzyme treatments. Results expressed as a mean ± SD. Each treated group was compared to control using Student t-test. Significant results; P< 0.05O, P< 0.01 (**), P < 0.001 (***). Figure 4 shows photomicrograph of the H&E stained sections from the distal part of the rats' small intestine demonstrating the presence of the fetal-type enterocytes containing supranuclear vacuoles in control (A), lipase (B), and amylase (C) treated groups, while protease (D) and enzymes mixture (E) treated groups demonstrate mucosa with total replacement of enterocytes containing supra-nuclear vacuoles with adult-type epithelium. Original magnification x10.
Figure 5 shows changes in brush-border enzyme activities for lactase (A), sucrase (B) and maltase (C) in the proximal part of the small intestine after administration of individual enzymes (amylase, lipase and protease) or their mixture to 14d old rat during 3 days. Results are expressed as mean ± SD. Treated groups were compared to control using Student t-test. Significant differences; P<0.05 (*), P<0.01 (**)
Figure 6 shows the effect individual enzyme administration: amylase, protease, lipase and their mixture (administered to the 14d old rats for 3 days), on the level of marker molecules absorption BIgG (A) and BSA (B) to the plasma in comparison to control. The results are given as mean ± SD. Treated groups were compared to control using Student t-test. Significant results; P<0.001 (***).
BIgG, bovine immunoglobulin G; BSA, bovine serum albumin. Figure 7 shows the effects of different doses of protease on rat body weight gain during treatment (14, 15 and 16 days of age: Bwt1 , Bwt2, Bwt3, respectively) and 24 hours after last feeding (Bwt4). Results are expressed as mean ± SD. Treated groups were compared to control using Student t-test. *P<0.05
Bwt, body weight. Non-filled triangle -15 000USP, non-filled circle - 7 500USP, filled triangle - 3 750 USP, filled circle - 1875 USP and filled square - control.
Figure 8 shows the maturity of the rat intestinal epithelium in the distal small intestine after treatment with different doses of protease: (P 15 000= Protease 15 000USP; P 7500= Protease 7 500USP; P 3750=Protease 3 750USP; P 1875= Protease 1 875USP). Results are expressed as mean ± SD. Treated groups were compared to control using Student t-test. * PO.05, ** P<0.01 .
USP, United States Pharmacopeia
Figure 9 shows the effect of high dose of protease (P 15 000USP) on body weight gain of rats during treatment, early and normal weaning up to 38 days of life in comparison to control groups. Results are expressed as mean ±SD. Dotted bars are control, early weaning/EW, horizontally striped bars are control, normal weaning/NW, diagonally striped bars are Enzyme mixture, early weaning/EW, Black barrs are enzyme mixture, normal weaning/NW.
USP, United States Pharmacopeia
Figure 10 shows the effect of microbial-derived enzymes with pancreatic activity: protease, lipase, amylase and their mixture on rat trypsin activity in the pancreatic
homogenates after 3d of oral gavage to suckling 14d old rats. Treated groups were compared to control, *p<0.05.
Figure 11 shows the growth of young rats treated at age 14-16d of life once a day with microbial-derived enzymes having lipase and amylase activities, n=7 per group. Black bars are amylase, striped bars are lipase and open bars are control.
Figure 12 shows the effects of proteases on body weight of suckling rats during 14 to 17 days of age, n=7-8 per group. Graph is demonstrating the growth of suckling pups during experiment. There is no effect of protease or papain in dose 10 000 USP on body growth was observed. Control is shown in circles, papain is shown in squares and protease is shown in triangles.
Figure 13 shows results of activities of the brush-border enzymes lactase (13A), maltase (13B) and sucrase (13C) analyzed in the proximal part of the rats SI in groups treated with papain and protease. Results are expressed as mean ± SD. *p<0.05.
Figure 14 shows the effect of microbial protease and fruit protease on the level of marker molecules absorption to the plasma in rats, after feeding them with cocktail of BSA (14B) and Big G (14A) on day 17, (at 3 hours before dissection). These data are given as mean ± SD. Significant results; * p<0.05; ***p<0.001.
Figure 15 shows the effect of enzyme treatment with porcine Creon and microbial enzymes mixture on pigs body growth , n= 12-6 per group. Open circles are control, mixture of microbial enzymes are black circles and Creon are open squares.
Figure 16 shows the Crypt cell proliferation in the small intestine of suckling 14-15d old piglets after 1 week gavage treatment (twice a day) with preparation of enzymes having pancreatic-like activities of porcine and microbial origin. Groups were compared to control, *p<0.05. Cont, control; LM, low dose mixture; HM, high dose mixture; LC, low dose Creon, HC, high dose Creon.
Figure 17 shows weight of the the small intestine of suckling 1 4-1 5d old piglets after 1 week gavage treatment (twice a day) with preparation of enzymes having pancreatic-like activities of porcine and microbial origin. Cont, control; LM, low
dose mixture; HM, high dose mixture; LC, low dose Creon, HC, high dose Creon. Result demonstrate tendency of small intestine to increase its weight in dose- respond manner. Figure 18 disaccharidase activities: A-lactase, B-maltase, C-sucrase in the small intestine of suckling 14-15d old piglets after 1 week gavage treatment (twice a day) with high dose preparation of enzymes having pancreatic-like activities of porcine and microbial origin. Groups were compared to control (n=3-5), *p<0.05. Figure 19 shows effect of microbial-derived protease on bogy weight gain in % where striped bars show treated pigs and open bars show control.
Figure 20 shows the effects of microbial enzyme on marker molecules absorption in pigs. The results demonstrate decreased intestinal permeability for both BSA (20A) and NaF (20B) molecules in protease treated piglets (n=8) in comparison to control (n=8). *p<0.05.
Figure 21 shows the effect of protease on pancreatic function after 3 times administration, starting at 8d of life and every other day, the results represent material taken at 48h after last enzyme treatment (14d) and at weaning time (27d). Figure 21A shows pancreas weight, 21 B trypsin like activity. Black bars are enzyme treated and open bars are control.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
As used herein the "gastrointestinal (Gl) tract" is, when referring to humans, non-human mammals and avian species, intended to mean the stomach and the intestine and gut accessory organs, pancreas and liver, and sometimes to all the structures from the mouth to the anus. The upper gastrointestinal tract consists of the esophagus, stomach and duodenum. Some sources also include the mouth cavity and pharnyx. The exact demarcation between "upper" and "lower" can vary. Upon gross dissection, the duodenum may appear to be a unified organ, but it is often divided into two parts based upon function, arterial supply, or embryology.
The lower gastrointestinal tract includes most of the small intestine and all of the large intestine. According to some sources, it also includes the anus. The intestine - or bowel - is divided into the small intestine and the large intestine. The small intestine has three parts: i) duodenum where the digestive juices from pancreas and liver mix together, ii) jejenum which is the midsection of the intestine, connecting duodenum to ileum and iii) ileum which has villi in where all soluble molecules are absorbed into the blood. The large intestine also has three parts: i) cacum where the vermiform appendix is attached to the cecum, ii) colon which consists of the ascending colon, transverse colon, descending colon and sigmoid flexure, and iii) rectum. The Gl tract in humans thus also include liver, pancreas, small and large intestine, if applicable to that particular species. Other mammals or avian species may have the same or different organs of the Gl-tract. Thus, the particular organs included in Gl-tract are species dependent.
As used herein, a "small intestine" is intended to mean the part of the "gastrointestinal part following the stomach and followed by the large intestine, and is where the vast majority of digestion and absorption of food takes place. The small intestine in an adult human measures on average about 5 meters (16 feet), with a normal range of 3 - 7 meters; it can measure around 50% longer at autopsy because of loss of smooth muscle tone after death. It is approximately 2.5-3 cm in diameter. Although the small intestine is much longer than the large intestine (typically around 3 times longer), it gets its name from its comparatively smaller diameter. Although as a simple tube the length and diameter of the small intestine would have a surface area of only about 0.5m2, the surface complexity of the inner lining of the small intestine increase its surface area by a factor of 500 to approximately 200m2, or roughly the size of a tennis court. The small intestine, both for mammals and avian species, is divided into three structural parts, i) duodenum, ii) jejenum and iii) ileum.
As used herein, "pancreatic like activity" and/or "pancreatic like action" is intended to mean any enzyme activity having the same, equal or similar activity or action as pancreatic enzymes. "Pancreatic enzymes" or "enzymes with pancreatic activity or action" are enzymes secreted by the pancreas. Examples of pancreatic enzymes or enzymes with pancreatic activity are given herein.
As used herein, "subject" is intended to mean any mammal including human having or suspected of having a disease, as well as a normal healthy subject. A "subject" includes a patient, such as a human patient having or suspected of having a disease. "Subject" as used herein also denotes a mammal, such as a rodent, e.g. a mouse or a rat, a pig, a feline, a canine, and a primate. Preferably a subject according to the invention is a human. A subject may also be of avian origin, such as a turkey, duck, hen, chicken or broiler.
As used herein, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a biomarker" includes a plurality of such biomarkers.
As used herein "d" refers to "day" or "days". As used herein "at least one" is intended to mean one or more, i.e. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.
As used herein "infant" is intended to mean a child or baby as the very young offspring of humans. Further, as used herein a "newborn" or "neonate" is an infant who is within hours, days, or up to a few weeks from birth. As used herein, a "newborn" or "neonate" also includes mammals of non-human species as well as avian species who is within hours, days, or up to a few weeks from birth. A "newborn" or "neonate" thus refers to an infant in the first 28 days of life (less than a month old) as well as mammals of non-human species in the first 28 days of life as well as avian species in the first 7 days of life. The term "newborn" includes premature infants, postmature infants and full term newborns.
As used herein "elderly" or "old" or "older" is intended to mean the definition according to WHO and UN as of today
(http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html). The definition as such is an arbitrary definition where most develop countries uses an age of 65+ to define elderly, whereas this does not adapt well to developing countries like Africa. At the moment, there is no United Nations standard numerical criterion, but the UN agreed cutoff is 60+ years to refer to the older population. Thus, the working definition of "elderly", "older" or "old" for the purposes of developing countries like Africa should be changed to the age of 50 years. It is acknowledged that this is also somewhat arbitrary but it is
believed to be a better representation of the realistic working definition in developing countries like Africa.
For animal species and "old", "older" or "elderly" differs between different species, of course. The case for gerbils, as used herein, is about 24 months of age and above. The case for mice is 24 and rat is 36 months.
"Detection", "detect", "detecting" as used herein includes qualitative and/or quantitative detection (measuring levels) with or without reference to a control, and further refers to the identification of the presence, absence, or quantity of a given substance, e.g. mRNA or protein or any other substance, or activity, such as e.g. any enzymatic activity.
"Healthy" refers to a subject possessing good health. Such a subject demonstrates a normal Gl tract including the intestine, e.g. the small intestine, mature or immature, and is wherein the maturation process of the intestine proceeds normal. In the context of this application, a "healthy individual" or "healty subject" is only healthy in that they have a normal intestinal maturation process, a "healthy individual" or "healthy subject" may have other diseases or conditions that would normally not be considered "healthy". "Treatment" or "therapy" as used herein is defined as the attempted remediation of a health problem and includes e.g. management of a patient through medical or surgical means. The treatment or therapy improves or alleviates at least one symptom of a medical condition or disease and is required to provide a cure. The term "treatment outcome" or "outcome of treatment" as used herein is the physical effect upon the patient of the treatment. Further, "treatment" includes both therapeutic and prophylactic treatment of a subject or patient. E.g. the term "prophylactic" is used to encompass the use of an enzyme mix or formulation described herein which improves intestinal maturation or alleviates at least one symptom of a medical condition or disease due to absence of intestinal maturation in a mammal such as a subject or a patient.
Persons skilled in the art will further appreciate that the enzyme mixtures or the enzyme alone described herein have utility in both the medical and veterinary fields. Thus, the enzyme mixture in all its embodiments herein may be used in the treatment of both human and non-human animals, such as horses, dogs, mice, rats, apes, monkeys, pigs, and cats. Preferably, however, the patient is human, such as a newborn infant or
neonatal. Also included here are wherein the enzyme mixtures described herein in all its embodiments are used in treatment of avian species, i.e. birds, e.g. in chickens or broilers of hens, ducks, turkeys etc. During the last decade, researchers have induced and accelerated gut maturation by using exogenous factor like PHA. As PHA is a compound accompanied by many undesirable effects and it can use only as tool, there is a need to search for a new source, ideally one that is endogenous. As revealed above, the present invention uses an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, to induce maturation of the Gl tract including the intestine, e.g. the small intestine.
Before the full maturation of a Gl tract including the intestine and accessory organs, e.g. the small intestine and pancreas, and simultaneous with the onset of maturation, many changes have been recorded - most of these events are related to the functional and architecture of the epithelial cell in the intestines and the weight of organs, e.g. the intestine as such. For instance, in rats it has been noted that there is an increase in maltase and sucrase activity of intestinal enterocytes as well as the disappearance of vacuolated epithelial cells of an immature intestine in distal parts, being replaced by adult phenotypes (see Fig 1 a and 1 b). These changes, therefore, may be used as a potential marker for the onset of gut maturation (see e.g. Baintner K. Vacuolization in the young. In: Zabielski R, Gregory PS, Westrom B (eds). Biology of the intestine in growing animals. Amsterdam: Elsevier Science B. V; 2002:55-1 10, and Walthall K, Cappon GD, Hurtt ME, et al. Postnatal development of the gastrointestinal system: a species comparison. Birth Defects Res 2005;74:132-56 incorporated herein by reference).
Parallel with the events in the epithelial layer of the intestine during maturation many organs, proteins and cell profiles of the immune system in the lamina propria (LP) undergo modification as well in response to changes in the microenvironment during the maturation process. It has been shown there is an increase in inflammatory profile like IL- 6 and TNF, as well as T-cell expansion, during the weaning period as compared with the suckling period.
The present invention thus in one aspect relates to a method to induce and monitor maturation of an immature Gl tract including the intestine, e.g. the small intestine. Said method comprises the steps of
a) administering a mixture of enzymes to the immature Gl-tract, said enzymes having a pancreatic activity or action, or pancreatic like activity or action,
b) analysing the maturation process of the intestine to monitor said maturation process.
Said method may also in further embodiments include the step to prevent and monitor gut involution, disorders and dysfunctions at elderly by the steps a and b in the method to induce and monitor maturation of an immature Gl-tract. The enzyme mixture is described and exemplified further herein and all embodiments may be used in all the methods and uses herein.
The above method may relate to any subject of mammalian species, such as human or non-human origin or avian Gl tract, e.g. the intestine, more particularly the small intestine, such as an intestine of a rat, mouse, rabbit, guinea pig or any other rodent, cat, cow, sheep, horse, or a pig. It may also be an intestine of an avian species such as a bird, a hen, turkey, or duck, or chicken or broilers thereof, or it may also be a human intestine, from an adult or a child or infant, or even a newborn infant, including a premature infant, postmature infants and full term newborns. Newborns' digestive tracts, which of course have never been used prior to birth, are filled with a greenish-black, sticky material called meconium. This has the function of standing in for fecal material and allows the intestines to develop to the point where they can process milk immediately on birth. This meconium material is passed by the child in the first few days. The digestive tract is, during suckling and breast feeding still considered as relatively immature compared to adults and the process of maturation is further induced normally during the weaning process.
Further embodiments are thus wherein the immature Gl tract including the intestine, e.g. the small intestine, is of mammalian origin.
Even further embodiments are wherein the immature Gl tract including the intestine, e.g. the small intestine, is of human origin.
Still even further embodiments are wherein the immature human Gl tract including the intestine, e.g. the small intestine is of an infant, such as e.g. a newborn infant, including a premature infants, postmature infants and full term newborns. Even further embodiments are wherein the immature Gl-tract including the intestine, e.g. the small intestine, is of avian origin.
There are thus certain characteristics of an immature Gl tract including the intestine, e.g. the small intestine, and further certain characteristics associated to a mature intestine. Characteristical changes in between the immature and mature intestine, i.e. changes during the maturation process, include i) structural changes of enterocytes from foetal type enterocytes to adult type enterocytes, ii) functional changes of enterocytes that includes a change in disaccharide activities from a predominant lactase activity in the immature mode to a sucrase and maltase activity in the adult mode, and iii) a change in weight, e.g. an increase, in organ weight, for example weight of the intestine, such as the small intestine, or the liver or pancreas. The functional change of the enterocytes may thus be used as biomarkers if the maturation process.
Analysing the maturation process of the intestine to monitor said maturation process may thus be analysing at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the parts of the Gl-tract such as the intestine, e.g. small intestine, are analysed to monitor the maturation process in the methods given herein, and wherein a change in at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the organs of the Gl tract including the intestine, e.g. the small intestine, are indicative of gastrointestinal tract maturation, such as an intestinal e.g. small intestinal maturation.
Analysing the maturation process may further include, apart from the above
characteristics, analysing brush border disaccaridase activity asintestinal enterocyte biomarkers in the maturation process. Changes in disaccaridase activities from
predominant lactase activity to sucrase activity and maltase activity of enterocytes in the small intestine (IEC) are indicative of gastrointestinal tract maturation, such as an intestinal e.g. small intestinal, maturation.
Various disaccharidases (maltase, isomaltase, sucrase, and trehalase) falls into this category and thus their developmental patterns are indirect contrast to that of lactase. Maltase has low activity during the first two postnatal weeks and then undergoes a 5- to 10-fold increase during the next two weeks. For sucrase, isomaltase, and threalase, the transition is even more sudden. These enzymes cannot be detected in the intestine during the first and second postnatal week, but their activities appear on approximately day 16 and rise rapidly, reaching adult levels by the end of the fourth week. When providing an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, such a change in enzyme activity will appear much quicker, after a few days such as about 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
Disaccharidase is a group of enzymes which are components of the brush border of the intestinal epithelium and which hydrolyze disaccharides to monosaccharides. The disaccaridase enzymes include but are not limited to lactase, maltase, sucrase, trehalase, isomaltase and galactosidase. Enteric infections may cause a temporary deficiency of lactase leading to the development of an osmotic-type diarrhoea. All disaccharidases are not present immediately following birth and feeding sucrose to young calves will result in diarrhoea. Assays to measure intestinal brush-border disaccharidase activity are known in the art. It includes specific colorimetric assays of glucose with glucose oxidase of disaccharidase activities, since most naturally occurring disaccharides contain at least one molecule of glucose which is liberated on hydrolysis. The method is especially advantageous for the determination of the hydrolysis of reducing disaccharides (see e.g. Dahlqvist, A. Method for Assay of intestinal disaccharidases. ASALYTICAL BIOCHEMISTRY 7, 18-25 (1964) and Dahlqvist, A, Assay of intestinal disaccharidases, Scand J Clin Lab Invest, 44, 169- 172, 1984 incorporated herein by reference) and may thus be used to measure
disaccharidase activity in the methods given herein. Assays to analyse lactase activity are known in the art and include e.g. the assay of Dahlqvist and Asp (see e.g. Dahlqvist and Asp, Accurate assay of low intestinal lactase activity with a fluorometric method, Analytical Biochemistry, Vol 44, pg 654-657, Dahlqvist, A. Method for Assay of intestinal disaccharidases. ASALYTICAL BIOCHEMISTRY 7, 18- 25 (1964) and Dahlqvist, A, Assay of intestinal disaccharidases, Scand J Clin Lab Invest,
44, 169-172, 1984 all incorporated herein by reference) and may thus be used to measure lactase activity in the methods given herein.
Assays to analyse sucrase activity are known in the art and include the method described by Lee et al. (see e.g. Lee et al, A method for assaying intestinal brush-border sucrase in an intact intestinal preparation, PNAS March 3, 1998 vol. 95 no. 5 21 1 1 -21 16, Dahlqvist, A. Method for Assay of intestinal disaccharidases. ASALYTICAL BIOCHEMISTRY 7, 18- 25 (1964) and Dahlqvist, A, Assay of intestinal disaccharidases, Scand J Clin Lab Invest, 44, 169-172, 1984 all incorporated herein by reference) and may thus be used to measure sucrase activity in the methods given herein.
Assays to analyse maltase activity are known in the art and include e.g. the assay by Dahlqvist, A. (see Assay of intestinal disaccharidases. Scand. J. clin. Lab. Invest. 44, 169-172.1984, incorporated herein by reference) which is a modified and updated description of the author's method for the assay of intestinal disaccharidases from 1963 (supra, both incorporated herein by reference) and may thus be used to measure maltase activity in the methods given herein. In brief, an intestinal homogenate is incubated with the appropriate disaccharide, such as a maltase. The disaccharidase e.g. maltase activity is then interrupted by the addition of TRIS, and the glucose liberated is measured with a glucose oxidase reagent, and compared to standard.
Changes in intestinal enterocyte morphology in the maturation process may be changes from foetal-type intestinal enterocytes to adult type intestinal enterocytes. Said changes in morphology are thus indicative of intestinal maturation process in the methods given herein.
The function of the small intestine is the digestion of food and absorption of nutrients. The small intestine consist of three parts: the upper duodenum attached to the pyloric end of the stomach, the jejunum, and the ileum. The duodenum contains the entrances of both the pancreatic and the bile ducts, but in the rat there is only one common pancreatic- biliary duct.
The small intestine has a huge surface area formed by millions of finger-like extrusions - the villi and crypts, which are both covered by epithelial cells. In addition, the complex of
specialized membrane extrusions found on the apical side of the enterocytes, the microvilli, is usually referred to as the brush border. The crypt-villus complex is considered to be the functional unit of the small intestine - see fig 1 a and 1 b. In each intestinal crypt there is continuous cell proliferation, resulting in the production of new epithelial cells which migrate up along the villus and differentiate, simultaneously cells are shed from the top of the villi. Such complete cell replacement, called cell turnover, on the villous takes place every 2-5 days, depending on the species. In addition, in young mammals or infants, cell turnover occurs at lower rate in comparison to that in adult. There are four major types of cells making up the small intestinal mucosa, originating from the immature stem cells in the crypts: the enterocytes (absorptive cells), goblet cells (mucus-secreting), Paneth cells (secreting antibacterial peptides and enzymes) and several types of enteroendocrine cells (secreting hormones).
In neonatal rat and human infant the small intestine grows by crypt fission initiated by milk feeding, and then the cylindrical growth of the small intestine seen at weaning mostly is due to crypt hyperplasia.
During the suckling period, the immature intestine shows a high permeability for milk- borne macromolecules, hormones and other factors. The transport of macromolecules follows two pathways: specific receptor-mediated and non-specific absorption. Specific trancytosis has been reported for immunoglobulins which bind to the neonatal Fc-receptor expressed by the enterocytes in the proximal small intestine, while non-specific absorption is the pathway for the uptake of other milk proteins. The fetal-type enterocytes found universally in the distal part of small intestine contain large supranuclear vacuoles and have a high absorptive capacity for macromolecules compared to adult mature intestine. In addition, during suckling period, the intestinal mucosa expresses high activities of the brush-border enzyme lactase principally in relation to the digestion of milk components, while maltase activity is low and that of sucrase cannot be detected. The suckling period passes gradually into the weaning period, when the intake of solid food increases and milk decreases. For rats, in the third week of life, this process is characterized by rapid growth and vast structural and functional changes in the Gl tract. The crypt depth in the small intestine increases due to an increase in the cell proliferation, and the absorptive capacity of the small intestine enlarges due to epithelial hyperplasia. Important functional changes of the small intestine at this time are the increase in the
mucosal brush border disaccharidase activities of maltase and sucrase with a decrease in the lactase activity. Moreover, gut permeability declines for macromolecules, resulting in intestinal "closure". The fetal phenotype enterocytes with large supranuclear "digestive" lysosomal vacuoles disappear in the distal small intestine and are replaced by the adult phenotype enterocytes.
Thus, above changes may all be used, alone or in combinations, for measurements or monitoring of the maturation process in the methods given herein. Further,said weigh of the parts of the Gl tract including the intestine, e.g. the small intestine, may be analysed in combination with the other markers of the maturation process given herein such as changes of weight of the parts of the Gl tract including the intestine, e.g. the small intestine and wherein an increase of intestinal weigh is indicative of the maturation process.
Analysis of biomarkers and morphology is done in biopsies or autopsy material of a mammal. Said biopsy may be isolated from the small intestine the procedure is called a small-intestine (or small-bowel) biopsy. A larger tissue specimen may also be obtained by using an endoscope (a flexible viewing tube), or by using a thin tube with a small cutting instrument at the end. The latter procedure, using the cutting instrument, is ordered when larger specimens than those provided by endoscopic biopsy are needed, because it allows removal of tissue from areas beyond the reach of an endoscope.
As used herein a "biological sample" or "biopsy" encompasses a variety of sample types obtained from any parts of the small intestine of a mammal. A typical subject is a human infant or neonate; however, any mammal or avian species that has an intestine can serve as a source of a biological sample or biopsy. Exemplary biological samples and biopsies useful in the disclosed methods include but are not limited to biological samples disclosed herein such as e.g. solid tissue samples such as a biopsy specimen or tissue cultures or cells derived there from, and the progeny thereof. For example, biological samples include cells obtained from a tissue sample collected from an individual suspected of having an immature Gl tract including the intestine, e.g. the small intestine or a mature Gl tract including the intestine, e.g. the small intestine. Therefore, biological samples encompass clinical samples, cells in culture, cell supernatants, cell lysates, and tissue samples, e.g. a transrectal biopsy or endoscopic biopsy.
Several types of capsules are used for tissue collection. In each, a mercury-weighted bag is attached to one end of the capsule, while a thin polyethylene tube about 60 inches long is attached to the other end. Once the bag, capsule, and tube are in place in the small intestine, suction on the tube draws the tissue into the capsule and closes it, cutting off the piece of tissue within. This is an invasive procedure, but it causes little pain and complications are rare.
After application of a topical anesthetic to the back of the patient's throat, the capsule and the tube are introduced, and the patient is asked to swallow as the tube is advanced. The patient is then placed on the right side and the instrument tip is advanced another 20 inches or so. The tube's position is checked by fluoroscopy or by instilling air through the tube and listening with a stethoscope for air to enter the stomach.
The tube is advanced two to four inches at a time to pass the capsule through the stomach outlet (pylorus). When fluoroscopy confirms that the capsule has passed the pylorus, small samples of small intestine tissue are obtained by the instrument's cutting edge, after which the instrument and tube are withdrawn. The entire procedure may be completed in minutes.
This procedure will provide tissue specimens from the small intestine through means of a tube inserted into the stomach through the mouth. The patient is to withhold food and fluids for at least eight hours before the test. The patient should not have anything to eat or drink until the topical anesthetic wears off (usually about one to two hours). If intravenous sedatives were administered during the procedure, the patient should not drive for the remainder of the day. Complications from this procedure are uncommon, but may occur. The patient is to note any abdominal pain or bleeding and report either immediately to the doctor. Complications from this procedure are rare, but can include bleeding (hemorrhage), bacterial infection with fever and pain, and bowel puncture (perforation). The patient should immediately report any abdominal pain or bleeding to the physician in charge. Note: Biopsy is contraindicated in uncooperative patients, those taking aspirin or anticoagulants, and in those with uncontrolled bleeding disorders. Tissue biopsies are then analyzed for biomarkers and morphology on gross examination of the specimen(s) or under the microscope after tissue preparation.
Further examples are small intestinal biopsies and/or autopsy tissues, or intestinal cell samples. Samples may be fresh or processed post-collection (e.g., for archiving purposes). In some examples, processed samples may be fixed (e.g., formalin-fixed) and/or wax- (e.g., paraffin-) embedded. Fixatives for mounted cell and tissue preparations are well known in the art and include, without limitation, 95% alcoholic Bouin's fixative; 95% alcohol fixative; B5 fixative, Bouin's fixative, formalin fixative, Karnovsky's fixative (glutaraldehyde), Hartman's fixative, Hollande's fixative, Orth's solution (dichromate fixative), and Zenker's fixative (see, e.g., Carson, Histotechology: A Self-Instructional Text, Chicago:ASCP Press, 1997). In some examples, the sample (or a fraction thereof) is present on a solid support.
Solid supports useful in a disclosed method need only bear the biological sample/biopsy and, optionally, but advantageously, permit convenient detection of biomarkers or morphology of interest in the sample. Exemplary supports include microscope slides (e.g., glass microscope slides or plastic microscope slides), coverslips (e.g., glass coverslips or plastic coverslips), tissue culture dishes, multi-well plates, membranes (e.g., nitrocellulose or polyvinylidene fluoride (PVDF)) or BIACORE®; chips. Further, analysis of biomarkers, such as proteins, mRNA or enzyme activity may be determined by immunohistochemistry which includes a scoring system, such as of mRNA, protein expression or enzyme activity which may optionally be used. The scoring may be semi-quantitative; for example, with mRNA or protein expression levels recorded as 0, 1 , 2, or 3 (including, in some instances plus (or minus) values at each level, e.g., 1 +, 2+, 3+) with 0 being substantially no detectable mRNA or protein expression and 3 (or 3+) being the highest detected protein expression. In such methods, an increase or decrease in the corresponding protein expression is measured as a difference in the score as compared the applicable control (e.g. a standard value or a control sample); that is, a score of 3+ in a test sample as compared to a score of 0 for the control represents increased mRNA or protein expression in the test sample, and a score of 0 in a test sample as compared to a score of 3+ for the control represents decreased mRNA or protein expression in the test sample.
Immunohistochemistry (IHC) is one exemplary technique useful for detecting protein expression in the disclosed methods and uses. Antibodies (e.g., monoclonal and/or
polyclonal antibodies) specific for each protein expression marker are used to detect the expression. The antibodies can be detected, as further described herein, by direct labelling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horseradish peroxidase or alkaline phosphatase. Alternatively, an indirect labelling is used where unlabeled primary antibody is used in conjunction with a labelled secondary antibody, comprising e.g.
antiserum, polyclonal antiserum or a monoclonal antibody specific for the primary antibody. IHC protocols are well known in the art and are commercially available, see e.g. Antibodies: A Laboratory Manual, Harlow and Lane (Cold Spring Harbor Laboratoty press, Cold Spring Harbor, NY 1988) and Current Protocols in Immonology, and Current
Protocols in Molecular Biology, both John Wiley and Sons, Inc., N.Y.) incorporated herein by reference.
In humans, and particularly infants and newborn of other species, it may not be suitable to use an invasive method for analysing intestinal maturation. Further, ethical constraints associated with obtaining tissue biopsies from healthy infants have forced investigators to develop non-invasive methods.
Thus, further intestinal maturation may be analysed by a non-invasive method. Said non- invasive methods may, of course, be used in any mammal such as the mammals exemplified herein or any other mammal. Further embodiments are wherein the mammal is a human, such as e.g. an adult or an infant or neonatal.
Methods for analysing intestinal maturation by non-invasive methods are known in the art and examples of such methods include the methods developed by Chapkin et al. (Noninvasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells, Am. J. Physiol Gastrointest Liver Physiol, 298: G582-G589, 2010, incorporated herein by reference), by Veereman- Wauters, G et al., (Journal of Pediatric Gastroenterology & Nutrition: August 1996 - Volume 23 - Issue 2 - pp 1 1 1 -1 17, The 13C-Octanoic Acid Breath Test: A Noninvasive Technique to Assess Gastric Emptying in Preterm Infants incorporated herein by reference, or by T RAVES et al. (Alcohol & Alcoholism Vol. 42, No. 5, pp. 407-412, 2007).
In brief, the method by Chapman et al. encompasses a non-invasive stool-based detection of infant gastrointestinal development using gene expression profiles from
exfoliated epithelial cells. The method by Chapman is a molecular methodology whereby stool samples containing intact sloughed epithelial cells are used to quantify intestinal gene expression profiles in the developing human neonate and where particular gene sets are used as identifiers for the maturation process including structural and functional adaptation of the intestine as a response to feeding.
Exfoliated cells are isolated of its mRNA by standard procedures, e.g. directly from faeces, which contain sloughed small intestinal and colon cells, and thus, does not result in any discomfort to the subject. In brief, by using a sterile spoon about 10g of freshly voided faecal stool specimens may be collected into a sterile 50 ml conical tube containing 20 ml of guanidinium denaturation solution (e.g. provided by AMbion, Austin, TX). Samples may then be mixed by hand to create a homogenous sample, which may be immediately frozen at -20°C until transported on ice for further analysis. Samples are held at -80°C and - if shipped or moved - on dry ice.
Poly-A mRNA may then be isolated according to any known method in the art, e.g.
Davidson et al. 'Quantification of human intestinal gene expression profiles using exfolicated colonocytes: a pilot study", biomarkers, 8:51 -61 , 2003 incorporated herein by reference). Further, the integrity of the isolated mRNA may be analysed using e.g. an Agilent 2100 Bioanalyzer, and quantified using spectrophotometrical methods, e.g. by a NanoDrop, (Wilmington, DE). Samples are then processed according to the CodeLink Gene Expression Assay manual (Applied Microarray, Temple, AZ), and analysed using the Human Whole Genome Expression Bioarray. Such each array contain the entire human genome derived from publicly available, well-annotated mRNA sequences. Arrays may be inspected for spot morphology. Marginal spots may be flagged as background spots (contaminated, irregularly shaped, or saturated) in the scanning software. Spots that passes the quality-control standards may, in the scanning software be categorized as good. In addition, a set L-value and reading thereof for "low" values, may indicate "near background", such as that low L-values may reflect true low gene expression levels or may have been caused by degradation of the mRNA. Further, for the purpose of normalisation, housekeeping genes may be used.
Examples of suitable genes analysed by non-invasive methods are one-, two-, and three gene sets, such as e.g. one genes: EPAS1 , NR5A2, NR3C1 , PCDH7, ITGB2, FGF5, TJP1 , MYB, EPIM, BAD; and for two-gene sets: EPAS1 and UCP1 , CTDSPL and NR3C1 ,
NR3C1 and TNFRSF10B, FOXP4 and NR3C1 , CDK4 and EPAS1 , EPAS1 and SYP, NR3C1 and SLC26A2, GPR41 and TJPI , F0XP1 and NR3C1 , HSPAIA and NR3C1. Further, examples of three gene sets are EPAS1 , FOXE3, and SYP; CTDSPL, FOXE3 and NR3C1 ; EPAS1 , TLR5, and UCP2; EPAS1 , REG4, and UCP2; EPAS1 , LIFR, and UCP2; EPAS1 , NODAL, and UCP2; EPAS1 , HIF3A, and UCP2; EPAS1 , HOXD10, and UCP2; EPAS1 , KIT, and UCP2 as well as ALOX, EPAS1 , and UCP2 (see Chapkin et al., Table 2 in Non-invasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells, Am. J. Physiol Gastrointest Liver Physiol, 298: G582-G589, 2010, incorporated herein by reference).
The mixture of enzymes or, as in some embodiments, comprising or consisting only of one of the enzymes such as an amylase or a protease, may be administered orally, or via stomach if a tube is placed into the stomach, enterally, intraperitoneal or intravenous or any other route known in the art.
The mixture of enzymes according to the invention comprises enzymes having a pancreatic activity or action or pancreatic like action or activity. The enzyme mixture, and also in its most simple form comprising or consisting of only one of the enzymes, e.g. amylase or protease, may be used in all its embodiments in all methods and uses herein, as is evident from the appending examples and claims.
Thus, further embodiments of the enzyme mixture are wherein the mixture of enzyme comprises or consist of at least one of a protease, a lipase or an amylase. It may further comprise protease and lipase, protease and amylase or lipase and amylase, or all three enzymes together in a mixture i.e. protease, lipase and amylase.
Even further embodiments are thus wherein the enzyme mixture comprises or consist of the enzymes protease, lipase and amylase. Commercial sources of enzyme mixtures with pancreatic activity or action, or pancreatic like activity or action, include but are not limited to, Creon® (Abbot, Inc., US).
Enzymes may also be bought separately from commercial sources, as given herein, and mixed where appropriate. The enzymes may be of eukaryotic or prokaryotic origin, or may be made by recombinant means of expressing proteins.
The pancreatic activity and pancreatic like action or activity is measured by measuring enzyme activity. Pancreatic enzymes are enzymes secreted by the panceras, the main digestive gland in our body. Pancreatic enzymes include, but are not limited to, trypsin, chymotrypsin, steapsin, carboxypeptidase, elastases, nucleases, pancreatic and amylase.
Trypsin is a protease that breaks down proteins at the basic amino acids. Chymotrypsin is a protease that breaks down proteins at the aromatic amino acids. Steapsin degrades triglycerides into fatty acids and glycerol. Carboxypeptidase is a protease that takes off the terminal acid group from a protein. Elastases are a group of enzymes that degrade the protein elastin and some other proteins. Nucleases are a group of enzymes that degrade nucleic acids, like DNAase and RNAase. Pancreatic amylase that, besides starch and glycogen, degrades most other carbohydrates. Humans lack the enzyme to digest the carbohydrate cellulose.
Thus, said mixtures may further comprise pancreatic enzymes, or, as in embodiments mentioned herein, wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase, e.g. only a protease, only an amylase or only a lipase as well in some embodiments. Even further embodiments are wherein the enzyme mixture comprises the enzymes protease, lipase and amylase. Said enzymes may be of mammalian origin, as in Creon®, or be of any eukaryotic or prokaryotic origin, such as e.g. bacterial origin, fungal origin. If said enzymes are of prokaryotic origin, such as bacterial or fungal, they possess the same, or similar, activity as mammalian, e.g. human, pancreatic enzymes and are herein referred to as enzymes with pancreatic like activity or action. With same enzymatic activity it is to be understood that a trypsin is a protease that breaks down proteins at the basic amino acids, chymotrypsin is a protease that breaks down proteins at the aromatic amino acids, steapsin degrades triglycerides into fatty acids and glycerol, carboxypeptidase is a protease that takes off the terminal acid group from a protein, elastases are a group of enzymes that degrade the protein elastin and some other protein, nucleases are a group of enzymes that degrade nucleic acids, like DNAase and RNAase, pancreatic amylase that, besides starch and glycogen, degrades most other carbohydrates. Humans lack the enzyme to digest the carbohydrate cellulose.
Thus, further embodiments are wherein said mixture comprises enzymes with pancreatic activity or action, or pancreatic like activity or action, or, as in embodiments mentioned
herein, wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase of eukaryotic or prokaryotic origin, or any microbiological origin, bacterial, fungal, or even recombinant origin. Even further embodiments are wherein the enzyme mixture comprises the enzymes protease, lipase and amylase of eukaryotic or prokaryotic origin, or any microbiological origin, bacterial, fungal, or even recombinant origin.
Enzymes like lipase, amylase, and protease are available commercially, from e.g. Novo Nordisk A/S (DK), Sigma and Amano Enzyme, Inc., Nagoya, Japan. Still even further embodiments are wherein the amount of enzymes is about 12 000 - 120 000 Ph Eur (equals USP) /kg bodyweight and day of lipase; 608 - 6 080 Ph Eur (38 000 - 380 000 USP) of protease /kg bodyweight and day, or amylase 14 458 - 144 580 Ph Eur (60 000 - 600 000 USP) /kg bodyweight and day of at least one of the enzymes. One embodiment comprises all the three enzymes, i.e. lipase, protease, and amylase.
In further embodiments, twice as much, three times as much or even four times as much are given as a daily dose of at least one of the enzymes i.e. about 25 000, 50 000, 100 000, 150 000, 200 000, 300 000, 400 000 or even 500 000 Ph Eur (equals USP) /kg bodyweight and day of lipase, 600, 1 200, 2 000, 2 500, 6 000, 12 000, 20 000, or even, 10 000 Ph Eur, e.g. 40 000, 80 000, 120 000, 160 000 US U) of protease /kg bodyweight and day, or 14 000, 28 000, 42 000, 56 000 - 150 000, 300 000, 450 000, or even 600 000 Ph Eur, e.g. 60 000, 120 000, 180 000, 240 000, - 600 000, 1 200 000, 1 800 000, or even 2 400 000 USP) of amylase.
In each individual, dosage duration and frequency of enzyme delivery during treatment needs to be set individually. As discussed further herein, this is a routine task for someone skilled in the art.
Further, the pancreatic activity or action, or pancreatic like activity or action, may be measured by standard methods known in the art for enzyme activity of e.g. trypsin, chymotrypsin, steapsin, carboxypeptidase, elastases, nucleases, pancreatic and amylase. Examples of suitable assays are given herein. In brief, the following enzymatic assays for measuring enzyme activity may be used;
For Lipase; a Lipase Olive Oil assay may be used:The lipase samples may be assessed for activity against olive oil at pH 7.7 using slight modifications to the procedure described
by Ruyssen and Lauwers. The lipase activity is determined by titrating the released fatty acids from olive oil against sodium hydroxide. The assay may be automated using a Radiometer pH-Stat titrator (Titralab™). Activity units are defined as microequivalents (mEq) of NaOH required per min to maintain a constant pH of 7.7. Fatty acids released during the assay by lipase hydrolysis of triglycerides are titrated by NaOH. The mEq of NaOH represent the mEq of fatty acid hydrogen liberated. The initial rate is equivalent to base consumption in mL/min. The specific activity ^moles/min/mg protein) = initial rate x 1000 x concentration of the titrant/amount of enzyme. The ratio of activity units of the Olive Oil Assay: USP assay is ca. 1.75. The lipase activity may be determined by USP Assay for Lipase determined by titrating the released fatty acids from olive oil against sodium hydroxide as described by U.S. Pharmacopeia (Assay for lipase activity in Pancreatin, USP 24). The lipase activity in USP units are calculated by comparison to the activity of the standard, using the lipase activity stated on the label of USP Pancreatin Lipase RS. The activity of proteases may be determined by an USP Assay for Protease determined by using casein as a substrate as described by U.S. Pharmacopeia (Assay for protease activity in Pancreatin, USP 24). The protease activity in USP units may be calculated by comparison to the activity of the standard, using the protease activity stated on the label of USP Pancreatin Amylase and Protease RS. The activity of amylases may be estimated using starch as substrate as described by U.S. Pharmacopeia (Assay for amylase activity in Pancreatin, USP 24). The amylase activity in USP units was calculated by comparison to the activity of the standard, using the amylase activity stated on the label of USP Pancreatin Amylase and Protease RS.
Development and maturation of the Gl tract and related organs is different between species during the fetal period. It mostly depends on the gestational period. If a species has a longer gestational period, they have a more mature Gl tract at the birth.
Several research groups have been investigating the different steps of maturation in different mammals like, mice, rats, guinea pigs and pigs. They have shown that despite these differences, the main steps of development of the Gl tract are common among mammalian an non-mammalian, such as avian, species. The main development of Gl takes place in five main different steps; morphogenical changes, cytodifferentiation, birth/early suckling, suckling and weaning. Morphogenesis and cytodifferentiation
changes take place during the gestation period and lead to structural and functional changes in the intestinal epithelium. Birth suckling is the time that infant is transferred from the intrauterine (amniotic liquid) to the extra uterine environment. In the suckling period the infant starts to use maternal milk as the only source of nutrition. During the weaning period, replacement of milk (high fat and low carbohydrate diet) with solid food (low fat and high carbohydrate diet) occurs. Protein level before and after weaning is in principle the same. Genetic background, body size, age, hormones secreted from intestine and other parts of the body (i.e. insulin, corticoesterone)and also milk-born hormones and as endogenous factors and diet, microflora as exogenous sources are the main factors that affect Gl tract development during the postnatal period.
Rats are well studied in their development and for many studies could be used as a model. In rat pups, the main changes in the Gl tract are visible after 3 weeks of life. These changes include morphological changes, epithelial cell kinetic changes, mucosal enzyme activity and transport function changes. Increase in the number of chief cells and decrease in the number of parietal cells are signs of maturation in the stomach. Increase in the number of chief cells makes the glandular part of stomach thicker (the mucosal epithelium is thinner during early age). The secretion of pepsin, after a few days of the birth is 1.5 times higher than in adults. The pH of the stomach is higher in the neonates compared to that in the adults and decreases with time. Gastrin levels are low till day 18. As in rat pups, the stomach does not secrete pepsin so the milk proteins are not broken down but are absorbed directly from the intestine intact.
In rats at day 15 of age, the weight of the Gl increases due to extension of villi and crypt cells proliferation. Formation of crypts in species with shorter gestational period is slower than in those with longer gestational period. In rodents, the visible cell proliferation of crypts, takes place after the suckling period. During the postnatal period before weaning, formation of crypts is slow, while after weaning, proliferation and migration of the cells in the crypts increases. The proliferation of stem cells takes place at the base part of the crypts. After division, one of the daughter cells is still stem cell, while another go through differentiation to become enterocytes, enteroendocrine cells, goblet or paneth cell. All of new cells, excluding Paneth cells migrate upward toward the villi. Enterocyte cells divide a few more times along the villi and change to become absorptive cells. Vacuolated fetal type enterocytes
(VFE) are created in the distal part of the small intestine and then diffuse to the lower part into the jejunum and ileum. VFEs are located along the villi (mostly on the tip of the villi) and have two main functions. These cells transfer colostral and milk protein from the lumen of the intestine into the circulation and also have a digestive function. VFEs in the duodenum exist only during birth time. In the proximal part of the jejunum they remain for 3 or 4 days and then disappear. In the middle and distal section of the jejunum VFEs stay longer, until 14 days of age, and then fade away. During the weaning period, VFEs disappear from jejunum and ileum. The mature enterocytes have no large supranuclear vacuoles and have different pattern in function.
The main carbohydrate during the suckling is lactose but in the weaning period the diet changes to a rich source of sucrose and maltose. To break down disaccharides into absorbable monosaccharides, brush-border disaccharidases (lactase, maltase, and sucrase in respective periods) are required. While maturation is happening, the activity and secretion of brush border enzymes changes such that the secretion of lactase decreases and the activity of maltase and sucrase increased.
Studies in rats have shown that postponing the weaning period and extending the suckling period may delay the decrease in lactase activity but does not affect the elevation of sucrase and maltase activity.
Many of the mammalian neonates have permeable intestine for macromolecules during first days of life (i.e. rat pups has open intestine up to 20 days after birth). It means that macromolecules can be absorbed intact to the general circulation via specific FcRn receptor, e.g. maternal IgG, or unspecificaly, e.g. epidermal growth factor. Decreasing of intestinal permeability for macromolecules is one of several markers for intestinal maturation during development.
As mentioned above, many factors are responsible for maturation of Gl tract and studying of Gl regulation is very important issue for developing the treatment for neonates having immature gut, i.e. human preterm born babies. Neonatal immaturity and, as a result, dysfunction of Gl tract is a big problem for Neonatal Intensive Care Unit because of Necrotizing enterocolitis (NEC)syndrome. NEC is mostly developing in premature infants 75-95%and has a high mortality (around 30%). The inventors along with colleagues have
demonstrated that Gl maturation can be induced precociously by feeding young suckling rats and pigs to the PHA, lectin from red kidney beans.
Moreover, data included herein demonstrates that exogenous enzyme preparation with pancreatic like activities, e.g. Creon and microbial enzymes preparation showed a positive and promoting effects on gut maturation and development. This phenomenon is probably possible since animals during suckling period produce a lot of endogenous enzyme inhibitors, thus effect of enzymes can be limited. The trypsin inhibitors are probably most important since active trypsin is activator of all other pro-enzymes. To further investigate this aspect three experimental sets were designed and performed in suckling rat model.
The maturation process depends on species and other factors. Normally, the process of maturation after induction takes 1 -10 days, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9, or even 10 days.
In one embodiment, it takes about 3-10 days, in another embodiment 3-9, 3-8, 3-7, 3-6, 3- 5 or 3-4 days, or 3, 4, 5, 6, 7, 8, 9, or 10 days. In one embodiment, the maturation process takes about 3 days. Use of a mixture of enzymes
A further aspect of the invention is the use of a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, to induce maturation of an immature Gl tract including the intestine, e.g. the small intestine.
Said uses are wherein the immature Gl tract including the intestine, e.g. the small intestine is of a new-born infant of a mammal, such as exemplified herein, e.g. a human, rat or pig, or, a human infant such as a new-born human infant. It may also be an immature Gl-tract of a non-mammal, such as from an avian species e.g. a chicken, broiler, turkey or hen.
Ways of measuring maturation of the Gl tract including the intestine, e.g. the small intestine, are given herein as well as examples of enzyme mixtures. The enzyme mix may, depending on circumstances, comprise at least one of the enzymes with pancreatic
activity or action, or pancreatic like activity or action, e.g. at least one of a protease, a lipase of an amylase. Said mixtures may also be of a lipase or an amylase or a protease, or a protease and a lipase, or a protease and an amylase, or a lipase and an amylase, or a protease, an amylase and a lipase. Thus, in further embodiments, said enzyme mixture comprises at least two enzymes, such as a protease and a lipase; a protease and an amylase; a lipase and amylase. In still further embodiments, the enzyme mixture according to the invention comprises three enzymes, such as a protease, an amylase and a lipase. In one embodiment, it is only a protease of the above enzymes in said mixture. Thus, further aspects of the invention encompass a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, for inducing maturation of an immature Gl tract including the intestine, e.g. the small intestine, in a mammal or avian species, as exemplified herein, e.g. in a human newborn. A further aspect of the invention is a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, for treatment of an immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder.
Further embodiments are wherein said immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder is necrotizing enterocolitis. Necrotizing enterocolitis (NEC) is a medical condition primarily seen in premature infants where portions of the bowel undergo necrosis (tissue death). The condition is typically seen in premature infants, and the timing of its onset is generally inversely proportional to the gestational age of the baby at birth, i.e. the earlier a baby is born, the later signs of NEC are typically seen. Initial symptoms include feeding intolerance, increased gastric residuals, abdominal distension and bloody stools. Symptoms may progress rapidly to abdominal discoloration with intestinal perforation and peritonitis and systemic hypotension requiring intensive medical support. Even further aspects of the invention are use of a mixture of enzymes having pancreatic activity or action, or pancreatic like activity or action, for the preparation of a medicament for treatment of an immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder, e.g. wherein said immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder is necrotizing enterocolitis.
Thus, one further aspect is a method of treating an individual or subject or patient, all of which may be a newborn, with an immature Gl-tract disorder, e.g. intestinal disorder, such as a small intestinal disorder, said method comprising the steps of administering to a patient in the need thereof an effective amount of a mixture of enzymes with pancreatic activity or action, or pancreatic like activity or action, to induce Gl-tract, e.g. intestinal, such as a small intestinal maturation, e.g., wherein said disorder of an immature Gl-tract, e.g. intestinal, such as a small intestinal, is necrotizing enterocolitis.
Thus, as mentioned throughout the application, further embodiments are wherein said subject, individual or patient in the need thereof is an infant, such as a newborn.
A further aspect of the invention provides a pharmaceutical composition comprising an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, as disclosed herein and a pharmaceutically acceptable excipient, diluent or carrier. As used herein, "pharmaceutical composition" means a therapeutically effective formulation.
A "therapeutically effective amount", or "effective amount", or "therapeutically effective", as used herein, refers to that amount which provides a therapeutic effect for a given condition and administration regimen; for example, an amount sufficient to induce maturation of the Gl tract including the intestine, e.g. the small intestine. This is a predetermined quantity of active material calculated to produce a desired therapeutic effect in association with the required additive and diluent, i.e. a carrier or administration vehicle. Further, it is intended to mean an amount sufficient to reduce or prevent a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in a host. As is appreciated by those skilled in the art, the amount of a compound may vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of active composition calculated to produce the desired therapeutic effect in association with the required diluent.
In the methods, uses, kits and for manufacture of compositions of the invention, a therapeutically effective amount of the active component is provided. A therapeutically effective amount can be determined by the ordinary skilled medical or veterinary worker based on patient characteristics, such as age, weight, sex, condition, complications, other diseases, etc., as is well known in the art.
It will be appreciated by persons skilled in the art that such an effective amount of the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, or formulation thereof may be delivered as a single bolus dose (i.e. acute administration) or, 5 more preferably, as a series of doses over time (i.e. chronic administration).
It will be further appreciated by persons skilled in the art that the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, for use in the methods, kits and uses of the invention may be administered in combination with one or more other 10 conventional agents for the treatment of immature gastrointestinal tract, e.g. intestine, such as small intestine.
For example, suitable conventional agents include, but are not limited to, PHA, and/or IL2.
15 The enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, according to the invention may be formulated at various concentrations, depending on the efficacy and toxicity. In further embodiments the amount of enzymes is about 12 000 - 120 000 Ph Eur (equals US U) /kg bodyweight and day of lipase, 608 - 6 080 Ph Eur (38 000 - 380 000 US U) of protease /kg bodyweight and day or amylase 14 458 -
20 144 580 Ph Eur (60 000 - 600 000 Us U) /kg bodyweight and day of at least one of the enzymes, i.e. a protease, or an amylase or a lipase. In one embodiment, it is only a protease. One embodiment comprises all the three enzymes, i.e. lipase, protease, and amylase. Further embodiments comprise at least two of the enzymes, such as a protease and a lipase, or a protease and an amylase, and an amylase and a lipase.
25
In even further embodiments, twice as much, three times as much or even four times as much are given as a daily dose of at least one of the enzymes i.e. about 25 000, 50 000, 100 000, 150 000, 200 000, 300 000, 400 000 or even 500 000 Ph Eur (equals US U) /kg bodyweight and day of lipase, 600, 1 200, 2 000, 2 500, 6 000, 12 000, 20 000, or even, 30 10 000 Ph Eur, e.g. 40 000, 80 000, 120 000, 160 000 US U) of protease /kg bodyweight and day, or 14 000, 28 000, 42 000, 56 000 - 150 000, 300 000, 450 000, or even 600 000 Ph Eur, e.g. 60 000, 120 000, 180 000, 240 000, - 600 000, 1 200 000, 1 800 000, or even 2 400 000 US U) of amylase.
For in vitro applications, formulations may comprise a lower concentration of a compound of the invention.
Thus, there is provided a pharmaceutical formulation comprising an amount of enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, effective to treat a condition of an immature Gl tract including the intestine, e.g. the small intestine, e.g. NEC (as described above).
It will be appreciated by persons skilled in the art that the medicaments and agents will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice (for example, see Remington: The Science and Practice of Phamtacy, 1 9 edit ion, 1995, Ed. Alfonso Gennaro, Mack Publishng Company,
Pennsylvania, USA, which is incorporated herein by reference.
For example, the medicaments and agents can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or
suspensions, which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release applications. The medicaments and agents may also be
administered via intracavernosal injection.
Tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (for example, corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as
polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Exemplary excipients in this regard include lactose, starch, cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
The medicaments and agents can also be administered parenterally, for example, intravenously, intra-articularly, intra-arterially, intraperitoneally, intrathecally,
intraventricularly, intrasternally, intracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (for example, to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
Formulations suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
For oral and parenteral administration to human patients, the daily dosage level of the medicaments and agents will usually be as exemplified herein administered in single or divided doses.
It is appreciated that for the prevention or treatment of disease, the appropriate dosage of an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, will depend on the type of disease to be treated, the severity and of course of the disease, whether the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, is administered for preventative or therapeutic purposes, the course of previous therapy and the patient's clinical history and response to the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action according to the present invention is suitably administered to the patient at one time or over a series of treatments depending on the type and severity of the disease. Administration may be, for example, by one or more separate administrations, or by continuous infusion.
For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression or alleviation of the disease symptoms occurs, and a desired Gl-tract, e.g. intestinal, such as a small intestinal, maturation.
However, other dosage regimens may be useful and are not excluded. The effectiveness of enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, in alleviating the symptoms, preventing or treating disease may be improved by serial administering or administration in combination with another agent that is effective for the same clinical indication, such as another enzyme, or one or more conventional therapeutic agents known for the intended therapeutic indication, or any other substance with effect such as i.e. PHA or IL2.
The enzyme mixture, medicaments and agents can also be administered intranasal or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoro-methane,
dichlorotetrafluoro-ethane, a hydrofluoroalkane such as 1 ,1 ,1 ,2-tetrafluoroethane (HFA 134A3 or 1 ,1 ,1 ,2,3,3,3 -heptafluoropropane (HFA 227EA3), carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container, pump, spray or nebulizer may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
Aerosol or dry powder formulations may be arranged so that each metered dose or puff contains at least 1 mg of a compound of the invention for delivery to the patient. It will be appreciated that the overall daily dose with an aerosol will vary from patient to patient, and may be administered in a single dose or, more usually, in divided doses throughout the day.
It may be preferable to use a sustained-release drug delivery system, such as a microsphere. These are designed specifically to reduce the frequency of injections. An
example of such a system is Nutropin Depot which encapsulates recombinant human growth hormone (rhGH) in biodegradable microspheres that, once injected, release rhGH slowly over a sustained period. This system may thus be useful as a slow release for delivering at least one enzyme composition according to the invention, alone or in a mixture. Sustained-release enzyme compositions also include liposomally entrapped enzymes. Liposomes containing the enzymes are prepared by methods known per se. See, for example Epstein et al., Proc. Natl.
Acad. Sci. USA S2:3688-92 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA
77: 4030-4 (1980); U.S. Patent Nos. 4,485,045; 4,544, 545; 6,139,869; and
6,027,726, which are incorporated herein by reference. Ordinarily, the liposomes are of the small (about 200 to about 800 Angstroms), unilamellar type in which the lipid content is greater than about 30 mole percent (mol. %) cholesterol; the selected proportion being adjusted for the optimal enzyme therapy. Alternatively, polypeptide medicaments and agents can be administered by a surgically implanted device that releases the drug directly to the required site.
An alternative method of enzyme delivery is the thermosensitive ReGel injectable. Below body temperature, ReGel is an injectable liquid while at body temperature it immediately forms a gel reservoir that slowly erodes and dissolves into known, safe, biodegradable polymers or enzyme. The active drug or enzyme is delivered over time as the biopolymers dissolve.
Enzyme mixture with pancreatic activity or action, or pancreatic like activity or action as described herein in all its embodiments, can also be delivered orally. Such a system employs a natural process for oral uptake.
A kit Further aspects of the invention encompass a kit for inducing maturation of a Gl tract including the intestine and accessory organs, e.g. the small intestine and pancreas, or beinga kit to improve body weight gain, said kit comprising
a) a mixture of enzymes with pancreatic activity or action, or
pancreatic like activity or action, to induce Gl tract maturation, e.g. intestinal maturation, or to improve body weight gain
b) instructions to induce Gl tract, e.g. intestinal, maturation
according to any of the methods described herein or to improve body weight gain.
The enzyme mixture is desribed further herein and all its embodiments may be used in the kit format. In some embodiments, a kit includes positive or negative controls and control samples, such as a cell line or tissue known to be mature or immature samples or tissues of intestine of species to be analysed, such as a mammal, e.g. a human new-born, or an avian species such as a bird, e.g. a turkey, duck, hen, chicken or broiler thereof.
In some embodiments, a kit includes instructional materials disclosing, for example, means of use of the enzyme mixture with pancreatic activity or action, or pancreatic like activity or action, for induction of Gl-tract, e.g. intestinal, such as a small intestinal maturation according to the detection means, or means of use for a particular reagent. The instructional materials may be written, in an electronic form (e.g., computer diskette or compact disk) or may be visual (e.g., video files). The kits may also include additional components to facilitate the particular application for which the kit is designed. Thus, for example, the kit can include buffers and other reagents routinely used for the practice of a particular disclosed method. Such kits and appropriate contents are well known to those of skill in the art. The kit may further comprise, in an amount sufficient for at least one assay, the enzyme mixture described herein to as a separately packaged reagent, as well as separate instructions for its use to induce Gl-tract, e.g. intestinal, such as a small intestinal, maturation. Instructions for use of the packaged reagent are also typically included. Such instructions typically include a tangible expression describing reagent concentrations and/or at least one assay method parameter such as the relative amounts of reagent and sample to be mixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like.
Certain kit embodiments can include a carrier means, such as a box, a bag, a satchel, plastic carton (such as moulded plastic or other clear packaging), wrapper (such as, a sealed or sealable plastic, paper, or metallic wrapper), or other container. In some examples, kit components will be enclosed in a single packaging unit, such as a box or other container, which packaging unit may have compartments into which one or more components of the kit can be placed. In other examples, a kit includes a one or more containers, for instance vials, tubes, and the like that can retain, for example, one or more biological samples to be tested.
Other kit embodiments include, for instance, syringes, cotton swabs, or latex gloves, which may be useful for handling, collecting and/or processing a biological sample. Kits may also optionally contain implements useful for moving a biological sample from one location to another, including, for example, droppers, syringes, and the like. Still other kit embodiments may include disposal means for discarding used or no longer needed items (such as subject samples, etc.). Such disposal means can include, without limitation, containers that are capable of containing leakage from discarded materials, such as plastic, metal or other impermeable bags, boxes or containers. Anti-aging effect
Enzyme mixture with pancreatic activity or action, or pancreatic like activity or action in all its embodiments described herein may according to the invention also be used to feed an elderly population of most species, e.g. subjects defined herein, to prevent or limit aging of the gastro-intestinal tract. The present invention thus provides an enzyme mixture with pancreatic activity or action, or pancreatic like activity or action for use in preventing, postponing, limiting, reducing aging of the Gl-tract in a subject. It may thus further be used for treating aging as an anti-aging composition or mixture. As used herein, an anti-aging effect means to postpone, limit, reduce, reverse or even prevent aging of the Gl-tract.
Aging of the Gl-tract is often seen as impaired absorption of molecules from the Gl-tract, resulting in loss of body weight, reduced exocrine pancreatic function, morphological changes of vili, mucosa, crypt depth, reduction in intestinal disaccharidase, increased permeability for macromolecules.. This will result in a malnutrition, maldigestion and malabsorption of the elderly subject which may result in a shortening of life and have negative impact on age-related sicknesses, e.g. osteroporosis, sarcopeny, muscle fatigue, cholesteremia, ect.
Thus, the enzyme mixtures described herein in all its embodiments may be used in an anti-aging composition or formulation as f.ex. a food, a feed supplement or a medicament for preventing aging of the Gl-tract, or preventing gut involution, disorders and dis- functions of elderly.
Further examples are as described in grater details elsewhere herein are wherein the mixture of enzyme comprises at least one of protease, lipase and amylase. It may further comprise protease and lipase, protease and amylase or lipase and amylase, or all three enzymes together in a mixture i.e. protease, lipase and amylase.
Thus, the enzyme mixture described herein, in all its embodiments, may be used for the manufacture of a medicament, food- or feed-supplement for treating or preventing aging of the Gl-tract.
The enzyme mixture provided herein may further be used in postpone, limit, reduce, reverse or even prevent aging of the Gl-tract, or to prevent gut involution, disorders and disfunctions. The enzyme mixture provided herein may further be used in a specific embodiment comprising amylase. Amylase stimulates growth, i.e. improvement of body weight gain, as seen in e.g. figure 1 1 , but less or no maturation. Proteases, however are excellent stimulators of maturation of the Gl-tract, but stimulates growth or improvement of body weight gain less (see e.g. figure 7 and 4). Thus, one aspect of the invention provides a mixture of enzymes comprising amylase to stimulate growth, i.e. increase in body weight or improvement of body weight gain.
A further aspect provides a mixture of enzymes comprising both an amylase and a protease, as described in further embodiments herein, stimulating both growth, i.e. gain in body weight or improvement of body weight gain as well as maturation of an immature Gl- tract, or even preventing gut involution, disorders and disfunction of a Gl-tract of an elderly subject.
Thus, in further aspects of the invention a use of a mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action to induce an increase in body- weight or improve body weight gain in a subject. Further aspects are use of a mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action for the preparation of a medicament for increasing body-weight or improving body weight gain in a subject.
Thus, the uses to increase or improve body-weight gain, both as a medicament and as a use, are wherein the mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity are according to any of the embodiments of the enzyme mixtures as described herein. Particularly, for the use to increase bodyweight, are wherein mixture of enzyme comprises or consists of amylase. Examples of doses of amylase and other enzymes are mentioned elswhere herein and may also be used for improving body weight gain.
Any composition, mixture or formulation mentioned herein in all its embodiments may be used together with an acceptable carrier and/or diluent, which may be pharmaceutically acceptable, salts and other nutrients if appropriate.
Non-limiting examples which embody certain aspects of the invention will now be described.
EXAMPLES
Below are experiments and examples shown. The first one involved set of three enzyme which had pancreatic-like actions (Creon), and the remai n ing one was free from pancreatic-like action (Rovabio), introduced in two doses by intragastric gavage to 14 days old suckling rats model. Rovabio™, e.g. Rovabio™ Excel AP, is a concentrated powder whose main enzymatic activities are xylanase and β-glucanase obtained from a fermentation broth of Penicillium funiculosum. Rovabio™ Excel AP product hydrolyses pentosans and β-glucans in vegetable raw materials. Thus, Rovabio™ does not possess any pancreatic or pancreatic like activity.
Assays for measuring endo-1 ,4-3-xylanase activity are based on the enzymatic hydrolysis of a standard wheat arabinoxylan solution, the activity being determined by the reduction in relative viscosity (viscometer developed by Orange Leaf Company), or by measuring absorbance at 590 nm that enables endo-1 ,4-3-xylanase activity to be determined by a colorimetric method with a chromophore substratum
Assays for endo-1 ,3(4)-3-glucanase activity includes measuring absorbance at 590 nm that enables endo-1 ,3(4)-3-glucanase activity to be determined by a colorimetric method with a chromophore substratum.
Assays for cellulase (endo 1 ,4-3-glucanase) activity include the reaction, catalysed by cellulase, involving the endohydrolysis of the 1 ,4-3-D-glucosidic bonds in cellulose (lichenin and cereal β-D-glucans) forming β-1 ,4 glucan oligosaccharides. Assays are available form e.g. Adisseo (France).
I n the second experiment we studied the link between inflammation cascades and intestine maturation by blocking cyclooxygenase pathway using Ibuoprfen and Celecoxib, administered orally one hour prior to introduce of the enzymes. In both experiments there was particular emphasis on morphological and functional changes as parameters.
The results showed only Creon have increased the weight of intestine, sucrase and maltase activity, and the ratio of adult phenotype along the villi with significant values. Also the responses of the immune system to each one was various. However, small single dose of anti-inflammatory drug could not block maturation; instead it left very mild effect on enterocyte development.
Our results demonstrates that a mix of pancreatic enzyme participate in the gut maturation. Furthermore this maturation could be T-cell independent as with Creon. On the other hand, the maturation was slightly inhibited with Celocoxib, suggesting that the cyclooxgynase pathway maybe involved in the mechanism(s) that induced maturation in this model, if it blocked in precise way.
Previous published data about precocious maturation in pre-weaning rats, showed the maturation of gut was always consistent with increasing the weight of organs like the intestine and pancreas furthermore the morphological and functional changes in the
enterocytes of intestine. The examples below study the effect of the following enzyme mixes: Creon® and Rovabio® on gut development, we found that only Creon® - which have pancreatic like activity - shown effect on intestine maturation, moreover these effects were dose-related.
Similarly to organ weight, Creon® have shown some effects on disaccharidases activities, as there was significant increase in sucrase and maltase activity, while these changes were not observed in the case of Rovabio®. The higher sucrase and maltase expression in the intestine of rats indicates the presence of a higher number of mature enterocytes in it. The results revealed that only the intestine which gave high sucrase and maltase activity, expressed high levels of matured entrocytes, so only Creon® induced expressions of new mature enterocytes. By comparing the effect of Creon® (animal origin) on intestine specifically, it seems that Creon® was potent.
However, nonpancreatic like enzyme preparation (Rovabio®) yielded no effects on intestine weight, disaccharidesases nor on the development of enterocytes to mature phenotypes, supporting the ability or possibility of pancreatic enzymes to induce maturation which is safer than other materials like PHA, opening a door for a new generation of therapies for treatment of immature intestine.
Although the effects of Creon® on the digestive system are similar, responses of the immune system to each differs. There were slightly decreased and increased immune cell expansions with Creon®. It was noted that both CD25 and CD45 marker shrunk and expanded together within both enzymes.
This variation could be explained in two ways depending on the location of the material, if it was in the lumen or in L.P. In studies performed in the 1930s, pancreatic enzymes were shown to be quite effective in preventing food allergies, due to its roles in food digestion and the breaking up of food antigens into small fragments, preventing sensitivity of intestinal epithelial cells to many intact antigens, furthermore, individuals who do not produce enough pancreatic enzymes will typically suffer from multiple allergies and, and for this reason pancreatic enzymes have been used as anti-inflammatory materials. Thus
both Creon® can decrease the sensitivity of cell to luminal antigens which could be decreased some inflammatory mediators leading to decrease of immune cells in LP later on, as with Creon®. Both of the anti-inflammatory drugs Celocoxib® (selective COX2 blocker) and Ibuprofen (nonseletive blocker of COX2 and COX1 ) did not abolish the effects of Creon® on the intestine. However, the effect of Creon® did slightly decrease in the presence of Celocoxib® but not with Ibuprofen®. Those pups which were pretreated with Celocoxib® showed a decrease in sucrase and maltase activity, and a decrease in the adult phenotype ratio along the villi as compared with the Creon® group. These findings indicate some signs of a delay in gut maturation in the Celocoxib® pretreated group.
In spite of both Ibuprofen® and Celocoxib® having the same mechanism of action the outcomes was dissimilar, this distinctive effect may be related to the half life which is 2 hr, and 12 hr for Ibuprofen® and Celocoxib® respectively or may be due to different targets for each drug.
However, the reason why there was little action with Celocoxib® could be due to its dose, which was the minimum allowed dose administered once daily while the recommended dose (loaded dose) was four times more than what was used, and administered twice daily.
Since no significant data was noticed in groups which were pretreated with drugs and fed with Creon® as compared with the group fed with Creon® only, the full answer for roles of inflammatory mediators is still vague. Moreover, we do not consider other factors like, other inflammatory pathways which cannot be blocked by nonsteroidal anti-inflammatory drugs [NSAIDs], severity and duration of COX expression.
The results below demonstrates that enzymes with pancreatic like activity or action participates in the signalling pathways involved in the gut maturation. Interestingly, the importance of T-cell expansion not being observed in Creon®-induced maturation in preweaning rats suggests that the gut maturation could be T-cell independent.
Materials and methods for Example 1 and 2.
Animal model: This study was performed on rats {Rattus norvegicus) of Sprague-Dawley stock (Mol:SPRD Han; Taconic M&B A/S, Ry, Denmark) conventionally bred in the Departmental animal unit in a controlled environment with a temperature of about 20 ±1 °C, with a relative humidity of 50±10% and a dark-light cycle of 12:12h. Dams with their litters housed individually in a polycarbonate cage on chopped aspen wood bedding with free access to water and chow from a lid feed hoper. Experimental procedures: In both of the following experiments 14-d-old pups were weighed and divided into groups and further to subgroups depending on the aim of each experiment. Pups were fed intragastrically via a feeding tube (0.96mm outer diameter, PE50, Becton Dickinson, Sparks, MD, USA), in a volume 0.01 mL/g b.wt. The dose(s) for each pup was repeated once daily in corresponding manner for three days (14, 15, 16-d- old).
At 17 days of age, all the pups were separated from their dams and then anesthetized by a subcutaneous injection of a mixture of of azaperone® (Stresnil; Janssen
Pharmaceutica, Beerse, Belgium), 30 μg g body weight (b.wt), and ketamine® (Ketalar; Pfizer, New York, NY, USA), 170 μg g b.wt. Once sure of anesthesia, the abdomen and thorax were then opened, euthanized via heart puncture. The small intestine was, after it was dissected out, length measured and then divided into two equally long proximal and distal parts, both of which were flashed with cold saline followed by a measurement of each one's weight. A 2cm piece was collected from the midsection of the distal part and fixed in bouin's solution for 24hr at room temperature for morphological changes measurements, while the rest parts of it were immediately frozen on dry ice and stored for functional analysis.
Assay of disaccharidases: The distal part of the small intestine was homogenized in cold 0.9%NaCI (1 :10 w/v). Then, the disaccharidase activities were measured by the Dahlqvist A method, by incubating the homogenates with the appropriate disaccharide for 1 h at 37°C, thereafter the liberated glucose was measured by using a glucose oxidase reagent (Sigma chemicals), as described in Dahlqvist, A, in 1984 (Assay of intestinal
disaccharidases, Scand J Clin Lab Invest, 1984;44: 169-172).
Protein estimation: The protein contents were determined by the method of Lowry et al (Lowry OH, Rosebrough NJ, Farr AL & Randall RJ Protein measurement with the Folin phenol reagent, J Biol Chem ; 1951 : 193, 265-275.), modified for 96- well microplates as described in Pierzynowsk et al (Pierzynowsk SG, Westrom BR, Svendsen J & Karlsson BW. Development of exocrine pancreas function in chronically cannulated pigs during 1- 13 weeks of postnatal life. J Pediatr Gastroenterol Nutr 1990;10:206-212), and using serial dilutions of BSA (Sigma chemicals) as a standard.
Histology and morphomertry: All the samples from the distal SI were embedded into paraffin, cut laterally into 5mm thick sections, deparaffinated, and stained with hematoxylin and eosin according to standard procedures. All the samples were then imaged by using an Olympus PROVIS microscope (objective x10) utilizing an Olympus DP50 camera (Olympus, Tokyo, Japan). Morphomertic analysis by measuring the ratio of the length of the adult-like epithelium to whole villi length was done by using ImageJ 1 .36 program (National Institute of Health, Bethesda, MD).
Immunohistochemistry (Staining of immune cells): All samples from distal part were embedded, cut, deparaffinated, followed by incubation in PBS pH 7.2 containing 0.5% peroxidise, washed in PBS (pH 7.2), and incubated overnight at 4°C with specific primary Abs. It was rabbit polyclonal Ab against rat CD45 (diluted 1 :50) and mouse Ab against rat CD25 (diluted in1 :50), markers expressed on all leukocytes and effector T cells respectively (3).
The next day, the samples were washed in PBS followed by incubation for two hours at room temperature with secondary Abs (antibodies) conjugated with horseradish peroxidase, it was anti rabbit (diluted 1 :1400) and anti mouse Abs (diluted 1 :1000) for
CD45 Ab and CD25 Ab respectively. To visualize the targets of CD45 and CD25, complex of 3,3-diaminobenzidine tetrahydrochloride (Sigma Chemicals) was used as the substrate.
Before mounting, all the samples were counter-stained with haematoxylin. Thereafter, different images for treated and control group were viewed, using the same microscope and same program which were prescribed, followed by calculating numbers of CD45 and
CD25 per cubic millimetre.
Calculations and statistics
In order to compensate for individual variations in BW, the organ measurements are presented per g BW. All data are presented as mean values and standard deviations. Statistical comparisons between all groups were carried out using a one-way ANOVA analysis (SigmaStat 2.0; Jandel Scientific, San Rafael, CA, USA) with all pairwise multiple-comparison procedures (Student Newman-Keuls method). Differences were considered to be significant when Ρ<0 5.
Example 1
The 1 st experiment involved three litters (n=34), each litter receiving one enzyme mix as explained below. The pups in each litter were divided into three groups: One group received a dose of one enzyme mix (see below) and was referred to as high dose, while the second group received a dose five times lower than the first group and was referred to as low dose while the last group received DW (distilled water) and this group is referred to as control. The first group fed with Creon® (Abbotte, Germany) in doses of 1.5 and 0.3 mg/g b.wt (body weight) for high and low dose respectively, diluted in a DW with final volume of 0.01 mL/g b.wt for both. The second group were treated with Rovabio (Adisseo, France) respectively. In both cases, the dose was 0.5 and 0.1 mg/g b.wt for high and low doses respectively, diluted in DW giving final volume of 0.01 mL/g b.wt for both. The third group was treated with microbial-derived enzyme mixture in high dose 0.7 mg/ g b.wt. and low dose as 0.14 mg/g b.wt., in volume 0.01 mL/g b.wt. The control group of the above litters received the same volume of DW (0.01 mL/g b.wt).
Each enzyme preparation contains such composition of enzymes with corresponding activities: 150mg of Creon capsule (lipase 10 000USP, potease 37 500USP, amylase 33 200USP); 100mg of microbial enzyme mixture powder (lipase 17 600USP, protease 12 500USP, amylase 1 875USP) and for 1 g of Rovabio Exel AP(endo-1 ,4-beta-xylanase 22 000 visco units and endo-1 ,3(4)-beta-glucanase 2 000 AGL units (explanation: 1 visco unit of endo-1 ,4-3-xylanase is defined as the amount of enzyme which will hydrolyze the substrate, reducing the viscosity of the solution, to give a change in relative fluidity of 1
(dimensionless) unit/mn/g of enzyme under the conditions of the assay (viscometer developed by Orange Leaf company); 1 AGL unit is defined as the release of oligomers from a chromophore-bound glucan which are not precipitable by ethanol, equivalent to an absorbance of 0.82 units at 590 nm).
Example 2
The 2nd exp. includes four litters; all pups (n=36) were randomly divided into two groups (Creon : 150mg of capsule (lipase 10 000USP, potease 37 500USP, amylase 33 200USP and water), the dose of Creon was 1 .5 mg/g b.wt), then each group divided into subgroup pretreated one hour prior to enzyme feeding with anti-inflammatory drugs, Ibuprofen or Celecoxib (celecoxib; Pfizer, New York, NY, USA) the dose of drugs was 0.01 mg/g b.wt per day for both, diluted to give volume 0.01 mL/g b.wt .Thus six groups were obtained water/water, I bupofen/water, Celecoxib/water, water/Creon , I buprofen/Creon and Celecoxib/Creon.
Results - Example 1 and 2
Effect of enzymes on gut maturation
There were no significant effects detected from Creon on proximal parts nor any from Rovabio doses on intestinal weight as compared with the control group (Table 1 ). In spite of there being little change in the intestinal length , none of the enzymes gave significant values (Table 1 ).
Effect on the structure and maturation of enterocytes: both doses of Rovabio did not show any effect on class switching of enterocyte to mature phenotype as compared with that of the control group. In contrast, the enterocytes were highly affected and replaced by a new generation of adult phenotypes in response to high doses of Creon. The morphometric analyses as a percentage of mature entrocytes to whole villi height were 32% with Creon, as compared with control (Table 3 and Figure 2a-c).
Effect on the immune cell in LP: With both markers CD45 and CD25, no significant decrease and increase in response to Creon were observed as compared with control (Table 4).
Effect on disaccharidases: In both cases of Creon treated rat pups, a significant increase in maltase and sucrase activities could be seen in the distal SI homogenate, as compared with control, while no effect could be detected in lactase activity (Table 2).
Effect of anti-inflammatory drugs on Creon-induced maturation
Effect on the Small Intestine (weight and lenght): In Example 2 the effect of Creon on intestinal weight and length could not be cancelled in pups which were pre-treated with Ibuprofen and Celocoxib (Table 5).
Effect on the structure of villi: The morphometric analysis of mature cells appeared to be unaffected in the presence of Ibuprofen, whereas there is slightly decrease in case of Celocoxib (Table 6).
Effect on disaccharidases: All disaccharidases activities have appeared to be unaffected in Ibuprofen pretreated pups, while it was slightly inhibited in Celocoxib pretreated pups especially with sucrase and maltase (Table 7).
Table 1
Distal wt. ΐ1 L- art
Ti-fis mer;! lv- ·½ = ··, 3. Mean JO SB
C n ra:: fwatsn _ 1.53 O.CS IS. S3 1 i.as 17. -S A 1.00
Pancre-sii-c enzymes c-f arsisns?
1...EJ C.B7 19.04 ** 2 ¾2 18 ,83 Si
1.S3 o.io 21. OS * 13.S4* 0.SO
Centra:! (wsierj
1.S3 0.Q9 17.51 * 1.31 1- T: * 0 71
Pan re^iic-tft;? e-n-syrnes f
law 1...SJ B.1I 15,43 i8 LIS 1.21
l.ss e.i. 13.53 * 0.32 17.15 i!
nt s:i iwsterj
1.55 C.12 n.ss 1.08 IS SI 0 S1
\ov; I.SS G.S 1778 1.73 1S1
1.E3 17.71 £.7s- 16- .55 1.60
Table 1 shows the results of a comparison between the effects of different doses of Creon (animal origin) and Rovabio (non-pancreatic like enzymes of microbial origin) as compared to their respective control on intestine length, and weight of proximal, and distal part. Values are means for all observations with standard deviation (n=3-7). Results considered to be significant if P<0.05. The different capital letters showed signiffican differences between compared groups.
Table 2
Disacrharidase specific activity, U/mg
Lactase MaStaie U
Treatment Mean SD Mean Mean SD
Control (water)
99.86 19.95 81.03 " 8.87 2.39 0:92
Pancreatic enzymes of
ammai origin 79.8; 3.48 152.99 " 12.50 15.08
Pancreatic-iike enzymes of
103.09 11.15 124.82■ 21.32 $.95 - 1.81 microbta! origin Table 2 shows the results of the effect of high doses of Creon® as compared to control on disaccharidase activity (lactase, maltase sucrase) in distal part of rat intestinal
homogenates. Values are means for all observations with standard deviation (n=4-5). Results considered to be significant if P<0.05. The different capital letters showed significant differences between compared groups.
Table 3
Mature epithelium,. %
Treatment Mean SD
Control (water)
8.92 k 1.84
Pancreatic enzymes of animal origin
38.89 C 5.54
Pancreatic-iike enzymes of microbial
origin 28.08 S 7.42
MOTpancreatic-!ike enzymes of
7.46 A 3.25
microbial origin
Table 3 shows the effects of the high doses of Creon (animal origin), and Robavio (nonpancreatic like enzymes of microbial origin), on appearance of adult like enterocytes along the villi in the distal part of intestine. Results are expressed as means with SD (n=4-5). Results considered to be significant if P<0.05. The different capital letters showed signiffican differences between compared groups.
Table 4
Small intestine
CD45+S n >/L < .
ceHs/mucosa ?Hs/roucos3
If est men t Mean Mean
Control (water)
91.14 24.61 39.01 45, OS
Pancreatic enzymes of animal:
64.24 33,13 53.71 48.50
Control (water)
30.96 20,34 29,88 20,86
Psrtcreatse-like enzymes of microbial origin
62.44 17,22 62.40 27.93
Table 4 shows a comparison between the effects of the high dose of Creon (enzymes of animal origin) on immune cells in the LP of distal small intestine. The figure shows numbers of leukocytes (CD45), and affector T-cell (CD25) after treated with the previous materials as compared with their respective control. Results are expressed as means with SD (n=3-8). No significant differences between groups are observed.
Table 5
m-n!: ir-testine
Length, cm/g i wt ProximaS -vvt, mgfg bwt Dis af t, mf g b wt
SD Mea SD Mean SD
Contro? (water)
1.66 0.05 16.23 4 0.88 14.39 s 1.30 none wat r)
i.6Ci G.15 16-24 * 1.25 13.S1 A 1.0S
Ibuprofen
1.64 0.09 IS.32 4 1.55 14.45 4 2.28
Cetexostb
Pa creatic enzymes f
1.83 0.11 22.29 s 1.16 17.79 3 0. 1 animal: S!"ig no e water}
1.82 0.13 21.40 s 3.42 18.02 3 1.07
Ibuprofen
I SO 0.10 20.95 * 2.03 1J3.17 5 1.88
Cetexoa
Table 5 shows effect of Creon at dose 1.5 mg/g body weight on small intestine length and weight in presence of Ibuprofen and Celecoxib. Figure shows effect of NSAIDs in absence and presence the prescribed dose of Creon. Results presented as means with standard deviation (n=4-6). Results considered to be significant if P<0.05; the different capital letters showed significant differences between compared groups. Table 6
Ma ure epithelium, %
Treatment Drug pre-treatroent Mean SD
none (water)
Control (water) 10.62A o.ss
ibuprofen
8.78A 1.44
Cefexosib
7.88* 1.82
Pa ncreetk: enzymes. none (wat r J
39.24s 17.21
of animal origin
Ibuprofen
40,29s 18,31
CeHexosib
30.84B 9,38
Table 6 illustrates the percentage of mature entrocytes along villi for each group of treatment. Values are expressed as means with standard deviations. Results considered to be significant if P<0.05; the different capital letters showed significant differences between compared groups.
Table 7
:handase * :if t activity, t
Lactase SV!a!i Sucra; ;e
Treatment Drug pre-treatrrserst ean SD Mean SD Mean SD
none (water)
Control {water} 113.51 10. S 3 78.28 s Ϊ9.70 1.G2 ¾ I.4S
t uprofen
114.17 11.76 S2.75 * 13.72 1.12 A 1.41
Ce!exossb
100.91 5.31 72.24 * 11.98 1,23 A 1.64
Pancreatic enzymes none {water}
108.04 17. S3 222.27 6 22.09 21. S9 E 9.S2 of animal ri in
[buproferi
115.86 21.64 211.45 s 55.84 22.21 E 1:1.65
Ce!exossb
10.5.41 14.63 190.22 2 36.75 1S.G9 B 6.94
Table 7 shows the disaccharidase activity in distal part of rat intestinal homogenates for each group as showed in the bottom of the columns. Values are expressed as means with standard deviation (n=4-5). Results considered to be significant if P<0.05; the different capital letters showed significant differences between compared groups.
Example 3-5
Material & Methods for Examples 3-5: All experiments were performed in young suckling rats by feeding them from 14 days of age via stomach tube for 3 continuous days (ones a day). One day after last treatment rats were euthanized and plasma and organs proceeded to study structural and functional changes of gastrointestinal system.
Animals
The examples 3-5 were carried out on Rattus norvegicus (14 day old pups) from Sprague- Dawley strain (Mol: SPRD Han; Taconic M & B, Denmark). The dams were placed in the animal facility under standard environment (20±1 C, 50±10 RH%, 12:12 hr light-dark cycle) in individual polycarbonate cages with the bedding material inside it. They had free access to the rodent laboratory chow (RM1 , SDS, Essex, England) and the bottled tap water placed over their cages. The cage of pregnant females was checked regularly to define the birth date as day 0. The litter size for each dam was restricted to 12 or 13 pups, to reduce variability. Pups were restricted to reach to the solid food by using 7 cm wall
extensor over each cage. The pups were kept with their dam until dissection day (day 17). The protocol for this experiment was approved by the Lund University Ethical Review Committee for Animal Experiments and conducted according to the European Community regulation concerning the protection of experimental animals.
Feeding procedure and dissection
All the experiments were done in split-litter model.
Source of enzymes
All enzymes used in experiments are commercially available and can be purchased from Sigma Aldrich:
1 ) a-Amylase from Aspergillus oryzae
2) Lipase from B. cepacia
3) Proteinase from Aspergillus melleus
Example 3 - Set I. In this set suckling pups were divided into five groups; control (water) amylase 10 OOOUSP/rat/day, lipase 4 OOOUSP/rat/day, protease 15 OOOUSP/rat/day, and mixture of these enzyme with corresponding activities per rat and day. This study was evaluating the effects of different pancreatic-like enzymes on the gut maturation and functioning and had 3 individual litters; n=12, n=10 and n=13, totally n=7 pups per each group. Each of the enzymes (Amylase, Protease and Lipase) (Sigma Aldrich) was available in the powder form and was resolved in distilled water prior to stomach feeding during days 14, 15 and 16. The volume of administered enzymes and distilled water (for control groups) was 0.01 ml/g BW. Each time, prior to the feeding procedure, the pups were weighed. At day 17, pups were starving for 2 hours prior to feeding with marker molecule solution containing BSA (1.25 mg/g BW) and BlgG (1 .25 mg/g BW),
administration volume 0.025 ml/g BW. Then 3 hours later, the pups were sedated with C02 and anaesthetized by subcutaneous injection with a mixture of ketamine (Ketalar®, Pfizer, New York, USA, NaCI and azaperone (Stresnil®, Janssen Pharmaceutica, Beerse, Belgium), 0.01 ml/g BW. After opening the abdomen of the rats, 1 ml of blood was collected from heart by using syringes containing protease inhibitor and EDTA (50μΙ) as anticoagulant and was transferred into ice-chilled tubes. After this, the pancreas was
immediately dissected and rinsed with cold 0.9% NaCI, weighted and stored at -70C. The SI was removed and its length was measured then divided into two halves, proximal and distal. Each segment was flushed out with cold 0.9% NaCI to clean the lumen and was then weighed separately. About 2 cm from middle part of these segments was taken for histology and the rest of the intestine was frozen in -70 for disaccharidase analysis, Dahlqvist method (1984). The stomach was removed and its content was collected into the tube (for measuring its pH) and frozen. Then cecum was dissected out, opened, rinse and weighed as well as liver and lymphoid organs spleen and thymus were dissected and weighted. All samples taken for histology were immediately fixed in the Bouin's solution for 24 hours then were transferred into the 70% ethanol. The plasma were collected after centrifuging at 3,000 for 15 minutes at 4°C and frozen at -20°C for further studies.
Example 4 - Set II. The second study was about comparing the effect of different doses of protease (15000USP, 7500USP, 3750USP and 1850USP) on the development of the Gl tract with control. In this experiment 2 litters of pups were used (n=13 and n=12). Pups were divided into five groups to fed with different doses of protease; 15000USP (n=3), P7500USP (n=6), P 3750USP (n=6), P 1875USP (n=5) and water as a control (n=5). The feeding was during 3 continuous days, once a day. 24 hours after the last feeding, on day 17, similar dissection steps and analytical procedures as mentioned for the previous experiment were followed.
Example 5- Set III. In the last study, the health and the growth of the pups were monitored for 3 weeks. Pups where treated at age 14 day of life with the protease 15 000 USP/rat/day for 3 days once a day (on days 14, 15, and 16). This study performed using 3 litters (n=9, n=1 1 and n=10) where pups were divided into 2 groups; enzyme treated and control. After last feeding rat were further divided into subgroups: early weaning started on day 17(n=8) and normal weaning started on day 21 (n=6). All animals were monitored via weighing for one week on a daily basis and then once a week for the next 2 weeks. Intestinal morphology
All samples collected for histology were fixed with Bouin's solution for 24 hours and then stored in 70% ethanol, dehydrated, embedded into the paraffin and then cut into sections with 5 μηη thickness. The tissue sections were transferred onto the slides, rehydrated and stained with H&E according to the standard technique. After mounting under cover slips
samples were examined using light microscopy to estimate ratio between total length of the villus and length of the adult type enterocytes using ImageJ program.
Intestinal enzymology
The proximal samples of the SI were de-frozen and weighted and then homogenized with 9 parts of 0.9% NaCI (9w/v). The homogenates (50μΙ diluted samples) were incubated with the appropriate disaccharide (50μΙ of 0.056M sucrose, maltose and lactose) for 1 hour at 37C. After this, the liberated glucose was determined by adding glucose oxidase reagent (Sigma Chemicals), and incubated for 30 minutes. Then samples were transferred into the 96-well plate in triplication and the absorbance was measured at 450 nm. To measure the protein contents of the homogenates, Lowry method, was used, where BSA (Bovine Serum Albumin) was used as a standard. The results are presented as specific activity units per mg of protein (u/mg).
Plasma concentration of marker molecules
The plasma level of marker molecules was quantified by using immunoassay rocket electrophoresis and SRI (single radial immunodiffusion) for plasma BSA and BlgG respectively.
Stomach PH
The contents of the stomach were de-frozen and then resolved with 1 ml of cold 0.9% NaCI. After resolving, they were centrifuged and the pH was measured in the supernatant using pH-meter.
Calculation and statistic All data are presented as mean ± standard deviation (SD). Statistical comparisons between each group and control group were performed using the i-test. Results were considered as significant when P< 0.05.
Results and discussion for Examples 3-5: Decreased intestinal permeability for macromolecule absorption, changes in disaccharidase activity from predominant lactase to maltase and sucrase as well as changes in structure of the small intestinal mucosa from the fetal type enterocytes to the adult types, demonstrated precociously induced maturation by protease enzyme. These effects on gut were found to be dose-dependent for protease.
Example 3 - Effects of individual pancreatic-like enzymes, amylase, lipase, protease and their mixture on gut maturation
Set I. Effects of individual enzymes with pancreatic-like activity on body and organ weights Table 8 shows the body weight of rats treated for 3 days with individual enzymes or their mixture and weights of the digestive and lymphoid organs. The results show that groups treated with protease and mixture had lower body weight compared to that in the other groups and control, may be due to diarrhoea observed after receiving the first dose. After one day of losing weight, they start to gain weight in a regular basis again. The result showed significant increase in organs along digestive tube: small intestine and cecum as well as accessory organ pancreas. Moreover both proximal and distal parts of SI had significantly higher weight, while the length of the SI was longer in comparison to other groups and control. In addition, in the pups treated with protease and mixture, the weight of the thymus was significantly lower compared to that in control showing developmental changes in immune system, while spleen weight was unchanged.
Table 8 - Effects of pancreatic-like enzymes and distilled water (control) on suckling rats Gl and l mphoid organs
In Table 8 the weight of different gastrointestinal and lymphoid organs presented per gram body weight (g BW), expressed as mean ± SD. Each group were compared to control by Student' t-test. The significant differences are demonstrated with P<0.05(*), P<0.01 (**). SI, small intestine; BW, body weight
Intestinal morphology
The slides prepared from the distal part of SI were analysed for the present of foetal and adult type enterocytes. In the control group, foetal-type epithelium with vacuolated enterocytes expanded along the whole villi (87.7%), where as in groups treated with amylase and lipase these cells limited to the middle and the tip of the villi(A=77%, L=77%) (Fig 3). In pups treated with protease and mixture, all of the vacuolated enterocytes were replaced with adult type enterocytes (Fig 4).
Disaccharidase activity
The activities of the brush-border disaccharidases, maltase, sucrase and lactase were analyzed in the proximal part of the small intestine (SI). In groups treated with protease and mixture, the activity of lactase decreased while maltase and sucrase activities were significantly increased. In contrast, lactase activity was higher in control, lipase and amylase groups while the sucrase and maltase activities stayed in a lower level (Fig 5). Effect on the pH
Stomach contents of the protease and mixture treated groups had significant lower pH compared to that in the control, amylase and lipase groups (Table 8).
Effects on macromolecule absorption
The uptake of marker molecule both BSA and BlgG was significantly lower among the groups treated with protease and enzyme mixture ,, demonstrating decreasing of intestinal permeability (intestinal "closure"). In contrast, the intestinal macromolecular
absorption capacity in control group and the pups treated with amylase and lipase remained in a higher level (Fig. 6).
Conclusion (Set I)
The results of this experiment evaluated that the administration of protease but not lipase to suckling rats induces morphological and functional development and maturation of the small intestine (SI), while amylase showed sign on maturation only in distal small intestine. Nevertheless, the results demonstrate that effect of protease in the most prominent for both gastrointestinal (Gl) system growth and maturation, while lipase has effect only on distal intestinal growth and showed no other signs of maturation.
Example 4 - Set II. Effects of different doses enzymes with pancreatic-like activity on body and organ weights
This study designed to compare the effects of different doses of protease on gut development to find the sufficient range of enzyme treatment. Table 9A demonstrates the weight of different organs, Table 9B showed the mean body weights of rats during treatment period (from 14 to 16 d of age and the day of dissection, 17d of life) and Fig 7. shows the rats body weight during treatment. The group treated with the highest dose of protease had signs of diarrhoea after receiving the first dose on day 14. The results of digestive organs demonstrate that rats treated with protease 15 000USP and 7 500USP had increased weight for Gl organs and the length of the SI was longer in this group compared to that in control. Additionally, the thymus weight was significantly lower in the highest dose compare to control.
Table 9A - Effects of different doses of protease (15000 USP, 7500 USP, 3750 USP, 1875 USP) and distilled water (control) on suckling rats Gl and lymphoid organs.
The weight of different gastrointestinal and lymphoid organs presented per gram body weight (g BW), expressed as mean ± SD. Each group were compared to control by Student' t-test. The significant differences are demonstrated with P<0.05(*), P<0.01 (**), and P < 0.001 (***).
SI, small intestine; P, protease; BW, body weight
Table 9B - mean body weights during treatment period and (14-16d of life) and day of dissection (17d)
Intestinal morphology
The slides prepared from the distal part of SI were analysed for the maturation degree of mucosa by measuring the apperance of adult type enterocytes. In the control group, fetal- type epithelium with vacuolated enterocytes still expanded along the whole villi, while in groups treated with proteases P 7500USP, 3750USP and 1875USP these cells limited to the middle and the tip of the villi, and in P 15000USP group all of the vacuolated
enterocytes disappeared by giving place to adult type enterocytes demonstrating dose- dependent effect of protease treatment on intestinal morphology (Fig. 8).
Effect on the pH
Stomach contents of the protease 15000USP treated group had lower pH compared to that in the control, and groups treated with other doses (Table 9).
Conclusion (Set II)
The results of this experiment evaluated that the effects of protease on the gut maturation and development were dose dependent. Hence, range with activity between 15 OOOUSP and 7 500USP must be deeply investigated to find the optimal effective dose.
Example 5 - Effects of individual enzymes with pancreatic-like activity on body and organ weights
In this set of experiment, after feeding pups with protease in dose 15 OOOUSP, their health and growth were monitored, in daily basis for the treatment days and one week after weaning, then every week for two more weeks. Some of rats after first treatment showed signs of diarrhea for highest dose of protease. Generally, the results demonstrated earlier observed decrease in growth after first treatment with highest dose of protease in comparison to control group (Fig.9).
The early and normal weaning did not show difference in growth between enzyme and control groups, however after normal weaning (NW) the body weight for both control and enzymes groups were significantly higher compared to early weaned (EW) rats.
Conclusion (Set III) All the pups were gaining weight regularly and had no systematic problem or growth disorder.
The early weaning showed no disadvantage for both groups, control and protease enzyme treated. However at second week after weaning, the body weight for both control and enzyme treated groups were lower compared to that in normally weaned groups.
General conclusion Experiment 3-5
The results from this study have demonstrated that pancreatic-like enzymes of microbial origin might contribute in Gl development after 3 days exposure. Furthermore, the protease has the most prominent effect on gut growth as well as structural and functional maturation of gut organs compared to other enzymes. However, amylase also had some effects on SI maturation seeing from change in the enterocyte replacement, while lipase had effect on small intestinal growth in the distal portion, respectively. Effects of enzymes on the gut maturation were concluded from alteration in the mucosal disaccharidase pattern (increased activity of sucrase and maltase and decreased lactase activity), gut "closure" (decreased intestinal permeability for macromolecules) and changes in mucosa morphology (the replacement of the supranuclear vacuole-containing enterocytes (fetal- type) with adult-type enterocytes).
Example 6 - Effects of individual pancreatic-like enzymes, amylase, lipase, protease and their mixture on exocrine pancreatic secretion
The same rat model as in Experiments 3-5 was used.
The effect of microbial-derived enzymes with pancreatic activity: protease, lipase, amylase and their mixture on exocrine pancreatic secretion after 3d of oral gavage to suckling 14d old rats (see experiment 3-5 above). Treated groups were compared to control, *p<0.05
As seen in figure 10, the results demonstrated that protease is the most efficient enzyme for stimulation of the pancreatic function in young rat.
Example 7 - Effect of microbial derived amylase and lipase on growth of rats.
This study was done to consider the effect of separated enzymes on body growth. The experiment is completing study done earlier to investigate effects of protease on body growth and was performed in similar mode (see experiment 3-5 above).
Suckling pups were divided into 3 groups depending on the treatment; amylase, lipase and water (n=7 per group). The enzymes are available in the market in form of powders and were resolved in distilled water prior to stomach feeding during 14-16d of age, ones a day. The administered dose for each single enzyme feeding was 4 000 USP for lipase/rat and 10 000 USP for amylase/rat. The control group received vehicle.
Fig 1 1 shows the growth of young rats treated once a day at age 14-16d of life with microbial-derived enzymes having lipase and amylase activities, n=7 per group. The result demonstrates the clear effect of amylase to stimulate growth of young rats in comparison to lipase and control group.
Example 8 - study on papain vs microbial-derived protease
The laboratory animals used in this experiment were Rattus norvegicus (14 day old pups) from Sprague-Dawley strain. The dams were placed in the animal facility under standard environment (20±1 C, 50±10 RH%, 12: 12 hr light-dark cycle) in individual polycarbonate cages with the bedding material inside it, with access to the rodent laboratory chow and the bottled tap water placed over the cages. The pregnant rats were checked regularly to define the birth date as day 0. The litter size for each dam was limited to 12 or 13 pups, to reduce variability. Pups were restricted to reach to the solid food by using 7 cm wall extensor over each cage and were kept with their dam until dissection day (day 17). Suckling pups were divided into 3 groups depending on the treatments; microbial protease as a positive control, water as negative control and enzyme from papaya fruit (papain) (in total; protease=7, papain=8, control=7). The enzymes are available in the market in form of powders and were resolved in distilled water prior to stomach feeding during 14-16d of age. The administered dose for each enzyme was 10000 USP/animal. The volume of administered enzymes and water (for control groups) was 0.01 ml/g b.wt. Prior to the feeding procedure, the pups were weighed. At day 17, pups were starving for 2 hours prior to the feeding with marker molecule solution containing BSA, as a marker for unspecific absorption (1.25 mg/g b.wt) and BlgG for specific absorption(1 .25 mg/g b.wt), in 0.025 ml/g b.wt. Three hours later, the pups were anaesthetized and organs were dissected out for analyses.
Effects of fruit papain on body and organ weight
Results are shown in Table 10 below showing effects of fruit papain on body and organ weight in comparison to microbial protease. By analysing the results from organ weights, it was obvious that pups treated with papain had heavier pancreas, cecum, proximal and distal SI while protease-treated pups showed significant increased weight in cecum, proximal and distal part of SI . There was also an increased weight of distal part of SI among group treated with trypsin. This increased in weight can be explained by hyperplasia, increased rate of stem cells proliferation in the SI.
Table 10 - Effects of fruit papain on body and organ weight.
The weight of different gastrointestinal and lymphoid organs presented per gram body weight (g BW), expressed as mean ± SD. Each group was compared with control by i-test. The significant differences were demonstrated with P<0.05(*), P<0.01(**), P < 0.001 (***). SI, small intestine
Effects of proteases on body weight
The effects of proteases on body weight of suckling rats during 14 to 17 days of age, n=7- 8 per group is shown in Figure 12, where control is circles, papain is squares, and protease triangles on respective line. The figure is demonstrating the growth of suckling pups during the experiment. There is no effect of protease or papain in dose 10 000 USP on body growth was observed. In figure 12 the effects of proteases on body weight of suckling rats during 14 to 17 days of age, n=7-8 per group is shown. The graph is demonstrating the growth of suckling pups during experiment. No effect of protease or papain in dose 10 000 USP on body growth was observed.
Effect on intestinal disaccharidase activity
The activities of the brush-border enzymes lactase, maltase and sucrase were analyzed in the proximal part of the SI in groups treated with papain and protease. Results are expressed as mean ± SD. *p<0.05 in Figure 13, where 13A shows lactase, 13B maltase and figure 13C surase.
In protease and papain groups the activity of maltase and sucrase were significantly increased compared to control . These functional changes demonstrate intestinal functional maturation where predominant lactase activity is decreasing while maltase and sucrase activity significantly increases. Such changes usually occur during weaning period due to dietary changes from milk to solid diet, however the animals in this experiment were used during their suckling period, having only milk as a diet. Hence the direct effect of papain and protease on small intestine cells might be concluded.
Effect on macromolecule absorption
The specific uptake of macromolecules was significantly lower among the pups treated with papain and protease as showed for BlgG absorption demonstrating decreased unspecific absorption. Furthermore, BSA concentration in rat plasma was significantly decreased in group treated with papain. I n contrast, the intestinal macromolecular absorptive capacity in control group and the pups treated with bromelain and trypsin remained in a higher level, as shown in Figure 14. Decreased absorption of BlgG and BSA can be explained by disappearance of neonatal Fc receptor (FcRn) in intestinal villi and decreased amount of supranuclear vacuoles due to replacement of adult type enterocytes lacking this ability. I n general, result demonstrated decreasing of small intestinal permeability after protease and papain treatment. I n Figure 14, the effect of microbial protease and fruit protease on the level of marker molecules absorption to the plasma, after feeding them with cocktail of BSA (14B) and Big G (14A) on day 17, (at 3 hours before dissection) is shown. These data are given as mean ± SD. Significant results; * p<0.05; ***p<0.001
Conclusion
The results demonstrates that fruit derived protease, here papain, can provoke precocious functional maturation of small intestine in young rats.
Experiment 9 - Gut maturation - Suckling pig model I
All piglets were kept with sow during experimental procedure. Piglets from 3 litters divided into 5 groups and treated with low 1 capsule and high dose 5 capsules per 15 ml of milk of Creon enzyme preparation (porcine origin: 150mg of Creon capsule (lipase 10 000USP, potease 37 500USP, amylase 33 200USP) and mixture of microbial derived enzymes having pancreatic-like activity 200mg of powder mixture per 15ml of milk as a low dose and 10OOmg of powder mixture in 15 of cow milk as a high dose (in activity per 10Omg of mixture powder (lipase 17 600USP, protease 12 500USP, amylase 1 875USP); while control group received only vehicle (n=6 per group). The administration volume was 2ml/kg b.wt. for all groups. Totally: control (n=12), porcine Creon (n= 12: low dose of Creon (LC) n=6, high dose of Creon (HC) n=6), microbial enzymes mixture (n=24: low dose of mixture (LM) n=12: high dose of mixture (HM) n=12) Piglets were treated via stomach tube twice a day (8-9am and 5-6pm) starting at age 7-8 d of life and for one week. At age 14-15d of life (next day after last evening treatment) the half from each groups of piglets were fed with macromolecule marker cocktail (Bovine serum albumin (BSA) in comcentration 125mg/ml and sodium fluorescein (NaF) i n concentration 2.5mg/ml; the administration volume was 4ml/kg b.wt) to study intestinal permeability in vivo. Blood was collected at 0, ½, 1 , 2, and 4 hours after marker-cocktail feeding. Then studied piglets were euthanized and gut organs dissected out and proceed for analyses. The rest of piglets were followed up to the slaughter.
The effect of enzyme treatment with porcine Creon and microbial enzymes mixture on body growth is shown in figure 15, as control (open circles), mixture of microbial enzymes (black circles) and Creon (open squares), n=12-6 per group.
The effect on intestinal crypt proliferation is shown in figure 16. The crypt cell proliferation in the small intestine of suckling 14-15d old piglets after 1 week gavage treatment (twice a day) with preparation of enzymes having pancreatic-like activities of porcine and microbial origin. In figure 16 Cont is control; LM is low dose mixture; HM is high dose mixture; LC is low dose Creon, HC is high dose Creon. Groups were compared to control, *p<0.05
The weight of small intestine of suckling 14-15d old piglets after 1 week gavage treatment (twice a day) with preparation of enzymes having pancreatic-like activities of porcine and microbial origin is shown in figure 17. Cont is control; LM is low dose mixture; HM is high
dose mixture; LC is low d ose Creon, HC is high dose Creon. Result demonstrate tendency of small intestine to increase its weight in dose-respond manner.
Disaccharidase activities in the small intestine of suckling 14-15d old piglets after 1 week gavage treatment (twice a day) with high dose preparation of enzymes having pancreatic- like activities of porcine and microbial origin is shown in figure 18, where A is lactase, B is maltase and C is sucrase. Groups were compared to control (n=3-5), *p<0.05
Experiment 10 - Gut maturation - Suckling pig model II
All piglets were kept with sow until the weaning day. Piglets from 5-6 litters divided into 2 groups and treated with microbial protease (Sigma) (enz group) or water (cont) (n=28 per group), total 56. The dose of enzymes was 60mg/ml with activity 1000USP per 1 mg, the adninistration volume was 4 ml/kg b. wt, the frequency of administration was every second day (ones a day). Treatment via gavage feeding was started at 8d of age and was done 3 times, (i.e. 8, 10, 12d of life).
48h after last feeding 12 piglets (6 contr, 6 enz) were separated from sow and transported to Dept, euthanized and proceed for organs dissected: stomach, small intestine, cecum, pancreas and liver.
Separate piglets (6 enzyme treated and 6 control pigs) were fed with marker molecule solution (Bovine serum albumin (BSA) in comcentration 125mg/ml and sodium fluorescein (NaF) in concentration 2.5mg/ml; the administration volume was 4ml/kg b.wt) at age 14d of life and 27d of life (the weaning day). Blood was collected at 0, ½, 1 , 2, 4, 8, and 24 hours after marker-cocktail feeding.
Additionally, at weaning, 27d of life, 12 piglets (6 cont and 6 enz) were separated from sow and transported to Dept, euthanized and proceed for organs dissected: stomach, small intestine, cecum, pancreas and liver. The rest was weaned according to standard procedure and followed to monitor their body weight up to the slaughter.
Effect of microbial-derived protease on bogy weight gain
Figure 19 shows the effect of microbial derived proteases on body weight gain in % where striped bars show treated piglets and open bars show control,
Effects of microbial enzyme on marker molecules absorption
Figure 20 shows the effects of microbial enzyme on marker molecules absorption in vivo. The results demonstrate decreased intestinal permeability for both BSA (20A) and NaF (20B) molecules in protease treated piglets (n=8) in comparison to control (n=8). *p<0.05
Effect of protease on exocrine pancreatic function
The effect of protease on pancreatic function after 3 times administration, starting at 8d of life and every other day, the results represent material taken at 48h after last enzyme treatment (14d) and at weaning time (27d) is shown in figure 21 . Figure 21A shows pancreas weight and 21 B trypsin like activity. Black bars are enzyme treated, open bars are control. Conclusion
Results indicated stimulating effect of enzyme treatment on young pig gut.
Example 11 - Long-lasting anti-aging dietary effect on old Monglian gerbils
This example will show the long-lasting anti-aging dietary effect on old Monglian gerbils, specifically analyzing gastro intestinal tract (GIT)mucosa amorphology and function of pancreatic like enzymes (lipase, amylase and proteinase of microbal origin). The morphological and biochemical changes in the gastrointestinal tract and general health after long dietary treatment by pancreatic like enzymes of microbial origin of old animalsn will be analysed. Particularly, it will be exploring of the brain-GIT function in the old gerbil after long-lasting dietary effect of Pancreatic like enzymes Description of the research started April 2, 2011 and lasting by the end September 2011
The experiment will a) investigate gastrointestinal tract after long-lasting dietary effect by pancreatic like enzymes to old gerbils, b) study the level of the dietary fat, protein, carbohydrate and mineral metabolities in the blood after long-lasting dietary effect by pancreatic like enzymes to old gerbils and c) study hormonal profile of aging animals.
Experimental setup
Aging model of Mongolian gerbil (n=48, ca 24 month of age).
Control group - (n = 24) recessive standard diet
Treatment group - (n =24) recessive standard diet + selected pancreatic like enzymes
Dietary treatment with pancreatic like enzymes during 6 month - expecting prolong life
Behavior test of studied animal during experiment - expecting improvement mobility
- Electron microscopy study of gerbil intestine - improved integrity of the intestine
Immunohistohemical study of gerbiPs gut mocosa - enhanced GALT function Morphological analyses: vili lengh - enhanced lengh; muscosa sicknes - enhanced; crypt depth - enhanced; intestinal disschardises - enhanced; host pancreatic enzyme and gal production - enhanced
Gut functional test: in vitro macromolecule absorption - minimized
Claims
A mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action for inducing maturation of an immature Gl-tract.
The mixture of claim 1 , wherein the immature Gl-tract is of a newborn.
The mixture of claim 1 -2, wherein the immature Gl-tract is of a mammal. The mixture of claim 1 -2, wherein the immature Gl-tract is of an avian species.
The mixture of claims 1 -4, wherein the mixture of enzyme comprises at least one of a protease, a lipase and an amylase.
6. The mixture of claims 1 -4, wherein the enzyme mixture comprises the enzymes protease, lipase and amylase.
7. The mixture of claims 1 -4, wherein the enzyme mixture comprises the enzyme protease. 8. The mixture of claims 1 -7, wherein the amount of enzymes is about 25 000 -
500 000 USP /kg bodyweight and day of the enzyme lipase, about 37 500 - 1 250 000 USP /kg bodyweight and day of the enzyme protease, and about 58 100 to 2 490 000 USP /kg bodyweight and day of the enzyme amylase. 9. A mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action for treatment of an immature Gl-tract disorder.
10. The mixture of claim 9, wherein the enzymes having pancreatic activity or
action, and/or pancreatic like activity or action are the mixture according to any of claims 1 -8.
1 1 . The mixture of claim 9-10, wherein said immature Gl-tract disorder is necrotizing enterocolitis.
12. A mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action for preventing aging of a mature Gl-tract.
13. The mixture of enzymes according to claim 12, wherein mature Gl-tract is of an elderly subject.
14. The mixture of enzymes according to any of claims 12-13, wherein the enzymes having pancreatic activity or action, and/or pancreatic like activity or action are the mixture according to any of claims 1 and 3-8.
15. A method to induce maturation of an immature Gl-tract, the method comprising the steps of
a) administering a mixture of enzymes to the immature Gl-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action,
b) analysing the maturation process of the Gl-tract to monitor said maturation process.
16. The method of claim 15, wherein the mixture of enzymes is according to any of claims 1 -8.
17. The method of claims 15-16, wherein the immature human Gl-tract is of a
newborn.
18. The method of claims 15-17, wherein the immature Gl-tract is of mammalian origin.
19 The method of claims 15-18, wherein the immature Gl-tract is of human origin, 20 The method of claims 15-17, wherein the immature Gl-tract is of an avian origin.
The method of claims 15-20, wherein at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the intestine are analysed to monitor the maturation process, and wherein a change in at least one of intestinal enterocyte morphology, intestinal enterocyte biomarkers and weight of the intestine are indicative of Gl-tract maturation.
The method of claims 15-21 , wherein said intestinal enterocyte biomarkers in the maturation process analysed are enterocyte disaccaridase activity and where changes in disaccaridase activities from lactase activity to sucrase activity and maltase activity of enterocytes in the intestine are indicative of Gl-tract maturation.
The method of claims 15-22, wherein said changes in intestinal enterocyte morphology in the maturation process are changes from foetal-type intestinal enterocytes to adult type intestinal enterocytes, and wherein said changes in morphology are indicative of Gl-tract maturation process.
The method of claims 15-23, wherein said weigh of the Gl-tract analysed in the maturation process are changes of weight of part of Gl-tract and wherein an increase of weight of part of Gl-tract is indicative of the maturation process.
The method of claims 15-24, wherein the mixture of enzymes is administered orally.
The method of claims 15-25, wherein the maturation process of the Gl tract takes about 3-10 days.
Use of a mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity or action to induce maturation of an immature Gl-tract.
The use according to claim 27, wherein the mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity are according to any of claims 1 -8.
. The use according to claims 27-28, wherein the immature Gl-tract is of a newborn.
30. Use of a mixture of enzymes having pancreatic activity or action, and/or
pancreatic like activity or action for the preparation of a medicament for treatment of an immature Gl-tract disorder.
31 . The use according to claim 30, wherein the mixture of enzymes having
pancreatic activity or action, and/or pancreatic like activity or action is accord to any of claims 1 -8.
32. The use of claim 30-31 , wherein said immature Gl-tract disorder is necrotizing enterocolitis. 33. A method of treating a subject with an immature Gl-tract disorder, said method comprising the steps of administering to said subject in the need thereof an effective amount of a mixture of enzymes with pancreatic activity or action, and/or pancreatic like activity or action to induce Gl-tract maturation. 34. The method of claim 33, wherein the mixture of enzymes with pancreatic activity or action, and/or pancreatic like activity or action is according to any of claims 1 - 8.
35. The method of claims 33-34, wherein said disorder of an immature Gl-tract is necrotizing enterocolitis.
36. The method of claim 33-35, wherein said subject in the need thereof is an infant.
37. The method of claim 33-35, wherein said subject is of avian species.
38. A kit for inducing maturation of an Gl-tract, said kit comprising a) a mixture of enzymes with pancreatic activity or action, and/or pancreatic like activity or action to induce Gl-tract maturation,
b) instructions to induce Gl-tract maturation according to any of the methods of claims 1 -14.
39. The kit according to claim 38, wherein the mixture of enzymes with pancreatic activity or action, and/or pancreatic like activity or action is according to any of claims 1 -8.
40. Use of a mixture of enzymes having pancreatic activity or action, and/or
pancreatic like activity or action to improve body weigh gain.
41 . Use of a mixture of enzymes having pancreatic activity or action, and/or
pancreatic like activity or action for the preparation of a medicament for improving body weight gain.
42. The use according to claims 40-41 , wherein the mixture of enzymes having pancreatic activity or action, and/or pancreatic like activity are according to any of claims 1 -8.
43. The use according to any of claims 40-42, wherein mixture of enzyme comprises amylase.
44. Use of amylase to improve body weight gain.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11823857.5A EP2613800A4 (en) | 2010-09-08 | 2011-09-08 | Maturation of gastrointestinal tract |
CA2810498A CA2810498C (en) | 2010-09-08 | 2011-09-08 | Maturation of gastrointestinal tract |
US13/821,480 US9205137B2 (en) | 2010-09-08 | 2011-09-08 | Maturation of gastrointestinal tract |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38074010P | 2010-09-08 | 2010-09-08 | |
SE1050928-9 | 2010-09-08 | ||
SE1050928A SE535296C2 (en) | 2010-09-08 | 2010-09-08 | Maturation of the gastrointestinal tract |
US61/380,740 | 2010-09-08 | ||
US201161439090P | 2011-02-03 | 2011-02-03 | |
US61/439,090 | 2011-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012033459A1 true WO2012033459A1 (en) | 2012-03-15 |
Family
ID=45810887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2011/051089 WO2012033459A1 (en) | 2010-09-08 | 2011-09-08 | Maturation of gastrointestinal tract |
Country Status (5)
Country | Link |
---|---|
US (1) | US9205137B2 (en) |
EP (1) | EP2613800A4 (en) |
CA (1) | CA2810498C (en) |
SE (1) | SE535296C2 (en) |
WO (1) | WO2012033459A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015104404A1 (en) * | 2014-01-09 | 2015-07-16 | Universiteit Maastricht | Method for the treatment or prevention of gastrointestinal disease caused by chorioamnionitis |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
KR20170005191A (en) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | Compositions and methods for the treatment or the prevention oral infections by e. coli |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US10350278B2 (en) * | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US545A (en) | 1837-12-29 | Method of making fastenings for saddle-bags | ||
US4544A (en) | 1846-05-28 | Improvement in plow-clevises | ||
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US5902617A (en) * | 1992-05-19 | 1999-05-11 | Pabst; Patrea L. | Enzyme supplemented baby formula |
WO1999049882A2 (en) * | 1998-03-27 | 1999-10-07 | Eicher Dorothea J | Vegf and vegf-c as infant formula supplements |
US6027726A (en) | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
US6139869A (en) | 1991-06-28 | 2000-10-31 | Mitsubishi Kasei Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
WO2003051345A2 (en) * | 2001-12-14 | 2003-06-26 | Solvay Pharmaceuticals Gmbh | Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans |
CA2555516A1 (en) * | 2006-07-27 | 2008-01-27 | Noel Gauthier | Food additive for human and animal and uses thereof |
US20090324572A1 (en) | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of williams syndrome |
EP2198880A1 (en) | 2004-10-14 | 2010-06-23 | Altus Pharmaceuticals Inc. | Compositions containing lipase, protease and amylase for treating pancreatic insufficiency |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569458A (en) * | 1994-09-14 | 1996-10-29 | Greenberg; Mike | Nutritional formula |
-
2010
- 2010-09-08 SE SE1050928A patent/SE535296C2/en not_active IP Right Cessation
-
2011
- 2011-09-08 WO PCT/SE2011/051089 patent/WO2012033459A1/en active Application Filing
- 2011-09-08 EP EP11823857.5A patent/EP2613800A4/en not_active Withdrawn
- 2011-09-08 CA CA2810498A patent/CA2810498C/en not_active Expired - Fee Related
- 2011-09-08 US US13/821,480 patent/US9205137B2/en not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US545A (en) | 1837-12-29 | Method of making fastenings for saddle-bags | ||
US4544A (en) | 1846-05-28 | Improvement in plow-clevises | ||
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US6139869A (en) | 1991-06-28 | 2000-10-31 | Mitsubishi Kasei Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
US5902617A (en) * | 1992-05-19 | 1999-05-11 | Pabst; Patrea L. | Enzyme supplemented baby formula |
US6027726A (en) | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
WO1999049882A2 (en) * | 1998-03-27 | 1999-10-07 | Eicher Dorothea J | Vegf and vegf-c as infant formula supplements |
US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
WO2003051345A2 (en) * | 2001-12-14 | 2003-06-26 | Solvay Pharmaceuticals Gmbh | Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans |
EP2198880A1 (en) | 2004-10-14 | 2010-06-23 | Altus Pharmaceuticals Inc. | Compositions containing lipase, protease and amylase for treating pancreatic insufficiency |
CA2555516A1 (en) * | 2006-07-27 | 2008-01-27 | Noel Gauthier | Food additive for human and animal and uses thereof |
US20090324572A1 (en) | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of williams syndrome |
Non-Patent Citations (27)
Title |
---|
"Assay of intestinal disaccharidases", SCAND. J. CLIN. LAB. INVEST., vol. 44, 1984, pages 169 - 172 |
"Current Protocols in Immonology, and Current Protocols in Molecular Biology", JOHN WILEY AND SONS |
"Remington: The Science and Practice of Phamtacy", 1995, MACK PUBLISHNG COMPANY |
BAINTNER K.: "Biology of the intestine in growing animals", 2002, ELSEVIER SCIENCE, article "Vacuolization in the young", pages: 55 - 110 |
CARSON: "Histotechology: A Self-Instructional Text", 1997, CHICAGO:ASCP PRESS |
CHAPKIN ET AL.: "Non-invasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells", AM. J. PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 298, 2010, pages G582 - G589 |
CHAPKIN ET AL.: "Table 2 in Non-invasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells", AM. J. PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 298, 2010, pages G582 - G589 |
DAHLQVIST, A: "Assay of intestinal disaccharidases", SCAND J CLIN LAB INVEST, vol. 44, 1984, pages 169 - 172 |
DAHLQVIST, A: "Method for Assay of intestinal disaccharidases", ASALYTICAL BIOCHEMISTRY, vol. 7, 1964, pages 18 - 25 |
DAHLQVIST: "A. Method for Assay of intestinal disaccharidases", ASALYTICAL BIOCHEMISTRY, vol. 7, 1964, pages 18 - 25 |
DAHLQVIST; ASP: "Accurate assay of low intestinal lactase activity with a fluorometric method", ANALYTICAL BIOCHEMISTRY, vol. 44, pages 654 - 657 |
DAVIDSON ET AL.: "Quantification of human intestinal gene expression profiles using exfolicated colonocytes: a pilot study", BIOMARKERS, vol. 8, 2003, pages 51 - 61 |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. S2, 1985, pages 3688 - 92 |
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATOTY PRESS |
HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4 |
KOSLOSKE, A. M.: "Epidemiology of necrotizing enterocolitis", ACTA PAEDIATR. SUPPL., vol. 396, 1994, pages 2 - 7 |
LEBENTHAL ET AL.: "ENZYME THERAPY FOR PANCREATIC INSUFFICIENCY: PRESENT STATUS AND FUTURE NEEDS", PANCREAS, vol. 9, no. 1, 1 January 1994 (1994-01-01), pages 1 - 12 |
LEE ET AL.: "A method for assaying intestinal brush-border sucrase in an intact intestinal preparation", PNAS, vol. 95, no. 5, 3 March 1998 (1998-03-03), pages 2111 - 2116 |
LOWRY OH; ROSEBROUGH NJ; FARR AL; RANDALL RJ: "Protein measurement with the Folin phenol reagent", J BIOL CHEM, vol. 193, 1951, pages 265 - 275 |
PEULEN O; DANDRIFOSSE G: "Spermine-induced maturation in Wistar rat intestine: a cytokine-dependent mechanism", J PEDIATR GASTROENTEROL NUTR, vol. 38, 2004, pages 524 - 532 |
PIERZYNOWSK SG; WESTROM BR; SVENDSEN J; KARLSSON BW: "Development of exocrine pancreas function in chronically cannulated pigs during 1-13 weeks of postnatal life", J PEDIATR GASTROENTEROL NUTR, vol. 10, 1990, pages 206 - 212 |
RADBERG K; BIERNAT M; LINDEROTH A; ZABIELSKI R; PIERZYNOWSKI SG; WESTROM BR: "Enteral exposure to crude red kidney bean lectin induces maturation of the gut in suckling pigs", J ANIM SCI, vol. 79, 2001, pages 2669 - 2678 |
See also references of EP2613800A4 |
TRAV'ES ET AL., ALCOHOL & ALCOHOLISM, vol. 42, no. 5, 2007, pages 407 - 412 |
VEEREMAN-WAUTERS, G ET AL., JOURNAL OF PEDIATRIC GASTROENTEROLOGY & NUTRITION, vol. 23, no. 2, August 1996 (1996-08-01), pages 111 - 117 |
WALTHAL K ET AL., BIRTH DEFECTS RESEARCH, vol. 74, 2005, pages 132 - 156 |
WALTHALL K; CAPPON GD; HURTT ME ET AL.: "Postnatal development of the gastrointestinal system: a species comparison", BIRTH DEFECTS RES, vol. 74, 2005, pages 132 - 56 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015104404A1 (en) * | 2014-01-09 | 2015-07-16 | Universiteit Maastricht | Method for the treatment or prevention of gastrointestinal disease caused by chorioamnionitis |
Also Published As
Publication number | Publication date |
---|---|
US20130171121A1 (en) | 2013-07-04 |
EP2613800A4 (en) | 2014-01-22 |
SE1050928A1 (en) | 2012-03-09 |
US9205137B2 (en) | 2015-12-08 |
CA2810498C (en) | 2017-08-08 |
EP2613800A1 (en) | 2013-07-17 |
SE535296C2 (en) | 2012-06-19 |
CA2810498A1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9205137B2 (en) | Maturation of gastrointestinal tract | |
Verburg et al. | Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats | |
Pinier et al. | The copolymer P (HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues | |
Salden et al. | Randomised clinical study: Aspergillus niger‐derived enzyme digests gluten in the stomach of healthy volunteers | |
US8574863B2 (en) | Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract | |
Pinier et al. | Prevention measures and exploratory pharmacological treatments of celiac disease | |
Lindfors et al. | Future treatment strategies for celiac disease | |
Di Caro et al. | Effect of dietary cellulose supplementation on gut barrier function and apoptosis in a murine model of endotoxemia | |
Watson et al. | Glucose intake and utilization in pre-diabetes and diabetes: implications for cardiovascular disease | |
EP3586840B1 (en) | Mmp7 inhibitors for use in treating cystitis | |
Yamazaki et al. | A case of a teenage boy with eosinophilic gastroenteritis with esophageal involvement developing a hemorrhagic duodenal ulcer | |
López et al. | Practitioner's Corner | |
US20230405078A1 (en) | Detection and treatment of intestinal fibrosis | |
KR102109385B1 (en) | Composition for emitting glucose | |
Rivero-Gutiérrez et al. | Leptin-resistant Zucker rats with trinitrobenzene sulfonic acid colitis present a reduced inflammatory response but enhanced epithelial damage | |
Pacor et al. | Food allergy and seronegative arthritis: report of two cases | |
Kalinina et al. | P238 Neuroendocrine differons with duodenitis of various etiologies in children | |
Knoll | Consensus Conference on the Management of Cystic Fibrosis: Paris, June 3rd, 1994 | |
US20240082260A1 (en) | Inhibitor of protein kinase d for use in prevention or treatment of hyperlipidemia | |
Arevalo Sureda | Development of the gastrointestinal tract in young mammals: Effects of enteral provocation with protease or phytohaemagglutinin in neonatal rats | |
Sureda | Development of the gastrointestinal tract in young mammals: Effects of enteral provocation with protease or phytohaemagglutinin in neonatal rats | |
Martins et al. | Necrotizing enterocolitis: a potential protective role for intestinal alkaline phosphatase as lipopolysaccharide detoxifying enzyme | |
Keirns | Has Genetic Improvement of Wheat Resulted in Negative Effects on Gut Health? | |
Souza | Eosinophilic esophagitis: when to suspect and why to treat with proton pump inhibitors | |
Ferreira‐Duarte et al. | Angiotensin‐converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2, 4, 6‐trinitrobenzene sulfonic acid‐induced model of colitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11823857 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2810498 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13821480 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011823857 Country of ref document: EP |